WO2010032248A2 - Multifunctional albumin conjugates - Google Patents
Multifunctional albumin conjugates Download PDFInfo
- Publication number
- WO2010032248A2 WO2010032248A2 PCT/IL2009/000911 IL2009000911W WO2010032248A2 WO 2010032248 A2 WO2010032248 A2 WO 2010032248A2 IL 2009000911 W IL2009000911 W IL 2009000911W WO 2010032248 A2 WO2010032248 A2 WO 2010032248A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- conjugate
- cancer
- daidzein
- isoflavone
- Prior art date
Links
- 102000009027 Albumins Human genes 0.000 title claims abstract description 74
- 108010088751 Albumins Proteins 0.000 title claims abstract description 74
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 124
- 239000003814 drug Substances 0.000 claims abstract description 58
- 230000000975 bioactive effect Effects 0.000 claims abstract description 57
- 201000011510 cancer Diseases 0.000 claims abstract description 57
- 150000002515 isoflavone derivatives Chemical class 0.000 claims abstract description 57
- 229930012930 isoflavone derivative Natural products 0.000 claims abstract description 40
- 239000000032 diagnostic agent Substances 0.000 claims abstract description 31
- 229940039227 diagnostic agent Drugs 0.000 claims abstract description 31
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 31
- 210000004027 cell Anatomy 0.000 claims description 105
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims description 54
- 235000008696 isoflavones Nutrition 0.000 claims description 54
- 238000000034 method Methods 0.000 claims description 50
- 150000001875 compounds Chemical class 0.000 claims description 44
- 239000000203 mixture Substances 0.000 claims description 36
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 claims description 33
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N Daidzein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 claims description 32
- WUADCCWRTIWANL-UHFFFAOYSA-N biochanin A Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O WUADCCWRTIWANL-UHFFFAOYSA-N 0.000 claims description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 23
- 229940045109 genistein Drugs 0.000 claims description 23
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 claims description 23
- 235000006539 genistein Nutrition 0.000 claims description 23
- 239000000975 dye Substances 0.000 claims description 22
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 claims description 22
- 235000007240 daidzein Nutrition 0.000 claims description 21
- 229960000988 nystatin Drugs 0.000 claims description 21
- -1 fluroximidine Chemical compound 0.000 claims description 20
- 206010033128 Ovarian cancer Diseases 0.000 claims description 19
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 19
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 18
- 231100000433 cytotoxic Toxicity 0.000 claims description 18
- 230000001472 cytotoxic effect Effects 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 15
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 14
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims description 14
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims description 14
- HKQYGTCOTHHOMP-UHFFFAOYSA-N formononetin Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O)=CC=C2C1=O HKQYGTCOTHHOMP-UHFFFAOYSA-N 0.000 claims description 14
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 claims description 14
- 239000005090 green fluorescent protein Substances 0.000 claims description 14
- 229960003330 pentetic acid Drugs 0.000 claims description 14
- 102000004169 proteins and genes Human genes 0.000 claims description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 230000015572 biosynthetic process Effects 0.000 claims description 13
- 239000002245 particle Substances 0.000 claims description 13
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 12
- 230000005298 paramagnetic effect Effects 0.000 claims description 12
- 230000002285 radioactive effect Effects 0.000 claims description 12
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 11
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims description 11
- 230000027455 binding Effects 0.000 claims description 11
- 239000002738 chelating agent Substances 0.000 claims description 11
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 11
- 108010006654 Bleomycin Proteins 0.000 claims description 10
- 206010006187 Breast cancer Diseases 0.000 claims description 10
- 208000026310 Breast neoplasm Diseases 0.000 claims description 10
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 10
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims description 10
- 206010009944 Colon cancer Diseases 0.000 claims description 9
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 claims description 9
- 229910052693 Europium Inorganic materials 0.000 claims description 9
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 9
- 229960004630 chlorambucil Drugs 0.000 claims description 9
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 claims description 9
- RIKPNWPEMPODJD-UHFFFAOYSA-N formononetin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC=C2C1=O RIKPNWPEMPODJD-UHFFFAOYSA-N 0.000 claims description 9
- 229960001924 melphalan Drugs 0.000 claims description 9
- RXACEEPNTRHYBQ-UHFFFAOYSA-N 2-[[2-[[2-[(2-sulfanylacetyl)amino]acetyl]amino]acetyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)CNC(=O)CNC(=O)CS RXACEEPNTRHYBQ-UHFFFAOYSA-N 0.000 claims description 8
- 206010060862 Prostate cancer Diseases 0.000 claims description 8
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 8
- 229960001561 bleomycin Drugs 0.000 claims description 8
- 208000029742 colonic neoplasm Diseases 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 208000032839 leukemia Diseases 0.000 claims description 8
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims description 8
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 7
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 7
- 206010014733 Endometrial cancer Diseases 0.000 claims description 7
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 7
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 7
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 7
- 229940011871 estrogen Drugs 0.000 claims description 7
- 239000000262 estrogen Substances 0.000 claims description 7
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims description 7
- 239000007850 fluorescent dye Substances 0.000 claims description 7
- 238000011503 in vivo imaging Methods 0.000 claims description 7
- 201000001441 melanoma Diseases 0.000 claims description 7
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 7
- 229910052688 Gadolinium Inorganic materials 0.000 claims description 6
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 6
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 claims description 6
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 6
- 229940009456 adriamycin Drugs 0.000 claims description 6
- 125000004450 alkenylene group Chemical group 0.000 claims description 6
- 239000002168 alkylating agent Substances 0.000 claims description 6
- 239000003242 anti bacterial agent Substances 0.000 claims description 6
- 229940088710 antibiotic agent Drugs 0.000 claims description 6
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 6
- 229960004316 cisplatin Drugs 0.000 claims description 6
- 108010082025 cyan fluorescent protein Proteins 0.000 claims description 6
- 239000000824 cytostatic agent Chemical class 0.000 claims description 6
- 230000001085 cytostatic effect Effects 0.000 claims description 6
- 229960002949 fluorouracil Drugs 0.000 claims description 6
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 claims description 6
- 125000004474 heteroalkylene group Chemical group 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- 229960000485 methotrexate Drugs 0.000 claims description 6
- 229960004528 vincristine Drugs 0.000 claims description 6
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 6
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 6
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 5
- 229940100198 alkylating agent Drugs 0.000 claims description 5
- 125000002947 alkylene group Chemical group 0.000 claims description 5
- 230000000340 anti-metabolite Effects 0.000 claims description 5
- 230000000692 anti-sense effect Effects 0.000 claims description 5
- 229940100197 antimetabolite Drugs 0.000 claims description 5
- 239000002256 antimetabolite Substances 0.000 claims description 5
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 claims description 5
- 239000003443 antiviral agent Substances 0.000 claims description 5
- 229960005243 carmustine Drugs 0.000 claims description 5
- 229960004397 cyclophosphamide Drugs 0.000 claims description 5
- 229960000684 cytarabine Drugs 0.000 claims description 5
- 229960001101 ifosfamide Drugs 0.000 claims description 5
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 5
- 229960002247 lomustine Drugs 0.000 claims description 5
- 229960001428 mercaptopurine Drugs 0.000 claims description 5
- 229960003048 vinblastine Drugs 0.000 claims description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 4
- 230000006820 DNA synthesis Effects 0.000 claims description 4
- 229910052765 Lutetium Inorganic materials 0.000 claims description 4
- 102000029749 Microtubule Human genes 0.000 claims description 4
- 108091022875 Microtubule Proteins 0.000 claims description 4
- 229930192392 Mitomycin Natural products 0.000 claims description 4
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 4
- 229960004562 carboplatin Drugs 0.000 claims description 4
- 229960003668 docetaxel Drugs 0.000 claims description 4
- 229940088597 hormone Drugs 0.000 claims description 4
- 239000005556 hormone Substances 0.000 claims description 4
- OHSVLFRHMCKCQY-UHFFFAOYSA-N lutetium atom Chemical compound [Lu] OHSVLFRHMCKCQY-UHFFFAOYSA-N 0.000 claims description 4
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 claims description 4
- 229960004961 mechlorethamine Drugs 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 210000004688 microtubule Anatomy 0.000 claims description 4
- 230000000394 mitotic effect Effects 0.000 claims description 4
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 claims description 4
- 229960002066 vinorelbine Drugs 0.000 claims description 4
- 229910052727 yttrium Inorganic materials 0.000 claims description 4
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 102000015790 Asparaginase Human genes 0.000 claims description 3
- 108010024976 Asparaginase Proteins 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 201000009273 Endometriosis Diseases 0.000 claims description 3
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 3
- 102000014150 Interferons Human genes 0.000 claims description 3
- 108010050904 Interferons Proteins 0.000 claims description 3
- 108010000817 Leuprolide Proteins 0.000 claims description 3
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 3
- 208000001132 Osteoporosis Diseases 0.000 claims description 3
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 3
- XWHUQXFERLNWEQ-UHFFFAOYSA-N Rosamine Natural products CCC1=CC2CN3CCC4(Nc5ccccc5C4=O)C(C2)(C13)C(=O)OC XWHUQXFERLNWEQ-UHFFFAOYSA-N 0.000 claims description 3
- 229960003272 asparaginase Drugs 0.000 claims description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 claims description 3
- 229960002685 biotin Drugs 0.000 claims description 3
- 239000011616 biotin Substances 0.000 claims description 3
- 229930017320 daidzein derivative Natural products 0.000 claims description 3
- 150000001950 daidzein derivatives Chemical group 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 229960002074 flutamide Drugs 0.000 claims description 3
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 claims description 3
- 229910052738 indium Inorganic materials 0.000 claims description 3
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 claims description 3
- 229940079322 interferon Drugs 0.000 claims description 3
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 claims description 3
- 229960004338 leuprorelin Drugs 0.000 claims description 3
- 229960004296 megestrol acetate Drugs 0.000 claims description 3
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 claims description 3
- 229960004857 mitomycin Drugs 0.000 claims description 3
- 238000012634 optical imaging Methods 0.000 claims description 3
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 3
- 229960001756 oxaliplatin Drugs 0.000 claims description 3
- 201000004240 prostatic hypertrophy Diseases 0.000 claims description 3
- 229910052702 rhenium Inorganic materials 0.000 claims description 3
- WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 claims description 3
- 229940043267 rhodamine b Drugs 0.000 claims description 3
- 238000002603 single-photon emission computed tomography Methods 0.000 claims description 3
- 229960001603 tamoxifen Drugs 0.000 claims description 3
- 229910052713 technetium Inorganic materials 0.000 claims description 3
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 claims description 3
- PQMJQYONVLIFOV-UHFFFAOYSA-N tetramethylrhodamine ethyl ester(1+) Chemical compound CCOC(=O)C1=CC=CC=C1C1=C2C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C21 PQMJQYONVLIFOV-UHFFFAOYSA-N 0.000 claims description 3
- KXVADGBQPMPMIQ-UHFFFAOYSA-M tetramethylrosamine chloride Chemical compound [Cl-].C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1 KXVADGBQPMPMIQ-UHFFFAOYSA-M 0.000 claims description 3
- 238000012285 ultrasound imaging Methods 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 235000020958 biotin Nutrition 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims 8
- 150000001949 daidzein Chemical class 0.000 claims 4
- 190000008236 carboplatin Chemical compound 0.000 claims 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 2
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 abstract description 18
- 238000011282 treatment Methods 0.000 abstract description 14
- 238000003745 diagnosis Methods 0.000 abstract description 12
- 239000000562 conjugate Substances 0.000 description 91
- 241000699670 Mus sp. Species 0.000 description 28
- 229940079593 drug Drugs 0.000 description 23
- 230000008685 targeting Effects 0.000 description 22
- 239000002872 contrast media Substances 0.000 description 18
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 16
- 229940098773 bovine serum albumin Drugs 0.000 description 16
- 239000012216 imaging agent Substances 0.000 description 16
- 230000001225 therapeutic effect Effects 0.000 description 16
- 238000001514 detection method Methods 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- 238000001727 in vivo Methods 0.000 description 13
- 238000002347 injection Methods 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- 238000002595 magnetic resonance imaging Methods 0.000 description 13
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
- 238000005192 partition Methods 0.000 description 12
- 238000012384 transportation and delivery Methods 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 230000014759 maintenance of location Effects 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 239000002246 antineoplastic agent Substances 0.000 description 9
- 239000000969 carrier Substances 0.000 description 9
- 150000002148 esters Chemical class 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 210000004323 caveolae Anatomy 0.000 description 7
- 230000010261 cell growth Effects 0.000 description 7
- 238000002059 diagnostic imaging Methods 0.000 description 7
- 238000003384 imaging method Methods 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 230000000670 limiting effect Effects 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 7
- 239000008280 blood Substances 0.000 description 6
- 239000013522 chelant Substances 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 230000021615 conjugation Effects 0.000 description 6
- 230000005284 excitation Effects 0.000 description 6
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 6
- 230000004807 localization Effects 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 230000002035 prolonged effect Effects 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 5
- QFWLLPSGSRVCSU-UHFFFAOYSA-N 4-oxo-3-phenylchromene-2-carboxylic acid Chemical class OC(=O)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 QFWLLPSGSRVCSU-UHFFFAOYSA-N 0.000 description 5
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 5
- 230000001093 anti-cancer Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000012202 endocytosis Effects 0.000 description 5
- 102000015694 estrogen receptors Human genes 0.000 description 5
- 108010038795 estrogen receptors Proteins 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- QGKMIGUHVLGJBR-UHFFFAOYSA-M (4z)-1-(3-methylbutyl)-4-[[1-(3-methylbutyl)quinolin-1-ium-4-yl]methylidene]quinoline;iodide Chemical compound [I-].C12=CC=CC=C2N(CCC(C)C)C=CC1=CC1=CC=[N+](CCC(C)C)C2=CC=CC=C12 QGKMIGUHVLGJBR-UHFFFAOYSA-M 0.000 description 4
- AUUIARVPJHGTSA-UHFFFAOYSA-N 3-(aminomethyl)chromen-2-one Chemical compound C1=CC=C2OC(=O)C(CN)=CC2=C1 AUUIARVPJHGTSA-UHFFFAOYSA-N 0.000 description 4
- HSHNITRMYYLLCV-UHFFFAOYSA-N 4-methylumbelliferone Chemical compound C1=C(O)C=CC2=C1OC(=O)C=C2C HSHNITRMYYLLCV-UHFFFAOYSA-N 0.000 description 4
- YMZMTOFQCVHHFB-UHFFFAOYSA-N 5-carboxytetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(C(O)=O)C=C1C([O-])=O YMZMTOFQCVHHFB-UHFFFAOYSA-N 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 4
- 230000010534 mechanism of action Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 238000011580 nude mouse model Methods 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical compound N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 3
- BGWLYQZDNFIFRX-UHFFFAOYSA-N 5-[3-[2-[3-(3,8-diamino-6-phenylphenanthridin-5-ium-5-yl)propylamino]ethylamino]propyl]-6-phenylphenanthridin-5-ium-3,8-diamine;dichloride Chemical compound [Cl-].[Cl-].C=1C(N)=CC=C(C2=CC=C(N)C=C2[N+]=2CCCNCCNCCC[N+]=3C4=CC(N)=CC=C4C4=CC=C(N)C=C4C=3C=3C=CC=CC=3)C=1C=2C1=CC=CC=C1 BGWLYQZDNFIFRX-UHFFFAOYSA-N 0.000 description 3
- NJYVEMPWNAYQQN-UHFFFAOYSA-N 5-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(C(=O)O)=CC=C21 NJYVEMPWNAYQQN-UHFFFAOYSA-N 0.000 description 3
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 3
- 108010092160 Dactinomycin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108091006905 Human Serum Albumin Proteins 0.000 description 3
- 102000008100 Human Serum Albumin Human genes 0.000 description 3
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 229930012538 Paclitaxel Natural products 0.000 description 3
- 108010004729 Phycoerythrin Proteins 0.000 description 3
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 3
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 3
- 239000012867 bioactive agent Substances 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000004700 cellular uptake Effects 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 229940039231 contrast media Drugs 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 3
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 3
- 238000000799 fluorescence microscopy Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 229960001592 paclitaxel Drugs 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 229960003087 tioguanine Drugs 0.000 description 3
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 3
- 239000003656 tris buffered saline Substances 0.000 description 3
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 3
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 2
- XDFNWJDGWJVGGN-UHFFFAOYSA-N 2-(2,7-dichloro-3,6-dihydroxy-9h-xanthen-9-yl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C1C2=CC(Cl)=C(O)C=C2OC2=CC(O)=C(Cl)C=C21 XDFNWJDGWJVGGN-UHFFFAOYSA-N 0.000 description 2
- ZVDGOJFPFMINBM-UHFFFAOYSA-N 3-(6-methoxyquinolin-1-ium-1-yl)propane-1-sulfonate Chemical compound [O-]S(=O)(=O)CCC[N+]1=CC=CC2=CC(OC)=CC=C21 ZVDGOJFPFMINBM-UHFFFAOYSA-N 0.000 description 2
- MJKVTPMWOKAVMS-UHFFFAOYSA-N 3-hydroxy-1-benzopyran-2-one Chemical compound C1=CC=C2OC(=O)C(O)=CC2=C1 MJKVTPMWOKAVMS-UHFFFAOYSA-N 0.000 description 2
- VIIIJFZJKFXOGG-UHFFFAOYSA-N 3-methylchromen-2-one Chemical compound C1=CC=C2OC(=O)C(C)=CC2=C1 VIIIJFZJKFXOGG-UHFFFAOYSA-N 0.000 description 2
- VWOLRKMFAJUZGM-UHFFFAOYSA-N 6-carboxyrhodamine 6G Chemical compound [Cl-].C=12C=C(C)C(NCC)=CC2=[O+]C=2C=C(NCC)C(C)=CC=2C=1C1=CC(C(O)=O)=CC=C1C(=O)OCC VWOLRKMFAJUZGM-UHFFFAOYSA-N 0.000 description 2
- IHHSSHCBRVYGJX-UHFFFAOYSA-N 6-chloro-2-methoxyacridin-9-amine Chemical compound C1=C(Cl)C=CC2=C(N)C3=CC(OC)=CC=C3N=C21 IHHSSHCBRVYGJX-UHFFFAOYSA-N 0.000 description 2
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 2
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 108091005941 EBFP Proteins 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 2
- 108700012941 GNRH1 Proteins 0.000 description 2
- 229910003317 GdCl3 Inorganic materials 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 2
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 2
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 2
- 238000012404 In vitro experiment Methods 0.000 description 2
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 2
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- YHIPILPTUVMWQT-UHFFFAOYSA-N Oplophorus luciferin Chemical compound C1=CC(O)=CC=C1CC(C(N1C=C(N2)C=3C=CC(O)=CC=3)=O)=NC1=C2CC1=CC=CC=C1 YHIPILPTUVMWQT-UHFFFAOYSA-N 0.000 description 2
- SHGAZHPCJJPHSC-UHFFFAOYSA-N Panrexin Chemical compound OC(=O)C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-UHFFFAOYSA-N 0.000 description 2
- KPKZJLCSROULON-QKGLWVMZSA-N Phalloidin Chemical compound N1C(=O)[C@@H]([C@@H](O)C)NC(=O)[C@H](C)NC(=O)[C@H](C[C@@](C)(O)CO)NC(=O)[C@H](C2)NC(=O)[C@H](C)NC(=O)[C@@H]3C[C@H](O)CN3C(=O)[C@@H]1CSC1=C2C2=CC=CC=C2N1 KPKZJLCSROULON-QKGLWVMZSA-N 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 2
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- PEJLNXHANOHNSU-UHFFFAOYSA-N acridine-3,6-diamine;10-methylacridin-10-ium-3,6-diamine;chloride Chemical compound [Cl-].C1=CC(N)=CC2=NC3=CC(N)=CC=C3C=C21.C1=C(N)C=C2[N+](C)=C(C=C(N)C=C3)C3=CC2=C1 PEJLNXHANOHNSU-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 2
- 229940045799 anthracyclines and related substance Drugs 0.000 description 2
- 230000001833 anti-estrogenic effect Effects 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 108010055151 bovine serum albumin-DTPA complex Proteins 0.000 description 2
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- TUESWZZJYCLFNL-DAFODLJHSA-N chembl1301 Chemical compound C1=CC(C(=N)N)=CC=C1\C=C\C1=CC=C(C(N)=N)C=C1O TUESWZZJYCLFNL-DAFODLJHSA-N 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- 229960002436 cladribine Drugs 0.000 description 2
- 229960000956 coumarin Drugs 0.000 description 2
- 235000001671 coumarin Nutrition 0.000 description 2
- GLNDAGDHSLMOKX-UHFFFAOYSA-N coumarin 120 Chemical compound C1=C(N)C=CC2=C1OC(=O)C=C2C GLNDAGDHSLMOKX-UHFFFAOYSA-N 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 229960000640 dactinomycin Drugs 0.000 description 2
- 229960000975 daunorubicin Drugs 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N dihydromaleimide Natural products O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- OOYIOIOOWUGAHD-UHFFFAOYSA-L disodium;2',4',5',7'-tetrabromo-4,5,6,7-tetrachloro-3-oxospiro[2-benzofuran-1,9'-xanthene]-3',6'-diolate Chemical compound [Na+].[Na+].O1C(=O)C(C(=C(Cl)C(Cl)=C2Cl)Cl)=C2C21C1=CC(Br)=C([O-])C(Br)=C1OC1=C(Br)C([O-])=C(Br)C=C21 OOYIOIOOWUGAHD-UHFFFAOYSA-L 0.000 description 2
- YJHDFAAFYNRKQE-YHPRVSEPSA-L disodium;5-[[4-anilino-6-[bis(2-hydroxyethyl)amino]-1,3,5-triazin-2-yl]amino]-2-[(e)-2-[4-[[4-anilino-6-[bis(2-hydroxyethyl)amino]-1,3,5-triazin-2-yl]amino]-2-sulfonatophenyl]ethenyl]benzenesulfonate Chemical compound [Na+].[Na+].N=1C(NC=2C=C(C(\C=C\C=3C(=CC(NC=4N=C(N=C(NC=5C=CC=CC=5)N=4)N(CCO)CCO)=CC=3)S([O-])(=O)=O)=CC=2)S([O-])(=O)=O)=NC(N(CCO)CCO)=NC=1NC1=CC=CC=C1 YJHDFAAFYNRKQE-YHPRVSEPSA-L 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 230000002121 endocytic effect Effects 0.000 description 2
- 229960001904 epirubicin Drugs 0.000 description 2
- IINNWAYUJNWZRM-UHFFFAOYSA-L erythrosin B Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 IINNWAYUJNWZRM-UHFFFAOYSA-L 0.000 description 2
- 229960001842 estramustine Drugs 0.000 description 2
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 2
- ADFOJJHRTBFFOF-RBRWEJTLSA-N estramustine phosphate Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 ADFOJJHRTBFFOF-RBRWEJTLSA-N 0.000 description 2
- 230000001076 estrogenic effect Effects 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- 229960000752 etoposide phosphate Drugs 0.000 description 2
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229960000961 floxuridine Drugs 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- DVGHHMFBFOTGLM-UHFFFAOYSA-L fluorogold Chemical compound F[Au][Au]F DVGHHMFBFOTGLM-UHFFFAOYSA-L 0.000 description 2
- MEANOSLIBWSCIT-UHFFFAOYSA-K gadolinium trichloride Chemical compound Cl[Gd](Cl)Cl MEANOSLIBWSCIT-UHFFFAOYSA-K 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 229950005911 hydroxystilbamidine Drugs 0.000 description 2
- 229960000908 idarubicin Drugs 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 2
- 229960004768 irinotecan Drugs 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-methyl-PhOH Natural products CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- HQCYVSPJIOJEGA-UHFFFAOYSA-N methoxycoumarin Chemical compound C1=CC=C2OC(=O)C(OC)=CC2=C1 HQCYVSPJIOJEGA-UHFFFAOYSA-N 0.000 description 2
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- AHEWZZJEDQVLOP-UHFFFAOYSA-N monobromobimane Chemical compound BrCC1=C(C)C(=O)N2N1C(C)=C(C)C2=O AHEWZZJEDQVLOP-UHFFFAOYSA-N 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 210000000651 myofibroblast Anatomy 0.000 description 2
- QWVGKYWNOKOFNN-UHFFFAOYSA-N o-cresol Chemical compound CC1=CC=CC=C1O QWVGKYWNOKOFNN-UHFFFAOYSA-N 0.000 description 2
- 229960002378 oftasceine Drugs 0.000 description 2
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 2
- AFAIELJLZYUNPW-UHFFFAOYSA-N pararosaniline free base Chemical compound C1=CC(N)=CC=C1C(C=1C=CC(N)=CC=1)=C1C=CC(=N)C=C1 AFAIELJLZYUNPW-UHFFFAOYSA-N 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229960003171 plicamycin Drugs 0.000 description 2
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
- INCIMLINXXICKS-UHFFFAOYSA-M pyronin Y Chemical compound [Cl-].C1=CC(=[N+](C)C)C=C2OC3=CC(N(C)C)=CC=C3C=C21 INCIMLINXXICKS-UHFFFAOYSA-M 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 229910052594 sapphire Inorganic materials 0.000 description 2
- 239000010980 sapphire Substances 0.000 description 2
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 2
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 2
- 235000021286 stilbenes Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- PVYJZLYGTZKPJE-UHFFFAOYSA-N streptonigrin Chemical compound C=1C=C2C(=O)C(OC)=C(N)C(=O)C2=NC=1C(C=1N)=NC(C(O)=O)=C(C)C=1C1=CC=C(OC)C(OC)=C1O PVYJZLYGTZKPJE-UHFFFAOYSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 229960002317 succinimide Drugs 0.000 description 2
- 229940032362 superoxide dismutase Drugs 0.000 description 2
- 229960004964 temozolomide Drugs 0.000 description 2
- 229960001278 teniposide Drugs 0.000 description 2
- JGVWCANSWKRBCS-UHFFFAOYSA-N tetramethylrhodamine thiocyanate Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(SC#N)C=C1C(O)=O JGVWCANSWKRBCS-UHFFFAOYSA-N 0.000 description 2
- 229960000303 topotecan Drugs 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000000482 two photon fluorescence microscopy Methods 0.000 description 2
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 2
- 239000001018 xanthene dye Substances 0.000 description 2
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 2
- AADVCYNFEREWOS-UHFFFAOYSA-N (+)-DDM Natural products C=CC=CC(C)C(OC(N)=O)C(C)C(O)C(C)CC(C)=CC(C)C(O)C(C)C=CC(O)CC1OC(=O)C(C)C(O)C1C AADVCYNFEREWOS-UHFFFAOYSA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- HBUBKKRHXORPQB-FJFJXFQQSA-N (2R,3S,4S,5R)-2-(6-amino-2-fluoro-9-purinyl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O HBUBKKRHXORPQB-FJFJXFQQSA-N 0.000 description 1
- NHQOULZCPKJYMM-UHFFFAOYSA-M (2e)-1,3,3-trimethyl-2-[(2e)-7-(1,3,3-trimethylindol-1-ium-2-yl)hepta-2,4,6-trienylidene]indole;perchlorate Chemical compound [O-]Cl(=O)(=O)=O.CC1(C)C2=CC=CC=C2N(C)C1=CC=CC=CC=CC1=[N+](C)C2=CC=CC=C2C1(C)C NHQOULZCPKJYMM-UHFFFAOYSA-M 0.000 description 1
- BPSIJFMUSNMMAL-UHFFFAOYSA-M (2e)-2-[(2e)-2-[2-chloro-3-[(e)-2-(1,3,3-trimethylindol-1-ium-2-yl)ethenyl]cyclohex-2-en-1-ylidene]ethylidene]-1,3,3-trimethylindole;chloride Chemical compound [Cl-].CC1(C)C2=CC=CC=C2N(C)\C1=C/C=C\1C(Cl)=C(\C=C\C=2C(C3=CC=CC=C3[N+]=2C)(C)C)CCC/1 BPSIJFMUSNMMAL-UHFFFAOYSA-M 0.000 description 1
- NALBXTAOVMLCIX-UHFFFAOYSA-M (2e)-2-[(2e)-2-[2-chloro-3-[(e)-2-(1,3,3-trimethylindol-1-ium-2-yl)ethenyl]cyclohex-2-en-1-ylidene]ethylidene]-1,3,3-trimethylindole;perchlorate Chemical compound [O-]Cl(=O)(=O)=O.CC1(C)C2=CC=CC=C2N(C)C1=CC=C1C(Cl)=C(C=CC=2C(C3=CC=CC=C3[N+]=2C)(C)C)CCC1 NALBXTAOVMLCIX-UHFFFAOYSA-M 0.000 description 1
- IRPKBYJYVJOQHQ-UHFFFAOYSA-M (2e)-2-[(2e)-2-[2-chloro-3-[(e)-2-(3,3-dimethyl-1-propylindol-1-ium-2-yl)ethenyl]cyclohex-2-en-1-ylidene]ethylidene]-3,3-dimethyl-1-propylindole;iodide Chemical compound [I-].CC1(C)C2=CC=CC=C2N(CCC)\C1=C\C=C/1C(Cl)=C(\C=C/C=2C(C3=CC=CC=C3[N+]=2CCC)(C)C)CCC\1 IRPKBYJYVJOQHQ-UHFFFAOYSA-M 0.000 description 1
- FLWWDYNPWOSLEO-HQVZTVAUSA-N (2s)-2-[[4-[1-(2-amino-4-oxo-1h-pteridin-6-yl)ethyl-methylamino]benzoyl]amino]pentanedioic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1C(C)N(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FLWWDYNPWOSLEO-HQVZTVAUSA-N 0.000 description 1
- PSVUJBVBCOISSP-SPFKKGSWSA-N (2s,3r,4s,5s,6r)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound OC[C@H]1O[C@@H](OP(=O)(NCCCl)NCCCl)[C@H](O)[C@@H](O)[C@@H]1O PSVUJBVBCOISSP-SPFKKGSWSA-N 0.000 description 1
- IJYUKSSLCNLVNM-UHFFFAOYSA-M (2z)-2-[(2z)-2-[3-[(e)-2-(3,3-dimethyl-1-propylindol-1-ium-2-yl)ethenyl]-2-phenylsulfanylcyclohex-2-en-1-ylidene]ethylidene]-3,3-dimethyl-1-propylindole;perchlorate Chemical compound [O-]Cl(=O)(=O)=O.CC1(C)C2=CC=CC=C2N(CCC)\C1=C\C=C1/CCCC(\C=C\C=2C(C3=CC=CC=C3[N+]=2CCC)(C)C)=C1SC1=CC=CC=C1 IJYUKSSLCNLVNM-UHFFFAOYSA-M 0.000 description 1
- VQVUBYASAICPFU-UHFFFAOYSA-N (6'-acetyloxy-2',7'-dichloro-3-oxospiro[2-benzofuran-1,9'-xanthene]-3'-yl) acetate Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(Cl)=C(OC(C)=O)C=C1OC1=C2C=C(Cl)C(OC(=O)C)=C1 VQVUBYASAICPFU-UHFFFAOYSA-N 0.000 description 1
- CHADEQDQBURGHL-UHFFFAOYSA-N (6'-acetyloxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-3'-yl) acetate Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(OC(C)=O)C=C1OC1=CC(OC(=O)C)=CC=C21 CHADEQDQBURGHL-UHFFFAOYSA-N 0.000 description 1
- WTSKMKRYHATLLL-UHFFFAOYSA-N (6-benzoyloxy-3-cyanopyridin-2-yl) 3-[3-(ethoxymethyl)-5-fluoro-2,6-dioxopyrimidine-1-carbonyl]benzoate Chemical compound O=C1N(COCC)C=C(F)C(=O)N1C(=O)C1=CC=CC(C(=O)OC=2C(=CC=C(OC(=O)C=3C=CC=CC=3)N=2)C#N)=C1 WTSKMKRYHATLLL-UHFFFAOYSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- AGNGYMCLFWQVGX-AGFFZDDWSA-N (e)-1-[(2s)-2-amino-2-carboxyethoxy]-2-diazonioethenolate Chemical compound OC(=O)[C@@H](N)CO\C([O-])=C\[N+]#N AGNGYMCLFWQVGX-AGFFZDDWSA-N 0.000 description 1
- 0 *c(cc1)ccc1C1=C(*)Oc2c(*)c(*)c(*)c(*)c2C1=O Chemical compound *c(cc1)ccc1C1=C(*)Oc2c(*)c(*)c(*)c(*)c2C1=O 0.000 description 1
- PXXBSYXTQAWFHV-UHFFFAOYSA-M 1,1,3-trimethyl-2-[5-(1,1,3-trimethylbenzo[e]indol-3-ium-2-yl)penta-2,4-dienylidene]benzo[e]indole;iodide Chemical compound [I-].C1=CC2=CC=CC=C2C(C2(C)C)=C1N(C)\C2=C\C=C\C=C\C1=[N+](C)C2=CC=C(C=CC=C3)C3=C2C1(C)C PXXBSYXTQAWFHV-UHFFFAOYSA-M 0.000 description 1
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 description 1
- CTTVWDKXMPBZMQ-UHFFFAOYSA-N 1-[6-(dimethylamino)naphthalen-2-yl]undecan-1-one Chemical compound CCCCCCCCCCC(=O)c1ccc2cc(ccc2c1)N(C)C CTTVWDKXMPBZMQ-UHFFFAOYSA-N 0.000 description 1
- YCMJMIVIVJRZPY-UHFFFAOYSA-N 10-oxa-3-azapentacyclo[12.8.0.02,11.04,9.015,20]docosa-1(14),2(11),4,6,8,12,15,17,19,21-decaene Chemical compound C1=CC=C2C3=CC=C4OC5=CC=CC=C5NC4=C3C=CC2=C1 YCMJMIVIVJRZPY-UHFFFAOYSA-N 0.000 description 1
- VWCLQNINSPFHFV-UHFFFAOYSA-N 10-oxapentacyclo[12.8.0.02,11.04,9.015,20]docosa-1(14),2(11),4,6,8,12,15,17,19,21-decaene Chemical compound C1=CC=C2C3=CC=C4OC5=CC=CC=C5CC4=C3C=CC2=C1 VWCLQNINSPFHFV-UHFFFAOYSA-N 0.000 description 1
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- FZJGGSUDHJDHRJ-UHFFFAOYSA-N 2,11,20,29-tetra-tert-butyl-2,3-naphthalocyanine Chemical compound C12=CC3=CC(C(C)(C)C)=CC=C3C=C2C(N=C2NC(C3=CC4=CC=C(C=C4C=C32)C(C)(C)C)=N2)=NC1=NC([C]1C=C3C=CC(=CC3=CC1=1)C(C)(C)C)=NC=1N=C1[C]3C=C4C=CC(C(C)(C)C)=CC4=CC3=C2N1 FZJGGSUDHJDHRJ-UHFFFAOYSA-N 0.000 description 1
- IVUBJNPDPBDVLT-UHFFFAOYSA-N 2,15,28,41,53,55-hexaza-54,56-diazanidatridecacyclo[40.10.1.13,14.116,27.129,40.04,13.06,11.017,26.019,24.030,39.032,37.043,52.045,50]hexapentaconta-1,3,5,7,9,11,13,15,17,19,21,23,25,27(55),28,30,32,34,36,38,40,42(53),43,45,47,49,51-heptacosaene oxovanadium(2+) Chemical compound [V+2]=O.[N-]1C(N=C2C3=CC4=CC=CC=C4C=C3C(N=C3C4=CC5=CC=CC=C5C=C4C(=N4)[N-]3)=N2)=C(C=C2C(C=CC=C2)=C2)C2=C1N=C1C2=CC3=CC=CC=C3C=C2C4=N1 IVUBJNPDPBDVLT-UHFFFAOYSA-N 0.000 description 1
- YTDHEFNWWHSXSU-UHFFFAOYSA-N 2,3,5,6-tetrachloroaniline Chemical compound NC1=C(Cl)C(Cl)=CC(Cl)=C1Cl YTDHEFNWWHSXSU-UHFFFAOYSA-N 0.000 description 1
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
- CAHMGWYMQPWRSF-UHFFFAOYSA-N 2,5-dioxopyrrolidine-1-sulfonic acid Chemical compound OS(=O)(=O)N1C(=O)CCC1=O CAHMGWYMQPWRSF-UHFFFAOYSA-N 0.000 description 1
- NOFPXGWBWIPSHI-UHFFFAOYSA-N 2,7,9-trimethylacridine-3,6-diamine;hydrochloride Chemical compound Cl.CC1=C(N)C=C2N=C(C=C(C(C)=C3)N)C3=C(C)C2=C1 NOFPXGWBWIPSHI-UHFFFAOYSA-N 0.000 description 1
- NNQWYGKROBKYQC-UHFFFAOYSA-N 2,9,16,23-tetra-tert-butyl-29h,31h-phthalocyanine Chemical compound C12=CC(C(C)(C)C)=CC=C2C(N=C2NC(C3=CC=C(C=C32)C(C)(C)C)=N2)=NC1=NC([C]1C=CC(=CC1=1)C(C)(C)C)=NC=1N=C1[C]3C=CC(C(C)(C)C)=CC3=C2N1 NNQWYGKROBKYQC-UHFFFAOYSA-N 0.000 description 1
- RHYBFKMCKVGBOA-UHFFFAOYSA-N 2,9,16,23-tetrakis(phenylthio)-29h,31h-phthalocyanine Chemical compound C=1C=C2C(N=C3NC(C4=CC=C(SC=5C=CC=CC=5)C=C43)=NC=3NC([C]4C=CC(SC=5C=CC=CC=5)=CC4=3)=NC=3N=C([C]4C=CC(SC=5C=CC=CC=5)=CC4=3)N=3)=NC=3C2=CC=1SC1=CC=CC=C1 RHYBFKMCKVGBOA-UHFFFAOYSA-N 0.000 description 1
- RUVJFMSQTCEAAB-UHFFFAOYSA-M 2-[3-[5,6-dichloro-1,3-bis[[4-(chloromethyl)phenyl]methyl]benzimidazol-2-ylidene]prop-1-enyl]-3-methyl-1,3-benzoxazol-3-ium;chloride Chemical compound [Cl-].O1C2=CC=CC=C2[N+](C)=C1C=CC=C(N(C1=CC(Cl)=C(Cl)C=C11)CC=2C=CC(CCl)=CC=2)N1CC1=CC=C(CCl)C=C1 RUVJFMSQTCEAAB-UHFFFAOYSA-M 0.000 description 1
- JHALWMSZGCVVEM-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl]acetic acid Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CC1 JHALWMSZGCVVEM-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- ALVZYHNBPIMLFM-UHFFFAOYSA-N 2-[4-[2-(4-carbamimidoylphenoxy)ethoxy]phenyl]-1h-indole-6-carboximidamide;dihydrochloride Chemical compound Cl.Cl.C1=CC(C(=N)N)=CC=C1OCCOC1=CC=C(C=2NC3=CC(=CC=C3C=2)C(N)=N)C=C1 ALVZYHNBPIMLFM-UHFFFAOYSA-N 0.000 description 1
- PDDJAJCJQXFQCW-UHFFFAOYSA-N 2-[4-[bis(carboxymethyl)amino]-3-(carboxymethoxy)phenyl]-1h-indole-6-carboxylic acid Chemical compound C1=C(N(CC(O)=O)CC(O)=O)C(OCC(=O)O)=CC(C=2NC3=CC(=CC=C3C=2)C(O)=O)=C1 PDDJAJCJQXFQCW-UHFFFAOYSA-N 0.000 description 1
- PDURUKZNVHEHGO-UHFFFAOYSA-N 2-[6-[bis(carboxymethyl)amino]-5-(carboxymethoxy)-1-benzofuran-2-yl]-1,3-oxazole-5-carboxylic acid Chemical compound O1C=2C=C(N(CC(O)=O)CC(O)=O)C(OCC(=O)O)=CC=2C=C1C1=NC=C(C(O)=O)O1 PDURUKZNVHEHGO-UHFFFAOYSA-N 0.000 description 1
- RAZLJUXJEOEYAM-UHFFFAOYSA-N 2-[bis[2-(2,6-dioxomorpholin-4-yl)ethyl]azaniumyl]acetate Chemical compound C1C(=O)OC(=O)CN1CCN(CC(=O)O)CCN1CC(=O)OC(=O)C1 RAZLJUXJEOEYAM-UHFFFAOYSA-N 0.000 description 1
- RJPSHDMGSVVHFA-UHFFFAOYSA-N 2-[carboxymethyl-[(7-hydroxy-4-methyl-2-oxochromen-8-yl)methyl]amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)CC1=C(O)C=CC2=C1OC(=O)C=C2C RJPSHDMGSVVHFA-UHFFFAOYSA-N 0.000 description 1
- QCXJFISCRQIYID-IAEPZHFASA-N 2-amino-1-n-[(3s,6s,7r,10s,16s)-3-[(2s)-butan-2-yl]-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-10-propan-2-yl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-4,6-dimethyl-3-oxo-9-n-[(3s,6s,7r,10s,16s)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propa Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N=C2C(C(=O)N[C@@H]3C(=O)N[C@H](C(N4CCC[C@H]4C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]3C)=O)[C@@H](C)CC)=C(N)C(=O)C(C)=C2O2)C2=C(C)C=C1 QCXJFISCRQIYID-IAEPZHFASA-N 0.000 description 1
- JVDYWBQJOUXQBB-UHFFFAOYSA-N 2-nitro-1,3-benzoxazole Chemical compound C1=CC=C2OC([N+](=O)[O-])=NC2=C1 JVDYWBQJOUXQBB-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- KFKRXESVMDBTNQ-UHFFFAOYSA-N 3-[18-(2-carboxylatoethyl)-8,13-bis(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-21,24-diium-2-yl]propanoate Chemical compound N1C2=C(C)C(C(C)O)=C1C=C(N1)C(C)=C(C(O)C)C1=CC(C(C)=C1CCC(O)=O)=NC1=CC(C(CCC(O)=O)=C1C)=NC1=C2 KFKRXESVMDBTNQ-UHFFFAOYSA-N 0.000 description 1
- HAPJROQJVSPKCJ-UHFFFAOYSA-N 3-[4-[2-[6-(dibutylamino)naphthalen-2-yl]ethenyl]pyridin-1-ium-1-yl]propane-1-sulfonate Chemical compound C1=CC2=CC(N(CCCC)CCCC)=CC=C2C=C1C=CC1=CC=[N+](CCCS([O-])(=O)=O)C=C1 HAPJROQJVSPKCJ-UHFFFAOYSA-N 0.000 description 1
- IXFSUSNUALIXLU-UHFFFAOYSA-N 3-[4-[2-[6-(dioctylamino)naphthalen-2-yl]ethenyl]pyridin-1-ium-1-yl]propane-1-sulfonate Chemical compound C1=CC2=CC(N(CCCCCCCC)CCCCCCCC)=CC=C2C=C1C=CC1=CC=[N+](CCCS([O-])(=O)=O)C=C1 IXFSUSNUALIXLU-UHFFFAOYSA-N 0.000 description 1
- WUIABRMSWOKTOF-OYALTWQYSA-N 3-[[2-[2-[2-[[(2s,3r)-2-[[(2s,3s,4r)-4-[[(2s,3r)-2-[[6-amino-2-[(1s)-3-amino-1-[[(2s)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2r,3s,4s,5r,6r)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)ox Chemical compound OS([O-])(=O)=O.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-OYALTWQYSA-N 0.000 description 1
- NJIRSTSECXKPCO-UHFFFAOYSA-M 3-[n-methyl-4-[2-(1,3,3-trimethylindol-1-ium-2-yl)ethenyl]anilino]propanenitrile;chloride Chemical compound [Cl-].C1=CC(N(CCC#N)C)=CC=C1\C=C\C1=[N+](C)C2=CC=CC=C2C1(C)C NJIRSTSECXKPCO-UHFFFAOYSA-M 0.000 description 1
- QWZHDKGQKYEBKK-UHFFFAOYSA-N 3-aminochromen-2-one Chemical compound C1=CC=C2OC(=O)C(N)=CC2=C1 QWZHDKGQKYEBKK-UHFFFAOYSA-N 0.000 description 1
- OYVFJKVYVDYPFV-UHFFFAOYSA-M 3-ethyl-2-[7-(3-ethyl-1,3-benzothiazol-3-ium-2-yl)hepta-2,4,6-trienylidene]-1,3-benzothiazole;iodide Chemical compound [I-].S1C2=CC=CC=C2[N+](CC)=C1/C=C/C=C/C=C/C=C1/N(CC)C2=CC=CC=C2S1 OYVFJKVYVDYPFV-UHFFFAOYSA-M 0.000 description 1
- PQJVKBUJXQTCGG-UHFFFAOYSA-N 3-n,6-n-dibenzylacridine-3,6-diamine;hydrochloride Chemical compound Cl.C=1C=CC=CC=1CNC(C=C1N=C2C=3)=CC=C1C=C2C=CC=3NCC1=CC=CC=C1 PQJVKBUJXQTCGG-UHFFFAOYSA-N 0.000 description 1
- XIINLOVCJKUOQC-UHFFFAOYSA-N 389927_sial Chemical compound N1=C(C2=CC3=CC=CC=C3C=C2C2=NC=3C4=CC5=CC=CC=C5C=C4C(=N4)N=3)N2[Si](Cl)(Cl)N2C4=C(C=C3C(C=CC=C3)=C3)C3=C2N=C2C3=CC4=CC=CC=C4C=C3C1=N2 XIINLOVCJKUOQC-UHFFFAOYSA-N 0.000 description 1
- YSCNMFDFYJUPEF-OWOJBTEDSA-N 4,4'-diisothiocyano-trans-stilbene-2,2'-disulfonic acid Chemical compound OS(=O)(=O)C1=CC(N=C=S)=CC=C1\C=C\C1=CC=C(N=C=S)C=C1S(O)(=O)=O YSCNMFDFYJUPEF-OWOJBTEDSA-N 0.000 description 1
- LHYQAEFVHIZFLR-UHFFFAOYSA-L 4-(4-diazonio-3-methoxyphenyl)-2-methoxybenzenediazonium;dichloride Chemical compound [Cl-].[Cl-].C1=C([N+]#N)C(OC)=CC(C=2C=C(OC)C([N+]#N)=CC=2)=C1 LHYQAEFVHIZFLR-UHFFFAOYSA-L 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- YOQMJMHTHWYNIO-UHFFFAOYSA-N 4-[6-[16-[2-(2,4-dicarboxyphenyl)-5-methoxy-1-benzofuran-6-yl]-1,4,10,13-tetraoxa-7,16-diazacyclooctadec-7-yl]-5-methoxy-1-benzofuran-2-yl]benzene-1,3-dicarboxylic acid Chemical compound COC1=CC=2C=C(C=3C(=CC(=CC=3)C(O)=O)C(O)=O)OC=2C=C1N(CCOCCOCC1)CCOCCOCCN1C(C(=CC=1C=2)OC)=CC=1OC=2C1=CC=C(C(O)=O)C=C1C(O)=O YOQMJMHTHWYNIO-UHFFFAOYSA-N 0.000 description 1
- NZVGXJAQIQJIOY-UHFFFAOYSA-N 4-[6-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-benzimidazol-2-yl]benzenesulfonamide;trihydrochloride Chemical compound Cl.Cl.Cl.C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(=NC4=CC=3)C=3C=CC(=CC=3)S(N)(=O)=O)C2=C1 NZVGXJAQIQJIOY-UHFFFAOYSA-N 0.000 description 1
- WCKQPPQRFNHPRJ-UHFFFAOYSA-N 4-[[4-(dimethylamino)phenyl]diazenyl]benzoic acid Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(C(O)=O)C=C1 WCKQPPQRFNHPRJ-UHFFFAOYSA-N 0.000 description 1
- BFXKASLQHBYWIJ-UHFFFAOYSA-N 412074_sial Chemical compound C=12C(OCCCC)=C3C=CC=C[C]3C(OCCCC)=C2C(N=C2N=C(C3=C(OCCCC)C4=CC=CC=C4C(OCCCC)=C32)N=C2NC(C3=C(OCCCC)C4=CC=CC=C4C(OCCCC)=C32)=N2)=NC=1N=C1[C]3C(OCCCC)=C4C=CC=CC4=C(OCCCC)C3=C2N1 BFXKASLQHBYWIJ-UHFFFAOYSA-N 0.000 description 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- UNGMOMJDNDFGJG-UHFFFAOYSA-N 5-carboxy-X-rhodamine Chemical compound [O-]C(=O)C1=CC(C(=O)O)=CC=C1C1=C(C=C2C3=C4CCCN3CCC2)C4=[O+]C2=C1C=C1CCCN3CCCC2=C13 UNGMOMJDNDFGJG-UHFFFAOYSA-N 0.000 description 1
- IPJDHSYCSQAODE-UHFFFAOYSA-N 5-chloromethylfluorescein diacetate Chemical compound O1C(=O)C2=CC(CCl)=CC=C2C21C1=CC=C(OC(C)=O)C=C1OC1=CC(OC(=O)C)=CC=C21 IPJDHSYCSQAODE-UHFFFAOYSA-N 0.000 description 1
- ZMERMCRYYFRELX-UHFFFAOYSA-N 5-{[2-(iodoacetamido)ethyl]amino}naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1NCCNC(=O)CI ZMERMCRYYFRELX-UHFFFAOYSA-N 0.000 description 1
- NNCKENWXWWOUHN-UHFFFAOYSA-M 54-chloro-13,26,39,52,53,55,56,57-octaza-54-gallatetradecacyclo[25.25.3.114,25.140,51.02,11.04,9.012,53.015,24.017,22.028,37.030,35.038,55.041,50.043,48]heptapentaconta-1,3,5,7,9,11,13,15,17,19,21,23,25(57),26,28,30,32,34,36,38,40(56),41,43,45,47,49,51-heptacosaene Chemical compound N1=C(C2=CC3=CC=CC=C3C=C2C2=NC=3C4=CC5=CC=CC=C5C=C4C(=N4)N=3)N2[Ga](Cl)N2C4=C(C=C3C(C=CC=C3)=C3)C3=C2N=C2C3=CC4=CC=CC=C4C=C3C1=N2 NNCKENWXWWOUHN-UHFFFAOYSA-M 0.000 description 1
- VDBJCDWTNCKRTF-UHFFFAOYSA-N 6'-hydroxyspiro[2-benzofuran-3,9'-9ah-xanthene]-1,3'-dione Chemical compound O1C(=O)C2=CC=CC=C2C21C1C=CC(=O)C=C1OC1=CC(O)=CC=C21 VDBJCDWTNCKRTF-UHFFFAOYSA-N 0.000 description 1
- VJXSSYDSOJBUAV-UHFFFAOYSA-N 6-(2,5-dimethoxy-benzyl)-5-methyl-pyrido[2,3-d]pyrimidine-2,4-diamine Chemical compound COC1=CC=C(OC)C(CC=2C(=C3C(N)=NC(N)=NC3=NC=2)C)=C1 VJXSSYDSOJBUAV-UHFFFAOYSA-N 0.000 description 1
- HWQQCFPHXPNXHC-UHFFFAOYSA-N 6-[(4,6-dichloro-1,3,5-triazin-2-yl)amino]-3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound C=1C(O)=CC=C2C=1OC1=CC(O)=CC=C1C2(C1=CC=2)OC(=O)C1=CC=2NC1=NC(Cl)=NC(Cl)=N1 HWQQCFPHXPNXHC-UHFFFAOYSA-N 0.000 description 1
- WYXSYVWAUAUWLD-SHUUEZRQSA-N 6-azauridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=N1 WYXSYVWAUAUWLD-SHUUEZRQSA-N 0.000 description 1
- YCWQAMGASJSUIP-YFKPBYRVSA-N 6-diazo-5-oxo-L-norleucine Chemical compound OC(=O)[C@@H](N)CCC(=O)C=[N+]=[N-] YCWQAMGASJSUIP-YFKPBYRVSA-N 0.000 description 1
- 229960005538 6-diazo-5-oxo-L-norleucine Drugs 0.000 description 1
- FWEOQOXTVHGIFQ-UHFFFAOYSA-N 8-anilinonaphthalene-1-sulfonic acid Chemical compound C=12C(S(=O)(=O)O)=CC=CC2=CC=CC=1NC1=CC=CC=C1 FWEOQOXTVHGIFQ-UHFFFAOYSA-N 0.000 description 1
- SGAOZXGJGQEBHA-UHFFFAOYSA-N 82344-98-7 Chemical compound C1CCN2CCCC(C=C3C4(OC(C5=CC(=CC=C54)N=C=S)=O)C4=C5)=C2C1=C3OC4=C1CCCN2CCCC5=C12 SGAOZXGJGQEBHA-UHFFFAOYSA-N 0.000 description 1
- WSMFVFRKDITEGM-UHFFFAOYSA-N 83484-76-8 Chemical compound C=1C=C(OC=2C=C3C=4N=C(N=C5NC(C6=CC=C(OC=7C=CC(=CC=7)C(C)(C)C=7C=CC=CC=7)C=C65)=NC5=NC(C6=CC=C(OC=7C=CC(=CC=7)C(C)(C)C=7C=CC=CC=7)C=C65)=NC=5NC(=C6C=CC(OC=7C=CC(=CC=7)C(C)(C)C=7C=CC=CC=7)=CC6=5)N=4)C3=CC=2)C=CC=1C(C)(C)C1=CC=CC=C1 WSMFVFRKDITEGM-UHFFFAOYSA-N 0.000 description 1
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 1
- HDZZVAMISRMYHH-UHFFFAOYSA-N 9beta-Ribofuranosyl-7-deazaadenin Natural products C1=CC=2C(N)=NC=NC=2N1C1OC(CO)C(O)C1O HDZZVAMISRMYHH-UHFFFAOYSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 108010000239 Aequorin Proteins 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- MWNLTKCQHFZFHN-UHFFFAOYSA-N CBQCA reagent Chemical compound C1=CC(C(=O)O)=CC=C1C(=O)C1=CC2=CC=CC=C2N=C1C=O MWNLTKCQHFZFHN-UHFFFAOYSA-N 0.000 description 1
- FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- SHHKQEUPHAENFK-UHFFFAOYSA-N Carboquone Chemical compound O=C1C(C)=C(N2CC2)C(=O)C(C(COC(N)=O)OC)=C1N1CC1 SHHKQEUPHAENFK-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- MKQWTWSXVILIKJ-LXGUWJNJSA-N Chlorozotocin Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)NC(=O)N(N=O)CCCl MKQWTWSXVILIKJ-LXGUWJNJSA-N 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 208000009798 Craniopharyngioma Diseases 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 102100021906 Cyclin-O Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- BRDJPCFGLMKJRU-UHFFFAOYSA-N DDAO Chemical compound ClC1=C(O)C(Cl)=C2C(C)(C)C3=CC(=O)C=CC3=NC2=C1 BRDJPCFGLMKJRU-UHFFFAOYSA-N 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- AADVCYNFEREWOS-OBRABYBLSA-N Discodermolide Chemical compound C=C\C=C/[C@H](C)[C@H](OC(N)=O)[C@@H](C)[C@H](O)[C@@H](C)C\C(C)=C/[C@H](C)[C@@H](O)[C@@H](C)\C=C/[C@@H](O)C[C@@H]1OC(=O)[C@H](C)[C@@H](O)[C@H]1C AADVCYNFEREWOS-OBRABYBLSA-N 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 description 1
- XOZIUKBZLSUILX-SDMHVBBESA-N Epothilone D Natural products O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C(/C)=C/C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C XOZIUKBZLSUILX-SDMHVBBESA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- OZLGRUXZXMRXGP-UHFFFAOYSA-N Fluo-3 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(Cl)C(=O)C=C3OC3=CC(O)=C(Cl)C=C32)N(CC(O)=O)CC(O)=O)=C1 OZLGRUXZXMRXGP-UHFFFAOYSA-N 0.000 description 1
- OUVXYXNWSVIOSJ-UHFFFAOYSA-N Fluo-4 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)N(CC(O)=O)CC(O)=O)=C1 OUVXYXNWSVIOSJ-UHFFFAOYSA-N 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 229940123414 Folate antagonist Drugs 0.000 description 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
- 102100023328 G-protein coupled estrogen receptor 1 Human genes 0.000 description 1
- 102220566453 GDNF family receptor alpha-1_Y66F_mutation Human genes 0.000 description 1
- 102220566451 GDNF family receptor alpha-1_Y66H_mutation Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000897441 Homo sapiens Cyclin-O Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- FGBAVQUHSKYMTC-UHFFFAOYSA-M LDS 751 dye Chemical compound [O-]Cl(=O)(=O)=O.C1=CC2=CC(N(C)C)=CC=C2[N+](CC)=C1C=CC=CC1=CC=C(N(C)C)C=C1 FGBAVQUHSKYMTC-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 102000006830 Luminescent Proteins Human genes 0.000 description 1
- 108010047357 Luminescent Proteins Proteins 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 description 1
- 190000032366 Miboplatin Chemical compound 0.000 description 1
- VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
- HRHKSTOGXBBQCB-UHFFFAOYSA-N Mitomycin E Natural products O=C1C(N)=C(C)C(=O)C2=C1C(COC(N)=O)C1(OC)C3N(C)C3CN12 HRHKSTOGXBBQCB-UHFFFAOYSA-N 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- SNIXRMIHFOIVBB-UHFFFAOYSA-N N-Hydroxyl-tryptamine Chemical compound C1=CC=C2C(CCNO)=CNC2=C1 SNIXRMIHFOIVBB-UHFFFAOYSA-N 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- AFLXUQUGROGEFA-UHFFFAOYSA-N Nitrogen mustard N-oxide Chemical compound ClCC[N+]([O-])(C)CCCl AFLXUQUGROGEFA-UHFFFAOYSA-N 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- HBPQPBSTHOHSFP-UHFFFAOYSA-N OC(=O)C([Pt])=O Chemical compound OC(=O)C([Pt])=O HBPQPBSTHOHSFP-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010067572 Oestrogenic effect Diseases 0.000 description 1
- 229930187135 Olivomycin Natural products 0.000 description 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 108010057150 Peplomycin Proteins 0.000 description 1
- 229920005439 Perspex® Polymers 0.000 description 1
- 108010009711 Phalloidine Proteins 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- AHHFEZNOXOZZQA-ZEBDFXRSSA-N Ranimustine Chemical compound CO[C@H]1O[C@H](CNC(=O)N(CCCl)N=O)[C@@H](O)[C@H](O)[C@H]1O AHHFEZNOXOZZQA-ZEBDFXRSSA-N 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 229920000398 Thiolyte Polymers 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 208000033781 Thyroid carcinoma Diseases 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 235000015724 Trifolium pratense Nutrition 0.000 description 1
- FYAMXEPQQLNQDM-UHFFFAOYSA-N Tris(1-aziridinyl)phosphine oxide Chemical compound C1CN1P(N1CC1)(=O)N1CC1 FYAMXEPQQLNQDM-UHFFFAOYSA-N 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- APJYDQYYACXCRM-UHFFFAOYSA-N Tryptamine Natural products C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 1
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 1
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- VGQOVCHZGQWAOI-UHFFFAOYSA-N UNPD55612 Natural products N1C(O)C2CC(C=CC(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-UHFFFAOYSA-N 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 241000021375 Xenogenes Species 0.000 description 1
- 229910052769 Ytterbium Inorganic materials 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- SPJCRMJCFSJKDE-ZWBUGVOYSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] 2-[4-[bis(2-chloroethyl)amino]phenyl]acetate Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)C(=O)CC1=CC=C(N(CCCl)CCCl)C=C1 SPJCRMJCFSJKDE-ZWBUGVOYSA-N 0.000 description 1
- ZYVSOIYQKUDENJ-UHFFFAOYSA-N [6-[[6-[4-[4-(5-acetyloxy-4-hydroxy-4,6-dimethyloxan-2-yl)oxy-5-hydroxy-6-methyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-7-(3,4-dihydroxy-1-methoxy-2-oxopentyl)-4,10-dihydroxy-3-methyl-5-oxo-7,8-dihydro-6h-anthracen-2-yl]oxy]-4-(4-hydroxy-5-methoxy-6 Chemical compound CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(OC(C)=O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1OC(C)=O)CC1OC1CC(O)C(OC)C(C)O1 ZYVSOIYQKUDENJ-UHFFFAOYSA-N 0.000 description 1
- PCLONZCDFMRSKV-UHFFFAOYSA-N ac1muxpu Chemical compound [Co+2].[N-]1C(N=C2C3=CC4=CC=CC=C4C=C3C(N=C3C4=CC5=CC=CC=C5C=C4C(=N4)[N-]3)=N2)=C(C=C2C(C=CC=C2)=C2)C2=C1N=C1C2=CC3=CC=CC=C3C=C2C4=N1 PCLONZCDFMRSKV-UHFFFAOYSA-N 0.000 description 1
- YQDBXZVRLZUHQK-UHFFFAOYSA-N ac1n5wkz Chemical compound [Zn+2].[N-]1C(N=C2C3=CC=C(C=C3C(N=C3C4=CC=C(C=C4C(=N4)[N-]3)[N+]([O-])=O)=N2)[N+]([O-])=O)=C(C=C(C=C2)[N+]([O-])=O)C2=C1N=C1C2=CC([N+](=O)[O-])=CC=C2C4=N1 YQDBXZVRLZUHQK-UHFFFAOYSA-N 0.000 description 1
- UZSWDSNUYFMFRO-UHFFFAOYSA-L ac1nlv6u Chemical compound Cl[Ti]Cl.[N-]1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)[N-]3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 UZSWDSNUYFMFRO-UHFFFAOYSA-L 0.000 description 1
- RZUBARUFLYGOGC-MTHOTQAESA-L acid fuchsin Chemical compound [Na+].[Na+].[O-]S(=O)(=O)C1=C(N)C(C)=CC(C(=C\2C=C(C(=[NH2+])C=C/2)S([O-])(=O)=O)\C=2C=C(C(N)=CC=2)S([O-])(=O)=O)=C1 RZUBARUFLYGOGC-MTHOTQAESA-L 0.000 description 1
- 229930188522 aclacinomycin Natural products 0.000 description 1
- LJZPVWKMAYDYAS-QKKPTTNWSA-N aclacinomycin T Chemical class O([C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)[C@H]1C[C@H](N(C)C)[C@H](O)[C@H](C)O1 LJZPVWKMAYDYAS-QKKPTTNWSA-N 0.000 description 1
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 1
- IVHDZUFNZLETBM-IWSIBTJSSA-N acridine red 3B Chemical compound [Cl-].C1=C\C(=[NH+]/C)C=C2OC3=CC(NC)=CC=C3C=C21 IVHDZUFNZLETBM-IWSIBTJSSA-N 0.000 description 1
- BGLGAKMTYHWWKW-UHFFFAOYSA-N acridine yellow Chemical compound [H+].[Cl-].CC1=C(N)C=C2N=C(C=C(C(C)=C3)N)C3=CC2=C1 BGLGAKMTYHWWKW-UHFFFAOYSA-N 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229940064305 adrucil Drugs 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229960001445 alitretinoin Drugs 0.000 description 1
- RGCKGOZRHPZPFP-UHFFFAOYSA-N alizarin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 description 1
- PWIGYBONXWGOQE-UHFFFAOYSA-N alizarin complexone Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C=C(CN(CC(O)=O)CC(=O)O)C(O)=C2O PWIGYBONXWGOQE-UHFFFAOYSA-N 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 229940098174 alkeran Drugs 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- BBDAGFIXKZCXAH-CCXZUQQUSA-N ancitabine Chemical compound N=C1C=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3OC2=N1 BBDAGFIXKZCXAH-CCXZUQQUSA-N 0.000 description 1
- 229950000242 ancitabine Drugs 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- VGQOVCHZGQWAOI-HYUHUPJXSA-N anthramycin Chemical compound N1[C@@H](O)[C@@H]2CC(\C=C\C(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-HYUHUPJXSA-N 0.000 description 1
- 239000000611 antibody drug conjugate Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 229940078010 arimidex Drugs 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- JPIYZTWMUGTEHX-UHFFFAOYSA-N auramine O free base Chemical compound C1=CC(N(C)C)=CC=C1C(=N)C1=CC=C(N(C)C)C=C1 JPIYZTWMUGTEHX-UHFFFAOYSA-N 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- 229950011321 azaserine Drugs 0.000 description 1
- 229950005567 benzodepa Drugs 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- VFIUCBTYGKMLCM-UHFFFAOYSA-N benzyl n-[bis(aziridin-1-yl)phosphoryl]carbamate Chemical compound C=1C=CC=CC=1COC(=O)NP(=O)(N1CC1)N1CC1 VFIUCBTYGKMLCM-UHFFFAOYSA-N 0.000 description 1
- OJVABJMSSDUECT-UHFFFAOYSA-L berberin sulfate Chemical compound [O-]S([O-])(=O)=O.C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2.C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 OJVABJMSSDUECT-UHFFFAOYSA-L 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 229960002938 bexarotene Drugs 0.000 description 1
- 229940108502 bicnu Drugs 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 201000007180 bile duct carcinoma Diseases 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 108091005948 blue fluorescent proteins Proteins 0.000 description 1
- 210000000120 body fluid compartment Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 108700002839 cactinomycin Proteins 0.000 description 1
- 229950009908 cactinomycin Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 208000029499 cancer-related condition Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000298 carbocyanine Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 229960002115 carboquone Drugs 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- XREUEWVEMYWFFA-CSKJXFQVSA-N carminomycin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XREUEWVEMYWFFA-CSKJXFQVSA-N 0.000 description 1
- XREUEWVEMYWFFA-UHFFFAOYSA-N carminomycin I Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XREUEWVEMYWFFA-UHFFFAOYSA-N 0.000 description 1
- 229960003261 carmofur Drugs 0.000 description 1
- 229950001725 carubicin Drugs 0.000 description 1
- 108010047060 carzinophilin Proteins 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 230000027448 caveolin-mediated endocytosis Effects 0.000 description 1
- 229940047495 celebrex Drugs 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 201000007455 central nervous system cancer Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- NAXWWTPJXAIEJE-UHFFFAOYSA-N chembl1398678 Chemical compound C1=CC=CC2=C(O)C(N=NC3=CC=C(C=C3)C3=NC4=CC=C(C(=C4S3)S(O)(=O)=O)C)=CC(S(O)(=O)=O)=C21 NAXWWTPJXAIEJE-UHFFFAOYSA-N 0.000 description 1
- HQKOBNMULFASAN-UHFFFAOYSA-N chembl1991515 Chemical compound OC1=CC=C(Cl)C=C1N=NC1=C(O)C=CC2=CC=CC=C12 HQKOBNMULFASAN-UHFFFAOYSA-N 0.000 description 1
- YOCIQNIEQYCORH-UHFFFAOYSA-M chembl2028361 Chemical compound [Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=CC2=C1N=NC1=CC=CC=C1 YOCIQNIEQYCORH-UHFFFAOYSA-M 0.000 description 1
- 230000002113 chemopreventative effect Effects 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 229960001480 chlorozotocin Drugs 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- MPMSMUBQXQALQI-UHFFFAOYSA-N cobalt phthalocyanine Chemical compound [Co+2].C12=CC=CC=C2C(N=C2[N-]C(C3=CC=CC=C32)=N2)=NC1=NC([C]1C=CC=CC1=1)=NC=1N=C1[C]3C=CC=CC3=C2[N-]1 MPMSMUBQXQALQI-UHFFFAOYSA-N 0.000 description 1
- XLJKHNWPARRRJB-UHFFFAOYSA-N cobalt(2+) Chemical compound [Co+2] XLJKHNWPARRRJB-UHFFFAOYSA-N 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- JJIWQZDKAOMTKU-UHFFFAOYSA-N copper 5,12,18,25,31,38,44,51-octabutoxy-2,15,28,41,53,55-hexaza-54,56-diazanidatridecacyclo[40.10.1.13,14.116,27.129,40.04,13.06,11.017,26.019,24.030,39.032,37.043,52.045,50]hexapentaconta-1,3,5,7,9,11,13,15,17,19,21,23,25,27(55),28,30,32,34,36,38,40,42(53),43,45,47,49,51-heptacosaene Chemical compound [Cu+2].C=12C(OCCCC)=C3C=CC=C[C]3C(OCCCC)=C2C(N=C2[N-]C(C3=C(OCCCC)C4=CC=CC=C4C(OCCCC)=C32)=NC2=NC(C3=C(OCCCC)C4=CC=CC=C4C(OCCCC)=C32)=N2)=NC=1N=C1[C]3C(OCCCC)=C4C=CC=CC4=C(OCCCC)C3=C2[N-]1 JJIWQZDKAOMTKU-UHFFFAOYSA-N 0.000 description 1
- XCJYREBRNVKWGJ-UHFFFAOYSA-N copper(II) phthalocyanine Chemical compound [Cu+2].C12=CC=CC=C2C(N=C2[N-]C(C3=CC=CC=C32)=N2)=NC1=NC([C]1C=CC=CC1=1)=NC=1N=C1[C]3C=CC=CC3=C2[N-]1 XCJYREBRNVKWGJ-UHFFFAOYSA-N 0.000 description 1
- 229940088547 cosmegen Drugs 0.000 description 1
- AFYCEAFSNDLKSX-UHFFFAOYSA-N coumarin 460 Chemical compound CC1=CC(=O)OC2=CC(N(CC)CC)=CC=C21 AFYCEAFSNDLKSX-UHFFFAOYSA-N 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229940070968 depocyt Drugs 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- XOZIUKBZLSUILX-UHFFFAOYSA-N desoxyepothilone B Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC(C)=CCC1C(C)=CC1=CSC(C)=N1 XOZIUKBZLSUILX-UHFFFAOYSA-N 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- HQQKMOJOCZFMSV-UHFFFAOYSA-N dilithium phthalocyanine Chemical compound [Li+].[Li+].C12=CC=CC=C2C(N=C2[N-]C(C3=CC=CC=C32)=N2)=NC1=NC([C]1C=CC=CC1=1)=NC=1N=C1[C]3C=CC=CC3=C2[N-]1 HQQKMOJOCZFMSV-UHFFFAOYSA-N 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- HRMOLDWRTCFZRP-UHFFFAOYSA-L disodium 5-acetamido-3-[(4-acetamidophenyl)diazenyl]-4-hydroxynaphthalene-2,7-disulfonate Chemical compound [Na+].OC1=C(C(=CC2=CC(=CC(=C12)NC(C)=O)S(=O)(=O)[O-])S(=O)(=O)[O-])N=NC1=CC=C(C=C1)NC(C)=O.[Na+] HRMOLDWRTCFZRP-UHFFFAOYSA-L 0.000 description 1
- BMAUDWDYKLUBPY-UHFFFAOYSA-L disodium;3-[[4-[(4,6-dichloro-1,3,5-triazin-2-yl)amino]-2-methylphenyl]diazenyl]naphthalene-1,5-disulfonate Chemical compound [Na+].[Na+].C=1C=C(N=NC=2C=C3C(=CC=CC3=C(C=2)S([O-])(=O)=O)S([O-])(=O)=O)C(C)=CC=1NC1=NC(Cl)=NC(Cl)=N1 BMAUDWDYKLUBPY-UHFFFAOYSA-L 0.000 description 1
- BDYOOAPDMVGPIQ-QDBORUFSSA-L disodium;5-[(4-anilino-6-methoxy-1,3,5-triazin-2-yl)amino]-2-[(e)-2-[4-[(4-anilino-6-methoxy-1,3,5-triazin-2-yl)amino]-2-sulfonatophenyl]ethenyl]benzenesulfonate Chemical compound [Na+].[Na+].N=1C(NC=2C=C(C(\C=C\C=3C(=CC(NC=4N=C(OC)N=C(NC=5C=CC=CC=5)N=4)=CC=3)S([O-])(=O)=O)=CC=2)S([O-])(=O)=O)=NC(OC)=NC=1NC1=CC=CC=C1 BDYOOAPDMVGPIQ-QDBORUFSSA-L 0.000 description 1
- MNQDKWZEUULFPX-UHFFFAOYSA-M dithiazanine iodide Chemical compound [I-].S1C2=CC=CC=C2[N+](CC)=C1C=CC=CC=C1N(CC)C2=CC=CC=C2S1 MNQDKWZEUULFPX-UHFFFAOYSA-M 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
- 229950005454 doxifluridine Drugs 0.000 description 1
- 229940115080 doxil Drugs 0.000 description 1
- FSIRXIHZBIXHKT-MHTVFEQDSA-N edatrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CC(CC)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FSIRXIHZBIXHKT-MHTVFEQDSA-N 0.000 description 1
- 229950006700 edatrexate Drugs 0.000 description 1
- 230000000235 effect on cancer Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229940087477 ellence Drugs 0.000 description 1
- 229940000733 emcyt Drugs 0.000 description 1
- 229910052876 emerald Inorganic materials 0.000 description 1
- 239000010976 emerald Substances 0.000 description 1
- 229950005450 emitefur Drugs 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 108010045262 enhanced cyan fluorescent protein Proteins 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 description 1
- QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 description 1
- XOZIUKBZLSUILX-GIQCAXHBSA-N epothilone D Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C(C)=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 XOZIUKBZLSUILX-GIQCAXHBSA-N 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- IIUMCNJTGSMNRO-VVSKJQCTSA-L estramustine sodium phosphate Chemical compound [Na+].[Na+].ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP([O-])([O-])=O)[C@@H]4[C@@H]3CCC2=C1 IIUMCNJTGSMNRO-VVSKJQCTSA-L 0.000 description 1
- 239000002834 estrogen receptor modulator Substances 0.000 description 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- NNMXSTWQJRPBJZ-UHFFFAOYSA-K europium(iii) chloride Chemical compound Cl[Eu](Cl)Cl NNMXSTWQJRPBJZ-UHFFFAOYSA-K 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229940087861 faslodex Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229940087476 femara Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 125000004387 flavanoid group Chemical group 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 1
- 238000002875 fluorescence polarization Methods 0.000 description 1
- 238000012632 fluorescent imaging Methods 0.000 description 1
- 108010021843 fluorescent protein 583 Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
- 229960004783 fotemustine Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 229950011595 glufosfamide Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000001046 green dye Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000009033 hematopoietic malignancy Effects 0.000 description 1
- 208000006359 hepatoblastoma Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 229940088013 hycamtin Drugs 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine group Chemical group NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- 229940096120 hydrea Drugs 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 229940099279 idamycin Drugs 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229950008097 improsulfan Drugs 0.000 description 1
- DBIGHPPNXATHOF-UHFFFAOYSA-N improsulfan Chemical compound CS(=O)(=O)OCCCNCCCOS(C)(=O)=O DBIGHPPNXATHOF-UHFFFAOYSA-N 0.000 description 1
- PNDZEEPOYCVIIY-UHFFFAOYSA-N indo-1 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C=2N=C3[CH]C(=CC=C3C=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 PNDZEEPOYCVIIY-UHFFFAOYSA-N 0.000 description 1
- 229960004657 indocyanine green Drugs 0.000 description 1
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000002977 intracellular fluid Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 1
- 201000010985 invasive ductal carcinoma Diseases 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 229940063725 leukeran Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- XJENLUNLXRJLEZ-UHFFFAOYSA-M lissamine rhodamine Chemical compound [Na+].C=12C=C(C)C(N(CC)CC)=CC2=[O+]C=2C=C(N(CC)CC)C(C)=CC=2C=1C1=CC=C(S([O-])(=O)=O)C=C1S([O-])(=O)=O XJENLUNLXRJLEZ-UHFFFAOYSA-M 0.000 description 1
- IOOMXAQUNPWDLL-UHFFFAOYSA-M lissamine rhodamine anion Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S([O-])(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-M 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- DLBFLQKQABVKGT-UHFFFAOYSA-L lucifer yellow dye Chemical compound [Li+].[Li+].[O-]S(=O)(=O)C1=CC(C(N(C(=O)NN)C2=O)=O)=C3C2=CC(S([O-])(=O)=O)=CC3=C1N DLBFLQKQABVKGT-UHFFFAOYSA-L 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 201000009546 lung large cell carcinoma Diseases 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- NGCVJRFIBJVSFI-UHFFFAOYSA-I magnesium green Chemical compound [K+].[K+].[K+].[K+].[K+].C1=C(N(CC([O-])=O)CC([O-])=O)C(OCC(=O)[O-])=CC(NC(=O)C=2C=C3C(C4(C5=CC(Cl)=C([O-])C=C5OC5=CC([O-])=C(Cl)C=C54)OC3=O)=CC=2)=C1 NGCVJRFIBJVSFI-UHFFFAOYSA-I 0.000 description 1
- LBAIJNRSTQHDMR-UHFFFAOYSA-N magnesium phthalocyanine Chemical compound [Mg].C12=CC=CC=C2C(N=C2NC(C3=CC=CC=C32)=N2)=NC1=NC([C]1C=CC=CC1=1)=NC=1N=C1[C]3C=CC=CC3=C2N1 LBAIJNRSTQHDMR-UHFFFAOYSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000031852 maintenance of location in cell Effects 0.000 description 1
- 229940107698 malachite green Drugs 0.000 description 1
- FDZZZRQASAIRJF-UHFFFAOYSA-M malachite green Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](C)C)C=C1 FDZZZRQASAIRJF-UHFFFAOYSA-M 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- ICIFYHOILPYQKB-UHFFFAOYSA-N manganese(ii) phthalocyanine Chemical compound [Mn+2].[N-]1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)[N-]3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 ICIFYHOILPYQKB-UHFFFAOYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229950008612 mannomustine Drugs 0.000 description 1
- MQXVYODZCMMZEM-ZYUZMQFOSA-N mannomustine Chemical compound ClCCNC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CNCCCl MQXVYODZCMMZEM-ZYUZMQFOSA-N 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 208000000516 mast-cell leukemia Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229940087732 matulane Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108091008588 membrane estrogen receptors Proteins 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 229950002676 menogaril Drugs 0.000 description 1
- LWYJUZBXGAFFLP-OCNCTQISSA-N menogaril Chemical compound O1[C@@]2(C)[C@H](O)[C@@H](N(C)C)[C@H](O)[C@@H]1OC1=C3C(=O)C(C=C4C[C@@](C)(O)C[C@H](C4=C4O)OC)=C4C(=O)C3=C(O)C=C12 LWYJUZBXGAFFLP-OCNCTQISSA-N 0.000 description 1
- 229960000901 mepacrine Drugs 0.000 description 1
- 229960004635 mesna Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- DWCZIOOZPIDHAB-UHFFFAOYSA-L methyl green Chemical compound [Cl-].[Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC(=CC=1)[N+](C)(C)C)=C1C=CC(=[N+](C)C)C=C1 DWCZIOOZPIDHAB-UHFFFAOYSA-L 0.000 description 1
- VWKNUUOGGLNRNZ-UHFFFAOYSA-N methylbimane Chemical compound CC1=C(C)C(=O)N2N1C(C)=C(C)C2=O VWKNUUOGGLNRNZ-UHFFFAOYSA-N 0.000 description 1
- HRHKSTOGXBBQCB-VFWICMBZSA-N methylmitomycin Chemical compound O=C1C(N)=C(C)C(=O)C2=C1[C@@H](COC(N)=O)[C@@]1(OC)[C@H]3N(C)[C@H]3CN12 HRHKSTOGXBBQCB-VFWICMBZSA-N 0.000 description 1
- DHBHEIQCZVJYBO-UHFFFAOYSA-N methylsilicon(iv) phthalocyanine chloride Chemical compound N1=C(C2=CC=CC=C2C2=NC=3C4=CC=CC=C4C(=N4)N=3)N2[Si](C)(Cl)N2C4=C(C=CC=C3)C3=C2N=C2C3=CC=CC=C3C1=N2 DHBHEIQCZVJYBO-UHFFFAOYSA-N 0.000 description 1
- 229950009847 meturedepa Drugs 0.000 description 1
- QTFKTBRIGWJQQL-UHFFFAOYSA-N meturedepa Chemical compound C1C(C)(C)N1P(=O)(NC(=O)OCC)N1CC1(C)C QTFKTBRIGWJQQL-UHFFFAOYSA-N 0.000 description 1
- 229950002777 miboplatin Drugs 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 231100000782 microtubule inhibitor Toxicity 0.000 description 1
- FZTMEYOUQQFBJR-UHFFFAOYSA-M mitoTracker Orange Chemical compound [Cl-].C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C1=CC=C(CCl)C=C1 FZTMEYOUQQFBJR-UHFFFAOYSA-M 0.000 description 1
- IKEOZQLIVHGQLJ-UHFFFAOYSA-M mitoTracker Red Chemical compound [Cl-].C1=CC(CCl)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 IKEOZQLIVHGQLJ-UHFFFAOYSA-M 0.000 description 1
- 229960005485 mitobronitol Drugs 0.000 description 1
- 229950010913 mitolactol Drugs 0.000 description 1
- VFKZTMPDYBFSTM-GUCUJZIJSA-N mitolactol Chemical compound BrC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-GUCUJZIJSA-N 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- PRMHOXAMWFXGCO-UHFFFAOYSA-M molport-000-691-708 Chemical compound N1=C(C2=CC=CC=C2C2=NC=3C4=CC=CC=C4C(=N4)N=3)N2[Ga](Cl)N2C4=C(C=CC=C3)C3=C2N=C2C3=CC=CC=C3C1=N2 PRMHOXAMWFXGCO-UHFFFAOYSA-M 0.000 description 1
- SUIPVTCEECPFIB-UHFFFAOYSA-N monochlorobimane Chemical compound ClCC1=C(C)C(=O)N2N1C(C)=C(C)C2=O SUIPVTCEECPFIB-UHFFFAOYSA-N 0.000 description 1
- 229940125645 monoclonal antibody drug Drugs 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 208000001611 myxosarcoma Diseases 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- VMCOQLKKSNQANE-UHFFFAOYSA-N n,n-dimethyl-4-[6-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-benzimidazol-2-yl]aniline Chemical compound C1=CC(N(C)C)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 VMCOQLKKSNQANE-UHFFFAOYSA-N 0.000 description 1
- 229940086322 navelbine Drugs 0.000 description 1
- QZGIWPZCWHMVQL-UIYAJPBUSA-N neocarzinostatin chromophore Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 1
- 208000025189 neoplasm of testis Diseases 0.000 description 1
- LVIYYTJTOKJJOC-UHFFFAOYSA-N nickel phthalocyanine Chemical compound [Ni+2].C12=CC=CC=C2C(N=C2[N-]C(C3=CC=CC=C32)=N2)=NC1=NC([C]1C=CC=CC1=1)=NC=1N=C1[C]3C=CC=CC3=C2[N-]1 LVIYYTJTOKJJOC-UHFFFAOYSA-N 0.000 description 1
- VOFUROIFQGPCGE-UHFFFAOYSA-N nile red Chemical compound C1=CC=C2C3=NC4=CC=C(N(CC)CC)C=C4OC3=CC(=O)C2=C1 VOFUROIFQGPCGE-UHFFFAOYSA-N 0.000 description 1
- 229960001420 nimustine Drugs 0.000 description 1
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
- 229940109551 nipent Drugs 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- KGTDRFCXGRULNK-JYOBTZKQSA-N nogalamycin Chemical compound CO[C@@H]1[C@@](OC)(C)[C@@H](OC)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=C4[C@@]5(C)O[C@H]([C@H]([C@@H]([C@H]5O)N(C)C)O)OC4=C3C3=O)=C3C=C2[C@@H](C(=O)OC)[C@@](C)(O)C1 KGTDRFCXGRULNK-JYOBTZKQSA-N 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 108091008589 nuclear estrogen receptors Proteins 0.000 description 1
- 102000006255 nuclear receptors Human genes 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 239000002777 nucleoside Chemical class 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 150000002889 oleic acids Chemical class 0.000 description 1
- CZDBNBLGZNWKMC-MWQNXGTOSA-N olivomycin Chemical class O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1)O[C@H]1O[C@@H](C)[C@H](O)[C@@H](OC2O[C@@H](C)[C@H](O)[C@@H](O)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@H](O)[C@H](OC)[C@H](C)O1 CZDBNBLGZNWKMC-MWQNXGTOSA-N 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- VYNDHICBIRRPFP-UHFFFAOYSA-N pacific blue Chemical compound FC1=C(O)C(F)=C2OC(=O)C(C(=O)O)=CC2=C1 VYNDHICBIRRPFP-UHFFFAOYSA-N 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 229940046231 pamidronate Drugs 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229940096763 panretin Drugs 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- 229950003180 peplomycin Drugs 0.000 description 1
- QIMGFXOHTOXMQP-GFAGFCTOSA-N peplomycin Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCN[C@@H](C)C=1C=CC=CC=1)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QIMGFXOHTOXMQP-GFAGFCTOSA-N 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- VPAWVRUHMJVRHU-VGDKGRGNSA-N perfosfamide Chemical compound OO[C@@H]1CCO[P@@](=O)(N(CCCl)CCCl)N1 VPAWVRUHMJVRHU-VGDKGRGNSA-N 0.000 description 1
- 229950009351 perfosfamide Drugs 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- NTGBUUXKGAZMSE-UHFFFAOYSA-N phenyl n-[4-[4-(4-methoxyphenyl)piperazin-1-yl]phenyl]carbamate Chemical compound C1=CC(OC)=CC=C1N1CCN(C=2C=CC(NC(=O)OC=3C=CC=CC=3)=CC=2)CC1 NTGBUUXKGAZMSE-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 229920002120 photoresistant polymer Polymers 0.000 description 1
- UHKHUAHIAZQAED-UHFFFAOYSA-N phthalocyaninatoiron Chemical compound [Fe].N=1C2=NC(C3=CC=CC=C33)=NC3=NC(C3=CC=CC=C33)=NC3=NC(C3=CC=CC=C33)=NC3=NC=1C1=CC=CC=C12 UHKHUAHIAZQAED-UHFFFAOYSA-N 0.000 description 1
- 239000001007 phthalocyanine dye Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- INAAIJLSXJJHOZ-UHFFFAOYSA-N pibenzimol Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(=NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 INAAIJLSXJJHOZ-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 208000024724 pineal body neoplasm Diseases 0.000 description 1
- 201000004123 pineal gland cancer Diseases 0.000 description 1
- NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 1
- 229960000952 pipobroman Drugs 0.000 description 1
- NUKCGLDCWQXYOQ-UHFFFAOYSA-N piposulfan Chemical compound CS(=O)(=O)OCCC(=O)N1CCN(C(=O)CCOS(C)(=O)=O)CC1 NUKCGLDCWQXYOQ-UHFFFAOYSA-N 0.000 description 1
- 229950001100 piposulfan Drugs 0.000 description 1
- 229960001221 pirarubicin Drugs 0.000 description 1
- 229950001030 piritrexim Drugs 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229940063179 platinol Drugs 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000889 poly(m-phenylene isophthalamide) Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950004406 porfiromycin Drugs 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960004694 prednimustine Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- RSRNHSYYBLEMOI-UHFFFAOYSA-M primuline Chemical compound [Na+].S1C2=C(S([O-])(=O)=O)C(C)=CC=C2N=C1C(C=C1S2)=CC=C1N=C2C1=CC=C(N)C=C1 RSRNHSYYBLEMOI-UHFFFAOYSA-M 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
- WOLQREOUPKZMEX-UHFFFAOYSA-N pteroyltriglutamic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(=O)NC(CCC(=O)NC(CCC(O)=O)C(O)=O)C(O)=O)C(O)=O)C=C1 WOLQREOUPKZMEX-UHFFFAOYSA-N 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 229940117820 purinethol Drugs 0.000 description 1
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 1
- KXXXUIKPSVVSAW-UHFFFAOYSA-K pyranine Chemical compound [Na+].[Na+].[Na+].C1=C2C(O)=CC(S([O-])(=O)=O)=C(C=C3)C2=C2C3=C(S([O-])(=O)=O)C=C(S([O-])(=O)=O)C2=C1 KXXXUIKPSVVSAW-UHFFFAOYSA-K 0.000 description 1
- CXZRDVVUVDYSCQ-UHFFFAOYSA-M pyronin B Chemical compound [Cl-].C1=CC(=[N+](CC)CC)C=C2OC3=CC(N(CC)CC)=CC=C3C=C21 CXZRDVVUVDYSCQ-UHFFFAOYSA-M 0.000 description 1
- GPKJTRJOBQGKQK-UHFFFAOYSA-N quinacrine Chemical compound C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 GPKJTRJOBQGKQK-UHFFFAOYSA-N 0.000 description 1
- UKOBAUFLOGFCMV-UHFFFAOYSA-N quinacrine mustard Chemical compound C1=C(Cl)C=CC2=C(NC(C)CCCN(CCCl)CCCl)C3=CC(OC)=CC=C3N=C21 UKOBAUFLOGFCMV-UHFFFAOYSA-N 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 229960004432 raltitrexed Drugs 0.000 description 1
- 229960002185 ranimustine Drugs 0.000 description 1
- 229910052761 rare earth metal Inorganic materials 0.000 description 1
- 150000002910 rare earth metals Chemical class 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 208000020615 rectal carcinoma Diseases 0.000 description 1
- 235000013526 red clover Nutrition 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- HSSLDCABUXLXKM-UHFFFAOYSA-N resorufin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3N=C21 HSSLDCABUXLXKM-UHFFFAOYSA-N 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 239000010979 ruby Substances 0.000 description 1
- 229910001750 ruby Inorganic materials 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- DYPYMMHZGRPOCK-UHFFFAOYSA-N seminaphtharhodafluor Chemical compound O1C(=O)C2=CC=CC=C2C21C(C=CC=1C3=CC=C(O)C=1)=C3OC1=CC(N)=CC=C21 DYPYMMHZGRPOCK-UHFFFAOYSA-N 0.000 description 1
- 229960003440 semustine Drugs 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- ZSOMPVKQDGLTOT-UHFFFAOYSA-J sodium green Chemical compound C[N+](C)(C)C.C[N+](C)(C)C.C[N+](C)(C)C.C[N+](C)(C)C.COC=1C=C(NC(=O)C=2C=C(C(=CC=2)C2=C3C=C(Cl)C(=O)C=C3OC3=CC([O-])=C(Cl)C=C32)C([O-])=O)C(OC)=CC=1N(CCOCC1)CCOCCOCCN1C(C(=C1)OC)=CC(OC)=C1NC(=O)C1=CC=C(C2=C3C=C(Cl)C(=O)C=C3OC3=CC([O-])=C(Cl)C=C32)C(C([O-])=O)=C1 ZSOMPVKQDGLTOT-UHFFFAOYSA-J 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- UGJCNRLBGKEGEH-UHFFFAOYSA-N sodium-binding benzofuran isophthalate Chemical compound COC1=CC=2C=C(C=3C(=CC(=CC=3)C(O)=O)C(O)=O)OC=2C=C1N(CCOCC1)CCOCCOCCN1C(C(=CC=1C=2)OC)=CC=1OC=2C1=CC=C(C(O)=O)C=C1C(O)=O UGJCNRLBGKEGEH-UHFFFAOYSA-N 0.000 description 1
- GFWRVVCDTLRWPK-KPKJPENVSA-N sofalcone Chemical compound C1=CC(OCC=C(C)C)=CC=C1\C=C\C(=O)C1=CC=C(OCC=C(C)C)C=C1OCC(O)=O GFWRVVCDTLRWPK-KPKJPENVSA-N 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- KAPOSTKECKHKAP-UHFFFAOYSA-N st51006858 Chemical compound N1=C(N=C2C3=C(OCCCC)C=CC(OCCCC)=C3C(N=C3N4)=N2)[C]2C(OCCCC)=CC=C(OCCCC)C2=C1N=C(N1)C2=C(OCCCC)C=CC(OCCCC)=C2C1=NC4=C1[C]3C(OCCCC)=CC=C1OCCCC KAPOSTKECKHKAP-UHFFFAOYSA-N 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- FQZYTYWMLGAPFJ-OQKDUQJOSA-N tamoxifen citrate Chemical compound [H+].[H+].[H+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 FQZYTYWMLGAPFJ-OQKDUQJOSA-N 0.000 description 1
- 229940099419 targretin Drugs 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- 229940061353 temodar Drugs 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- WGTODYJZXSJIAG-UHFFFAOYSA-N tetramethylrhodamine chloride Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C(O)=O WGTODYJZXSJIAG-UHFFFAOYSA-N 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- ACOJCCLIDPZYJC-UHFFFAOYSA-M thiazole orange Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1.C1=CC=C2C(C=C3N(C4=CC=CC=C4S3)C)=CC=[N+](C)C2=C1 ACOJCCLIDPZYJC-UHFFFAOYSA-M 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 1
- YFTWHEBLORWGNI-UHFFFAOYSA-N tiamiprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC(N)=NC2=C1NC=N2 YFTWHEBLORWGNI-UHFFFAOYSA-N 0.000 description 1
- 229950011457 tiamiprine Drugs 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- LLVONELOQJAYBZ-UHFFFAOYSA-N tin(ii) phthalocyanine Chemical compound N1=C(C2=CC=CC=C2C2=NC=3C4=CC=CC=C4C(=N4)N=3)N2[Sn]N2C4=C(C=CC=C3)C3=C2N=C2C3=CC=CC=C3C1=N2 LLVONELOQJAYBZ-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 229950001353 tretamine Drugs 0.000 description 1
- IUCJMVBFZDHPDX-UHFFFAOYSA-N tretamine Chemical compound C1CN1C1=NC(N2CC2)=NC(N2CC2)=N1 IUCJMVBFZDHPDX-UHFFFAOYSA-N 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229960001099 trimetrexate Drugs 0.000 description 1
- NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
- 229940086984 trisenox Drugs 0.000 description 1
- 229960000875 trofosfamide Drugs 0.000 description 1
- UMKFEPPTGMDVMI-UHFFFAOYSA-N trofosfamide Chemical compound ClCCN(CCCl)P1(=O)OCCCN1CCCl UMKFEPPTGMDVMI-UHFFFAOYSA-N 0.000 description 1
- HDZZVAMISRMYHH-LITAXDCLSA-N tubercidin Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O HDZZVAMISRMYHH-LITAXDCLSA-N 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 229960001055 uracil mustard Drugs 0.000 description 1
- 229950006929 uredepa Drugs 0.000 description 1
- SPDZFJLQFWSJGA-UHFFFAOYSA-N uredepa Chemical compound C1CN1P(=O)(NC(=O)OCC)N1CC1 SPDZFJLQFWSJGA-UHFFFAOYSA-N 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 229960000653 valrubicin Drugs 0.000 description 1
- 229940054937 valstar Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- NAWDYIZEMPQZHO-UHFFFAOYSA-N ytterbium Chemical compound [Yb] NAWDYIZEMPQZHO-UHFFFAOYSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 229950009268 zinostatin Drugs 0.000 description 1
- 229960004276 zoledronic acid Drugs 0.000 description 1
- 229940002005 zometa Drugs 0.000 description 1
- 229960000641 zorubicin Drugs 0.000 description 1
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/143—Peptides, e.g. proteins the protein being an albumin, e.g. HSA, BSA, ovalbumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the invention relates to conjugates comprising at least one isoflavone derivative bound to albumin and at least one bioactive moiety including a diagnostic agent or a therapeutic agent, the conjugate being capable of delivering the bioactive moiety into a tumor cell.
- the invention further relates to the use of said conjugate for the diagnosis and treatment of cancer.
- the detection of a target site benefits from a high signal-to-background ratio of detection agent. Therapy benefits from higher percentages of the administered therapeutic agent reaching the target site, as well as a reasonably long duration of uptake and binding. Furthermore, drug targeting spares normal cells and significantly diminishes drug-toxicity.
- Chemotherapy constitutes one of the major therapeutic approaches for the treatment of cancer, along with surgery and radiotherapy.
- anti-cancer drugs such as daunomycin and adriamycin
- these drugs are affected by the mechanisms of multi-drug resistance.
- Affinity targeting of these cytotoxic drugs to tumor cells offers an approach that might overcome some of these drawbacks.
- the targeting ratio and amount of agent delivered to a target site can be improved using targeting agents conjugated to diagnostic or therapeutic agents for preferential localization.
- a variety of materials have been developed over the years for targeted delivery of diagnostic agents and drugs. Examples include specific targeting of tumor cells with monoclonal antibody-drug conjugates (U.S. Patents No.
- albumin spherules as medicament carriers include their ease of preparation, complete removal from the body by metabolism, nonantigenicity, proven safety for intravascular administration and the capability of accommodating a wide variety of drug molecules in a relatively non-specific fashion.
- the use of albumin as a carrier of imaging probes has been described (U.S. Pat. No. 4,337,240; Kobayashi H and Brechbiel M.W. 2005 Adv. Drug Deliv. Rev. 57 2271- 2286).
- biotin-BS A-GdDTPA was used for tracking tumor stroma fibroblasts by MRI.
- histological staining by the biotinylated albumin based marker showed high specificity to myofibroblast stroma tracks.
- albumin is used as an immunogenic carrier for small molecules which are usually non immunogenic. Wang et al. J. Agric. Food. Chem., 1994, 42:1584-7, disclosed the preparation of a BSA-formononetin conjugate for the preparation of anti-formononetin antibodies.
- the present invention relates to conjugates comprising at least one isoflavone derivative bound to albumin and at least one bioactive moiety including but not limited to a diagnostic agent or a therapeutic agent, said conjugates being capable of delivering the bioactive moiety into a cell and their use for the diagnosis and treatment of cancer.
- the present invention also provides improved targeting methods where internalization and cellular retention of a bioactive moiety (e.g. a diagnostic or a therapeutic agent) are enhanced by binding of the bioactive moiety to an isoflavone- albumin conjugate. It is now disclosed that is the conjugates of the present invention are unexpectedly internalized in target cells to a greater extent and/or faster than without such internalization agent (e.g. isoflavone-albumin).
- the present invention is based in part on the unexpected discovery that the conjugation of carboxy isoflavone derivatives to albumin significantly increase the uptake of the conjugate by cancerous cell lines sensitive to isoflavone. Specifically it was shown, that an imaging agent attached to a daidzein-BSA conjugate was specifically localized in ovarian carcinoma tumor cells, and displayed prolonged retention in the tumor of up to 7 days after administration as compared to the same imaging agent attached to BSA alone. Furthermore, unexpectedly, addition of nystatin, which usually inhibits BSA cellular uptake, resulted in significant augmentation of the cellular uptake of the daidzein-BSA conjugate.
- the conjugate is regulating endocytosis by cancerous cell lines sensitive to isoflavone, involving competition between receptor mediated internalization through the binding of the carboxy isoflavone derivative and caveolae mediated internalization via binding of albumin.
- Cells sensitive to isoflavone refers to cells whose growth may be affected by isoflavones or by carboxy derivatives of isoflavones. At certain concentrations the isoflavones may enhance growth, while at other concentrations the isoflavones may result in inhibition of cancer cell growth.
- cells sensitive to isoflavone are cancer cells.
- Non limiting examples to cancer cells which are sensitive to isoflavones include ovarian carcinoma cells, colon cancer cells, breast cancer cells, melanoma, non-small lung cancer, leukemia, endometrial cancer and prostate cancer cells.
- cells sensitive to isoflavone may also be estrogen sensitive cells.
- cells sensitive to isoflavone are cells expressing an estrogen receptor.
- the cells sensitive to isoflavone are cells expressing a nuclear or putative membranal estrogen receptor subtype ⁇ .
- cell sensitive to isoflavone are cells susceptible to isoflavone.
- the present invention provides a conjugate comprising at. least one isoflavone derivative bound to albumin and at least one compound D, the conjugate represented by the structure of general formula (I): Albumin — Dn 1
- D is a active agent selected from the group consisting of a diagnostic agent (e.g. an imaging agent) and a therapeutic agent;
- R 7 is selected from the group consisting Of Cj-C 6 alkylene, (C 2 -C 2 o) alkenylene; and (C 2 -C 20 ) heteroalkylene;
- the conjugate of the invention is capable of delivering the bioactive moiety into a cell sensitive to isoflavone.
- the conjugate displays improved properties having at least one of increased partition into a cancer cell (e.g.
- conjugates of the invention comprising an isoflavone bound to albumin and a bioactive moiety bound to the isoflavone, albumin or both, have improved qualities selected from partition to the tumor, tumor retention and circulation time compared to the bioactive moiety alone, the bioactive moiety bound to albumin, or the bioactive moiety bound to isoflavone.
- the isoflavone derivative is selected from a derivative of diadzein, genistein, formononetin and biochanin A.
- the isoflavone derivative is daidzein derivative.
- the carboxy-isoflavone derivative is selected from the group consisting of 7-(O)-carboxymethyl daidzein, 6-carboxymethyl biochanin A, 2-carboxyalkyl biochanin A, 8-carboxymethyl biochanin A, 7-(O)- carboxymethyl formononetin, 2-carboxyalkyl genistein and 6-carboxymethyl genistein.
- the carboxy-isoflavone derivative is 2- carboxyalkyl biochanin A.
- the carboxy-isoflavone derivative is 6-carboxymethyl biochanin A.
- the carboxy-isoflavone derivative is 8-carboxymethyl biochanin A.
- the carboxy-isoflavone derivative is 7-(O)-carboxymethyl daidzein (i.e., R 1 is -0-CH 2 -C(O)- and R 2 - R 6 are all -H).
- D is an imaging agent selected from, yet not restricted to paramagnetic particles (such as gadolinium, yttrium, lutetium, europium and gallinium); radioactive moieties (such as radioactive indium, rhenium and technetium); fluorescent dyes (such as fluorescein isothiocyanate (FITC), green fluorescent protein (GFP), Cyan fluorescent protein
- paramagnetic particles such as gadolinium, yttrium, lutetium, europium and gallinium
- radioactive moieties such as radioactive indium, rhenium and technetium
- fluorescent dyes such as fluorescein isothiocyanate (FITC), green fluorescent protein (GFP), Cyan fluorescent protein
- the paramagnetic particles as well as the radioactive moieties can be provided within a chelator.
- chelators include: tetraazacyclododecanetetraacetic acid (DOTA), mercaptoacetylglycylglycyl-glycine (MAG3), diethylenetriamine pentaacetic acid (DTPA) and N-l- ⁇ -isothiocyanatopheny ⁇ diethylenetriamine-N ⁇ N ⁇ N 3 - tetraacetate(DTTA).
- D is a therapeutic agent selected from the group consisting of a cytotoxic compound, a cytostatic compound, an antisense compound and an anti-viral agent. According to some embodiments, D is a cytotoxic compound.
- the cytotoxic compound D is selected from, but not restricted to DNA synthesis and function inhibitory agents (such as adriamycin, bleomycin, chlorambucil, cisplatin, carboplatin, oxaloplatin, daunomycin, ifosfamide and melphalan); microtubule (mitotic spindle) formation and function inhibitory agents (such as vinblastine, vincristine, vinorelbine, paclitaxel (taxol) and docetaxel); anti metabolites (such as cytarabine, fluorouracil, fluroximidine, mercaptopurine, methotrexate, gemcitabin and thioquanine); alkylating agents (such as mechlorethamine, chlorambucil, cyclophosphamide, melphalan and methotrexate); antibiotics (such as bleomycin and mitomycin); nitrosoureas (such as carmustine (BC).
- the cytotoxic substance D is an anti-tumor agent.
- the anti-tumor agent D is selected from the group consisting of adriamycin, bleomycin, chlorambucil, cisplatin, daunomycin and melphalan.
- the anti-tumor agent is daunomycin.
- the conjugate of the present invention may further comprise an affinity molecule.
- the affinity molecule is attached to the albumin.
- the affinity molecule is selected from the group consisting of at least the antigen-binding portion of a specific antibody and biotin.
- n t is greater than 1 and D may be the same or different at each occurrence.
- the present invention provides a diagnostic composition comprising an effective amount (e.g. an amount effective for enhancing image contrast in an imaging procedure) of a conjugate comprising at least one isoflavone derivative which is bound to albumin and at least one compound D which is an imaging agent.
- a pharmaceutical composition comprising an effective amount of a conjugate comprising at least one isoflavone derivative which is bound to albumin and at least one compound D which is a therapeutic agent.
- the present invention provides a method of targeting cells sensitive to isoflavone comprising administering to a subject in need thereof an effective amount of a conjugate comprising at least one isoflavone derivative which is bound to albumin and at least one bioactive moiety.
- the invention provides a method for generating enhanced images of a human or animal body and generation of an image of at least part of said body.
- the present invention provides a method for diagnosing cancer in a subject comprising administering to the subject a conjugate comprising at least one isoflavone derivative bound to albumin and at least one diagnostic compound for affinity targeting of the diagnostic compound to cells sensitive to isoflavone.
- the cells are cancer cells.
- diagnosis of tumors may be performed in vitro or in vivo.
- diagnosis may be performed either directly or indirectly in an in vivo diagnostic imaging procedure e.g. by magnetic resonance imaging (MRI), near infrared (NIR), optical imaging, scintigraphy, SPECT, PET, X-ray, ultrasound imaging, electrical impedance or magnetometric procedures.
- MRI magnetic resonance imaging
- NIR near infrared
- optical imaging scintigraphy
- SPECT single photontigraphy
- PET PET
- X-ray X-ray
- ultrasound imaging electrical impedance or magnetometric procedures.
- the diagnostic imaging procedure is MRI.
- the diagnostic imaging procedure is NIR.
- in vivo diagnosis may be used to detect the presence of a disease state and/or monitor the progression of the disease.
- the conjugates (compositions of matter) of the invention are useful diagnostic contrast agents for in vivo imaging of a mammalian body.
- the present invention provides a method for treating cancer comprising administering to a subject in need thereof a therapeutical composition comprising a therapeutically effective amount of a conjugate comprising at least one isoflavone derivative bound to albumin and at least one compound D being a therapeutic agent, thereby targeting and internalizing the conjugate to cells susceptible to isoflavone.
- cancer treated by methods of the invention is selected from the group consisting of ovarian cancer, colon cancer, breast cancer, melanoma, non-small lung cancer, leukemia, endometrial cancer and prostate cancer.
- the present invention provides a method for treating ovarian cancer.
- the methods of the invention may be used to treat diseases other than cancer.
- the disease other than cancer is an estrogen related condition such as osteoporosis, endometriosis, atherosclerosis, cardiovascular disease, hypercholesterolemia, prostatic hypertrophy, obesity, menopausal syndromes, type-II diabetes, and Alzheimer's disease.
- an estrogen related condition such as osteoporosis, endometriosis, atherosclerosis, cardiovascular disease, hypercholesterolemia, prostatic hypertrophy, obesity, menopausal syndromes, type-II diabetes, and Alzheimer's disease.
- FIG. IA shows the specific binding and endocytosis of daidzein-BSA-FAM by MLS ovarian carcinoma cells.
- panel c overlay of panels a and b.
- Fig. IB shows the specific binding and endocytosis of BSA-ROX and Daidzein-BSA-FAM by MLS ovarian carcinoma cells.
- FIG. 2 shows the binding and endocytosis of BSA-ROX and Daidzein-B SA-FAM by
- BSA-ROX uptake grey-control, black- BSA-ROX uptake, dark gray-
- FIG. 3 Competition of Daidzein-BSA-FAM (light gray) by BSA-ROX (gray) in the absence (A) and presence of nystatin (B) (FLl filter for the collection of FAM fluorescence, FL2 filter for the collection of ROX fluorescence), C and D display control samples without and with nystatin respectively.
- B FLl filter for the collection of FAM fluorescence
- C and D display control samples without and with nystatin respectively.
- E Statistical analysis of the competition assay. Change in percent of positively stained fluorescent cells in the absence and presence of nystatin (n) (light gray-Daidzein-B SA-FAM (dbf), dark gray- BSA-ROX (br)).
- FIG. 4 shows the in vivo targeted delivery of daidzein-BSA-CyTE-777 to ovarian carcinoma tumors followed by NIR Imaging.
- daidzein-BSA-CyTE-777 A
- Control BSA-CyTE-777 B
- daidzein-BSA-CyTE-777 + BSA-FAM 48 hours (C) and 72 hours (D) respectively
- In Vivo Imaging of daidzein-BSA-CyTE-777 localization in tumor-free CD-I nude mice.
- CD-I nude mice were injected intravenously with daidzein-BSA-CyTE-777 (left) or non injected (right). The NIR signal after 24 hours is shown.
- FIG. 5 shows the biodistribution of daidzein-BS A-EuDTTA versus BSA-EuDTTA in MLS tumor bearing mice.
- A. Europium signal 24h after injection (n 3-5).
- FIG. 6 demonstrates that while Daidzein-BSA-FAM accumulates in tumor cells, BSA-FAM is localized in tumor blood vessels.
- FIG. 7 demonstrates the advantages of using daidzein-B SA-GdDTPA as a contrast material to MRI.
- Tl weighted MRI images and R 1 maps were obtained 24, 48 and 72h after injection, and used for derivation of mean R 1 values of the tumor;
- the present invention relates to conjugates comprising at least one isoflavone derivative bound to albumin and at least one bioactive moiety including but not limited to a diagnostic agent (e.g. imaging agent) or a therapeutic agent and their use for the diagnosis and treatment of cancer.
- a diagnostic agent e.g. imaging agent
- a therapeutic agent e.g. a therapeutic agent
- the present invention relates to the use of the conjugate comprising at least one isoflavone derivative bound to albumin and at least one bioactive moiety selected from an imaging agent for targeting of the imaging agent to cancer cells for diagnostic purposes.
- the cancer cells are sensitive to isoflavone.
- the present invention relates to the use of the conjugate comprising at least one isoflavone derivative bound to albumin and at least one bioactive moiety selected from a therapeutic agent for targeting of drugs to cancer cells for cancer treatment purposes.
- the cancer cells are sensitive to isoflavone.
- targeting means that the conjugate is able to induce the formation of a functional response (preferably the accumulation of a diagnostic agent or an anti-cancer drug in cells sensitive to isoflavone) in cancer cells preferentially over normal cells as compared with the diagnostic agents or drugs commonly used which are not given as part of the conjugate of the invention..
- a "diagnostic agent” is a molecule or atom which is conjugated to a targeting moiety (e.g. isoflavone or isoflavone-albumin), to produce a conjugate, which is useful for diagnosis.
- a targeting moiety e.g. isoflavone or isoflavone-albumin
- diagnostic agents include paramagnetic particles; radioactive moieties; fluorescent dyes and infrared dyes.
- the diagnostic agent is a contrast agent.
- the diagnostic agent may be provided within a chelator.
- the conjugate of the invention comprising isoflavone derivative bound to albumin and a diagnostic agent may be used as a contrast agent.
- therapeutic agent refers to a molecule or atom which is conjugated to a targeting moiety (e.g. isoflavone or isoflavone-albumin conjugate) to produce a conjugate which is useful for therapy.
- a targeting moiety e.g. isoflavone or isoflavone-albumin conjugate
- therapeutic agents include cytotoxic compounds, cytostatic compounds, antisense compounds or anti-viral agents. Delivery of bioactive moieties to tumor cells:
- the present invention is directed to a bifunctional targeted conjugate comprising isoflavone, albumin and an active agent (diagnostic and/or therapeutic agents) which effectively overcomes the tumor-blood barrier, thus increasing the delivery of the conjugate to the rumor cells.
- tumor cells escape from delivery of extravasated albumin based compounds, through caveolae mediated sequestration of the albumin based compound by perivascular myofibroblasts, thus generating an effective tumor-blood barrier.
- Evoking an alternate competing endocytic pathway using isoflavone resulted in significant partition of the isoflavone-albumin based compound (e.g. the conjugate of the invention) into the tumor.
- the partition of the conjugate of the invention into the tumor could be further enhanced in the presence of free albumin (non conjugated albumin).
- the partition of the conjugate of the present invention into the tumor could be further enhanced by the addition or co-administration of nystatin.
- nystatin a substance that influences the partition of the conjugate through suppression of caveolae mediated endocytosis by competition with the conjugate, in the absence of direct modulation of the tumor interstitial pressure.
- partition into a cell or “partition into a cancer cell” or “partition into a tumor cell” as used herein refers to the amount of bioactive moiety (diagnostic agent and/or therapeutic agent) found in the interior part of a cell versus the amount of the bioactive moiety found at the exterior part of the cell, specifically, within or on the cell's membrane.
- the partition into a tumor cell of the bioactive moiety is at least 10% higher than the partition into a tumor cell of the bioactive moiety when administered alone and/or bound to albumin alone and/or bound to isoflavone alone; alternatively, at least 20% higher; alternatively at least 30% higher; alternatively, at least 40% higher; alternatively, at least 50% higher; alternatively, at least 60% higher; alternatively, at least 70% higher; alternatively, at least 80% higher; alternatively, at least 90% higher; alternatively, at least 2 times higher; alternatively at least 3 times higher.
- the conjugate of the present invention displays prolonged tumor retention and/or increased circulation time as compared to tumor retention and circulation time of the bioactive agent alone, the bioactive agent bound to albumin alone, or the bioactive agent bound to isoflavone alone.
- tumor retention refers to the duration of the presence of a sufficient amount of a bioactive moiety inside a tumor cell since the time it was administered to a subject, or introduced to the cell, or internalized or up taken by the cell.
- the term "sufficient amount” implies a sufficient amount of a diagnostic agent that will enable detection (e.g. tumor detection) using various diagnostic methods, for example, the diagnostic imaging procedures described.
- "sufficient amount” implies an amount of a therapeutic agent which is sufficient to cause a desired therapeutic effect.
- the bioactive moiety of the conjugate is retained inside the tumor cell for at least 7 days; alternatively, for at least 5 days, alternatively, for at least 3 days, alternatively for at least 48 hours, alternatively, for at least 24 hours.
- Cirulation time refers to the duration of the presence of the conjugate of the invention in the blood or plasma; specifically, to the duration of the presence of the bioactive moiety, which is part of the conjugate, in the blood or plasma.
- the circulation time of the bioactive moiety is determined by its distribution, metabolism and its removal from the body via excretion.
- circulation time may be referred to as the half-life of the bioactive moiety in the plasma.
- Half- life refers to the period of time required for the concentration or amount of the bioactive moiety in the body to be reduced by one-half. A plasma half-life of a bioactive moiety depends on how quickly the bioactive moiety is eliminated from the plasma.
- a bioactive moiety that leaves plasma may have any of several fates. It can be eliminated from the body, or it can be translocated to another body fluid compartment such as the intracellular fluid or it can be destroyed in the blood.
- the removal of a the bioactive moiety from the plasma is known as clearance and the distribution of the bioactive moiety in the various body tissues is known as the volume of distribution. Both of these pharmacokinetic parameters are important in determining the circulation time or half life of a bioactive moiety.
- the half life can be determined by giving a single dose, usually intravenously, and then measure the concentration of the bioactive moiety in the plasma at regular intervals. The concentration of the drug will reach a peak value in the plasma and will then fall as the bioactive moiety is hydrolyzed or broken down and cleared from the blood.
- the circulation time or the half-life of a bioactive moiety is increased upon introduction or binding of the bioactive moiety to an isoflavone-albumin conjugate.
- the circulation time or half-life of the bioactive moiety is at least 10% higher than the circulation time or half-life of the bioactive moiety when administered alone, bound to albumin, or bound to isoflavone; alternatively, at least 20% higher; alternatively at least 30% higher; alternatively, at least 40% higher; alternatively, at least 50% higher; alternatively, at least 60% higher; alternatively, at least 70% higher; alternatively, at least 80% higher; alternatively, at least 90% higher; alternatively, at least 2 times higher; alternatively at least 3 times higher.
- Cl to C6 alkylene refers to a saturated, linear or branched hydrocarbon moiety, such as -CH 2 -, -CH 2 -CH 2 -; -CH 2 -CH 2 -CH 2 -; -CH 2 -(CH 2 ) 2 -CH 2 ; -CH 2 -(CH 2 ) 3 -CH 2 ; -CH 2 -(CH 2 ) 4 -CH 2 ;.
- C2 to C20 alkenylene denotes a divalent group derived from a straight chain or branch hydrocarbon moiety containing from two to twenty carbon atoms having at least one carbon-carbon double bond.
- Alkenylene groups include, but are not limited to, for example, ethenylene, 2-propenylene, 2- butenylene, l-methyl-2-buten-l-ylene, and the like.
- heteroalkylene refers to an alkylene or alkenylene moiety having at least one heteroatom (e.g., N, O, or S). Preferred are heteroalkylenes having at least one O.
- GIc denotes glucosyl or glucoside.
- Isoflavone compounds Epidemiological in vitro as well as in vivo animal studies indicate that isoflavones present in large quantities in soybeans and soy products (e.g., genistein, daidzein) and red clover (biochanin A) are promising agents for cancer therapy, chemoprevention and inhibition of tumor progression (Aggarwal, B. B. at al, Biochem. Pharmacol. 2006, 71, 1397).
- estrogen-sensitive cancer cell lines e.g., breast, colon, etc.
- these isoflavone compounds can act as weak estrogens and stimulate cell growth at concentrations ranging from 0.1 to 20 ⁇ M.
- the affinity of most isoflavones to the two subtypes of ER is low (Kuiper, G. G. at al, Endocrinology 1998, 139, 4252) with the exception of genistein, which shows a strong selectivity for Er ⁇ over Era.
- Both genistein and daidzein display 100-fold greater sensitivity for activating transcription in transfected cells via Er ⁇ compared to Era (Harris, D. M. at al., Exp. Biol. Med.
- isoflavones inhibit cell growth at concentrations greater than 20 ⁇ M.
- isoflavone compounds display estrogenic effects (e.g. stimulate cell growth).
- isoflavone compounds display anti-estrogenic effects (e.g. inhibit cell growth).
- isoflavone compounds may be referred to as modulators of cell growth.
- isoflavones show a wide spectrum of biological activities not ascribed to activation of the ER such as regulation of cell-signaling pathways, and can inhibit proliferation and induce apoptosis in ER-negative breast cancer cell lines as well as in ER-positive cell lines.
- Examples include genistein which was shown to inhibit the protein-tyrosine kinase pathway and was further used in a treatment of choroidal neovascularization (U.S. Pat. No. 6,028,099). Genistein was also shown to display topoisomerase II activity, and to induce apoptosis and cell differentiation. Moreover, genistein has been shown to inhibit the proliferation of both cancer and normal cells, and was used for prophylactic treatment of cataract (WO 00/37066).
- the 4-methoxy derivative of genistein, biochanin A, is equally potent to genistein as a growth inhibitor in breast cancer lines due to its conversion to genistein
- Daidzein exhibits unique properties. Daidzein is known to interact with the lipid interface on the cell surface (Lehtonen J.Y et al. Biochim Biophys Acta, 1996 1285: 91-100) thus facilitating endocytosis. Furthermore, acting as a weak estrogen, daidzein may recognize a putative plasma membrane estrogen receptor (Somjen D. et al. J Steroid Biochem MoI Biol, 2005 93: 293-303), a membranal ER ⁇ -related protein (De Wilde A. et al. J Cell Physiol, 2006 209: 786- 801) or a nuclear estrogen receptor of the ⁇ -type.
- albumin includes human serum albumin, animal albumin, recombinant albumin, and fragments thereof. Additionally, the albumin may exist as a monomer, a dimer, a polymer, or may be enclosed in microspheres. Albumin as disclosed herein may also be treated with polyethylene glycol (PEG) by well-known techniques to increase its immunocompatibility. According to one embodiment, albumin comprises human serum albumin. According to another embodiment, albumin comprises bovine serum albumin (BSA). It is to be appreciated that species-specific serum albumin is necessary for compatibility reasons. Thus, when treating or diagnosing human patients, human serum albumin may preferably be used and when treating or diagnosing other animals, the serum albumin should likewise be species-specific, e.g., bovine serum albumin for treating or diagnosing cattle.
- BSA bovine serum albumin
- the albumin in the conjugate is used as a carrier.
- the isoflavone carboxy derivatives and the bioactive moieties according to the invention may be conjugated to the albumin carrier by any means know in the art, non-limiting examples include: conjugation through the albumin's lysine residues (amino groups), conjugation through the N-terminus and conjugation through cy stein residues (thiol groups).
- amino groups conjugation through the albumin's lysine residues
- thiol groups conjugation through cy stein residues
- amino, hydroxyl and hydrazine groups can each form a covalent bond with a reactive carbonyl group (e.g., a carboxylic acid chloride or activated ester such as an N-hydroxysuccinimide ester (NHS)).
- a reactive carbonyl group e.g., a carboxylic acid chloride or activated ester such as an N-hydroxysuccinimide ester (NHS)
- carboxy derivatives of isoflavones as well as bioactive moieties may be coupled to an amino group of albumin (e.g. lysine group) via N-hydroxysuccinimide ester.
- N-sulfo succinimide and a water soluble carbodiimide may be used for coupling a carboxy group of the isoflavone or of the bioactive moiety to an amino group of albumin through the formation of a peptide linkage.
- the conjugate of the invention comprises a bioactive moiety selected from a diagnostic agent and a therapeutic agent.
- the bioactive moiety is a therapeutic agent selected from the group consisting of a cytotoxic compound, a cytostatic compound, an antisense compound, an anti-viral agent.
- the cytotoxic compound is selected from, but not restricted to DNA synthesis and function inhibitory agents; microtubule (mitotic spindle) formation and function inhibitory agents; anti metabolites; alkylating agents; antibiotics; nitrosoureas; hormones and proteins.
- the therapeutic agent is an anti-tumor agent.
- anti-cancer reagent refers to any type of reagent that may be used in the treatment of cancer and/or cancer related conditions.
- the anti-cancer reagent may include any naturally occurring or synthetically produced molecule that is capable of affecting directly or indirectly the growth and/or viability of cancer cells.
- the anti-cancer reagent may include, for example, a naturally occurring protein or peptide, a modified protein or peptide, a recombinant protein, a chemically synthesized protein or peptide, a chemical molecule, a synthetic chemical molecule, a chemotherapeutic drug, a biologically therapeutic drug, and the like, or any combination thereof.
- the anti-cancer reagent may be cytotoxic (toxic to cells) and/or cytostatic (suppress cell growth) and/or antiproliferative to the cancer cells and may exert its effect on cancer cells directly and/or indirectly.
- Non limiting examples of anti-cancer agents and chemotherapeutic drugs may include such drugs as, but not limited to: Alkaloids, such as, but not limited to: Docetaxel, Etoposide, Irinotecan, Paclitaxel, Teniposide, Topotecan, Vinblastine, Vincristine, Vindesine; Alkylating agents, such as, but not limited to: Busulfan, Improsulfan, Piposulfan, Benzodepa, Carboquone, Meturedepa, Uredepa, Altretamine, triethylenemelamine, Triethylenephosphoramide,
- Alkaloids such as, but not limited to: Docetaxel, Etoposide, Irinotecan, Paclitaxel, Teniposide, Topotecan, Vinblastine, Vincristine, Vindesine
- Alkylating agents such as, but not limited to: Busulfan, Improsulfan, Piposulfan, Benzodepa, Carboquone, Meturede
- taxanes including, but not limited to vincristine (Oncovin), vinblastine (Velban), paclitaxel (Taxol, Paxene), vinorelbine (Navelbine), epothilone B or D or a derivative of either, and discodermolide or its derivatives, nitrosoureas including, but not limited to procarbazine (Matulane), lomustine, CCNU (CeeBU), carmustine (BCNU, BiCNU, Gliadel Wafer), and estramustine (Emcyt); nucleoside analogs including, but not limited to mercaptopurine, 6-MP (Purinethol), fluorouracil, 5-FU (Adrucil), thioguanine, 6-TG (Thioguanine), hydroxyurea (Hydrea), cytarabine (Cytosar-U, DepoCyt), floxuridine (FUDR), fludarabine (Flu
- the bioactive moiety is a diagnostic agent selected from the group consisting of paramagnetic particles; radioactive moieties; dyes, fluorophores, and infrared dyes.
- Typical diagnostic radioactive moieties include " 01 Tc, 95 Tc, 111 In, 62 Cu, 64 Cu, 67 Ga, and 68 Ga; and therapeutic radioactive moieties include 186 Re, 188 Re, 153 Sm, 166 Ho, 177 Lu, 149 Pm, 90 Y, 212 Bi, 103 Pd, 109 Pd, 159 Gd, 140 La, 198 Au, 199 Au, 169 Yb, 175 Yb, 165 Dy, 166 Dy, 67 Cu, 105 Rh, 111 Ag, and 192 Ir.
- Typical paramagnetic particles include rare earth metals, typically, gadolinium, manganese, yttrium, ytterbium, europium, lutetium, gallinium and the like. Iron ions may also be used.
- Preferred fluorophore moieties include fluorescent dyes having (a) high fluorescence intensity; (b) sufficiently long excitation and emission wavelength maxima so that interference from natural fluorescence of either diseased or normal tissue is minimized; (c) sufficiently long measured fluorescence decay time to allow accurate measurement of emitted light over background fluorescence and scattering (at least about 2, preferably at least about 10 nanoseconds); and (d) high degree of fluorescence polarization.
- Fluorophores include macrocyclic fluorescent dye compounds, especially compounds having aromatic ⁇ -electron systems.
- fluorophore moieties may comprise a substantially planar multidentate macrocyclic ligand and may be coordinated to a complexing central ion or atom such as aluminum, phosphorous, and the group FVB elements, e.g. silicon, germanium, and tin.
- suitable fluorophores include coumarin dyes, nitrobenzoxazole dyes, cyanine dyes, dipyrrometheneboron dyes, xanthene dyes (including the benzo- and naphtho- xanthene dyes), phenoxazine dyes (as well as the benzo- and naphtho-phenoxazine dyes) and compounds from other classes of dyes well known to those of skill in the art.
- fluorophores include the fluorophores in the following non- exclusive list: 1,5 IAEDANS; 1,8-ANS; 4-Methylumbelliferone; 5-carboxy-2,7- dichlorofluorescein; 5-Carboxyfluorescein (5 -FAM); 5-Carboxynapthofluorescein; 5- Carboxytetramethylrhodamine (5-TAMRA); 5-FAM (5-Carboxyfluorescein); 5-HAT (Hydroxy Tryptamine); 5 -Hydroxy Tryptamine (HAT); 5 -ROX (carboxy-X- rhodamine); 5-TAMRA (5-Carboxytetramethylrhodamine); 6-Carboxyrhodamine 6G; 6-CR 6G; 6- JOE; 7-Amino-4-methylcoumarin; 7-Aminoactinomycin D (7-AAD); 7- Hydroxy-4-methylcoumarin; 9-Amino-6-chloro-2-meth
- Infrared dyes include cyanine dyes.
- cyanine dyes include l,r,3,3,3',3'-Hexamethylindotricarbocyanine iodide; 1,1',3,3,3',3'- Hexamethylindotricarbocyanine perchlorate; l,l'-Diethyl-2,2'-dicarbocyanine iodide; l,l'-Diethyl-2,2'-quinotricarbocyanine iodide; l,l'-Diethyl-4,4'-carbocyanine iodide; l,l '-Diethyl-4,4'-dicarbocyanine iodide; l,3-Bis[4-(dimethylamino)-2- hydroxyphenyl]-2,4-dihydroxycyclobutenediylium dihydroxide, bis(inner salt); 1 ,4,8, 11,15,
- the infarared dye is CyTEE-777.
- suitable cyanine dyes are described in U.S. Patent No. 7,514,069, the contents of the aforementioned reference are incorporated by reference herein in their entirety as if fully set forth herein.
- the paramagnetic particles as well as the radioactive moieties can be provided within a chelator.
- chelators include: tetraazacyclododecanetetraacetic acid (DOTA), mercaptoacetylglycylglycyl-glycine (MAG3), diethylenetriamine pentaacetic acid
- DTTA l,4,7-triaza-cyclononane-N-N'-N"-triacetic acid
- TETA tetraazacyclotetradecane-N,N',N",N'"-tetraacetic acid
- the conjugate comprising at least one isoflavone derivative bound to albumin and at least one diagnostic compound is selected from the group of 7-(O)-carboxymethyl daidzein-albumin-CyTE-777, 7-(O)- carboxymethyl daidzein-albumin-GdDTPA, 7-(O)-carboxymethyl daidzein-albumin- FAM and 7-(O)-carboxymethyl daidzein-albumin-EuDTTA.
- the present invention provides methods for the diagnosis and treatment of cancer in a subject comprising administering a conjugate comprising at least one isoflavone derivative bound to albumin and at least one bioactive moiety selected from a diagnostic agent and/or a therapeutic agent.
- the conjugate of the invention is useful for targeting cells sensitive to isoflavone, preferably, cancer cells sensitive to isoflavone.
- the cancer may include solid tumors, non-solid tumors, primary tumors, metastasis or any combination thereof.
- the cancer may include carcinomas, sarcomas, myelomas, leukemias, lymphomas or any combination thereof.
- the cancer may include lymphoproliferative disorders, breast cancer, ovarian cancer, prostate cancer, cervical cancer, endometrial cancer, bone cancer, liver cancer, stomach cancer, colon cancer, pancreatic cancer, cancer of the thyroid, head and neck cancer, cancer of the central nervous system, cancer of the peripheral nervous system, skin cancer, kidney cancer, a metastasis thereof or any combination thereof.
- the cancer may include hepatocellular carcinoma, hematoma, hepatoblastoma, rhabdomyosarcoma, esophageal carcinoma, thyroid carcinoma, ganglioblastoma, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, Ewing's tumor, leimyosarcoma, rhabdotheliosarcoma, invasive ductal carcinoma, papillary adenocarcinoma, melanoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, renal cell carcinoma, hypernephroma, hypernephroid adenocarcinoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, testicular tumor, lung carcinoma
- the cancer comprises cancer cells sensitive to isoflavone.
- cancer may include ovarian carcinoma, colon cancer, breast cancer, melanoma, non-small lung cancer, leukemia, endometrial cancer and prostate cancer.
- the cancer is ovarian cancer.
- the cancer is breast cancer.
- the cancer is colon cancer.
- the cancer is prostate cancer.
- detecting or imaging cancer cells in a subject comprising (a) administering to the subject an effective amount of a conjugate comprising at least one isoflavone derivative bound to albumin and at least one diagnostic agent; and (b) detecting or imaging cells that take up the conjugate to determine if cancer is present in a subject.
- Detection of the conjugate can be performed using essentially any detection device to obtain an image of the cancerous cells.
- diagnosis may be performed either directly or indirectly in an in vivo diagnostic imaging procedure e.g. by magnetic resonance imaging (MRI), near infrared (NIR), optical imaging, scintigraphy, SPECT, PET, X-ray, ultrasound imaging, electrical impedance or magnetometric procedures.
- MRI magnetic resonance imaging
- NIR near infrared
- optical imaging scintigraphy
- SPECT single photontigraphy
- PET PET
- X-ray X-ray
- ultrasound imaging electrical impedance or magnetometric procedures.
- the diagnostic imaging procedure is MRI. According to other embodiments, the diagnostic imaging procedure is NIR. According to some embodiments, in vivo diagnosis may be used to detect the presence of a disease state and/or monitor the progression of the disease. According to some embodiments, the conjugates of the invention are useful diagnostic contrast agents for in vivo imaging of a mammalian body.
- the diagnostic conjugates of the present invention can be used in a method which comprises administering to a subject's body, or to selected regions thereof, effective amounts of the diagnostic conjugate.
- the agent can be injected directly into the vicinity of the body to be imaged, or it can be intravenously, intradermaly, intralesionaly, intramusculary, intravesiculary, subcutaneously injections or gastrointestinally administered. Then, an image of the body or of the indicated region is obtained using conventional imaging equipment and techniques as described above.
- the image thus produced by that equipment can optionally be fixed in hard copy form, in photographic negative or positive form, or stored within a computer memory for subsequent recall onto a screen or for subsequent conversion into hard copy.
- a “diagnostically effective amount” as used herein refers to a dose of the diagnostic conjugate, or diagnostic agent that is sufficient for detection (e.g. tumor detection) using the various diagnostic methods described.
- Typical doses of the diagnostic conjugates are in the range from about 0.001 to about 20 mmol/kg body weight, and preferably in the range from about 0.005 to about 5 mmol/kg body weight.
- the diagnostically effective amount may be different depending on the diagnostic agent attached to the conjugate of the invention as well as the diagnostic apparatus used for detection.
- the present invention provides a method for site targeted chemotherapy in a subject in need thereof comprising administering to the subject a therapeutical composition comprising a therapeutically effective amount of a conjugate comprising at least one isoflavone derivative bound to albumin and at least one cytotoxic compound for targeting of the cytotoxic compound to cancer cells.
- a therapeutical composition comprising a therapeutically effective amount of a conjugate comprising at least one isoflavone derivative bound to albumin and at least one cytotoxic compound for targeting of the cytotoxic compound to cancer cells.
- the cancer cells are sensitive to isoflavone.
- therapeutically effective amount refers to that amount of the therapeutic conjugate of the invention which elicits a biological or medicinal response that will contribute to the cancer-treating ability of the therapeutic conjugate.
- treating refers to partial or total inhibition of the growth, spreading, or metastasis of cancer, as well as partial or total destruction of the cancer cells.
- treating includes the reduction or elimination of cancer, and also the reduction in the incidence of the disease.
- the present invention provides pharmaceutical composition i.e., diagnostic and therapeutic compositions, comprising as an active ingredient a conjugate comprising at least one isoflavone derivative bound to albumin and at least one compound selected from a diagnostic agent and a therapeutic agent according to embodiment of the invention and a pharmaceutically acceptable carrier, excipient or diluent.
- a "diagnostic composition” refers to a preparation of one or more of the active ingredients described herein, e.g. a conjugate comprising at least one isoflavone derivative bound to albumin and at least one compound which is a diagnostic agent, with other components such as physiologically suitable carriers and excipients.
- the purpose of a diagnostic composition is to facilitate the administration of the conjugate of the invention to a subject for diagnostic purposes.
- a "therapeutic composition” refers to a preparation of one or more of the active ingredients described herein, e.g. a conjugate comprising at least one isoflavone derivative bound to albumin and at least one compound which is a therapeutic agent, with other components such as physiologically suitable carriers and excipients.
- the purpose of a therapeutic composition is to facilitate the administration of the conjugate of the invention to a subject for treatment purposes.
- therapeutically acceptable carrier and “pharmaceutically acceptable carrier”, which may be used interchangeably, refer to a carrier or a diluent that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered compound.
- excipient refers to an inert substance added to a diagnostic or a pharmaceutical composition to further facilitate administration of an active ingredient.
- excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils, and polyethylene glycols.
- a diagnostic or a pharmaceutical composition further comprises a pharmaceutically acceptable carrier.
- a carrier refers to any substance suitable as a vehicle for delivering a conjugate of the present invention to a suitable in vivo or in vitro site.
- carriers can act as a pharmaceutically acceptable excipients of a diagnostic or a therapeutical composition containing a conjugate of the present invention.
- Preferred carriers are capable of maintaining a conjugate of the present invention in a form that, upon arrival of the conjugate to a cell, the conjugate is capable of entering the cell.
- Non limiting examples of suitable carriers include: water, phosphate buffered saline, Ringer's solution, dextrose solution, serum-containing solutions, Hank's solution, other aqueous physiologically balanced solutions, oils, esters and glycols.
- Aqueous carriers can contain suitable auxiliary substances required to approximate the physiological conditions of the recipient, for example, by enhancing chemical stability and isotonicity.
- Suitable auxiliary substances include, for example, sodium acetate, sodium chloride, sodium lactate, potassium chloride, calcium chloride, and other substances used to produce phosphate buffer, Tris buffer, and bicarbonate buffer.
- Auxiliary substances can also include preservatives, such as thimerosal, m- and o-cresol, formalin and benzol alcohol.
- Preferred auxiliary substances for aerosol delivery include surfactant substances non-toxic to a subject, for example, esters or partial esters of fatty acids containing from about six to about twenty-two carbon atoms.
- esters include: caproic, octanoic, lauric, palmitic, stearic, linoleic, linolenic, olesteric, and oleic acids. Diagnostic and therapeutic compositions of the present invention can be sterilized by conventional methods.
- composition for use in accordance with the present invention thus may be formulated in conventional manner using one or more acceptable diluents or carriers comprising excipients and auxiliaries as described, which facilitate processing of the active compounds into preparations, which can be used pharmaceutically. Proper formulation is dependent on the route of administration chosen.
- the diagnostic and therapeutic composition of the present invention may be formulated for administration by a route selected from the group consisting of intravenous injections, intravenous infusion, intradermal, intralesional, intramuscular, intravesicular and subcutaneous injections or depots.
- the composition of the invention may be administered parenterally by means other than injection, for example, they could be introduced laparascopically, intravesicularly, or via any orifice not related to the gastrointestinal tract.
- the compositions of the present invention may be formulated for oral administration.
- the diagnostic and therapeutic compositions can take the form of solutions, suspensions, emulsions, syrups, gels, tablets, pills, capsules, powders, suppositories and the like.
- Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc.
- Such compositions will contain an effective amount of the conjugate of the invention, preferably in a substantially purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the subject.
- composition of the present invention may be manufactured by processes well known in the art, e.g. by means of conventional mixing, dissolving, granulating, grinding, pulverizing, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.
- albumin conjugate isoflavone derivative bound to a bioactive moiety such as an imaging agent or a therapeutic agent for selective delivery to cells susceptible to isoflavone according to the present invention
- BSA BSA
- nystatin diethylenetriamine pentaacetic acid (DTPA) anhydride
- Carboxyfluorescein succinimide ester (FAM-NHS)
- Carboxy-X-rhodamin succinimide ester (ROX-NHS) - Molecular Probes, Invitrogen (California, USA).
- the conjugates were prepared in a three-step procedure.
- both the carboxy derivative of daidzein and the imaging agent were treated with N-hydroxysuccinimide and carbodiimide to form an active ester.
- the activated ester of the imaging agent reacted at pH 8.5 with the amino group of lysine residues of BSA to form a BSA-imaging agent conjugate.
- the activated ester of daidzein reacted at pH 8.5 with the amino group of lysine residues of BSA to form a daidzein-BSA-imaging agent conjugate
- BSA-DTPA was synthesized as described (Dafni et al., 2003, Magn. Reson. Med.; 50:904-14). Briefly, DTPA anhydride 1.6 gr (suspended in 4 ml of dry DMF) was slowly added with stirring to BSA 1.3 gr (in 40 ml Hepes 0.1 M, pH 8.8) while the reaction was titrated with NaOH 5N and stirred for 2 hours.
- the product was dialyzed against NaHCO 3 . Afterwards, the N- hydroxysuccinimide ester of 7-(O)-carboxymethyl (daidzein-NHS), synthesized according to Kohen et al, 2007, J Med. Chem.; 50:6405-10, (11 mg in 800 ⁇ l of anhydrous DMF) was added to BSA-DTPA (in 40 ml OfNaHCO 3 , 0.1M, pH 8.5) and stirred overnight. The product was dialyzed first against NaHCO 3 , followed by sodium citrate (0.1 M, pH 6.5).
- GdCl 3 650 mg (in 5 ml sodium acetate 0.1M, pH 6.0) was added to Daidzein-B SA-DTPA in sodium citrate (0.1 M pH 6.5). The final product (Daidzein-BSA-GdDTPA) was dialyzed extensively against water and lyophilized.
- CyTE-777-NHS (44 mg) prepared according to Hilderbrand et al., 2005, Bioconjug. Chem.; 16:1275-81, or FAM-NHS (35 mg) or ROX-NHS (35 mg) (in 200 ⁇ l of dry DMF) were added to BSA (450 mg in 15 ml NaHCO 3 , 0.1M, pH 8.5), slowly with stirring. The reaction was stirred overnight, and the product was dialyzed against NaHCO 3 , 0.1M, pH 8.5, followed by several changes of water and lyophilized.
- N-hydroxysuccinimide ester of 7-(O)-carboxymethyl (daidzein-NHS), (8 mg in 600 ⁇ l of anhydrous DMF) was added to BSA-CyTE-777 (100 mg in 6 ml of NaHCO 3, 0.1M, pH 8.5) and stirred overnight.
- the product was purified by dialyzed against NaHCO 3 0.1M, pH 8.5, followed by extensive dialysis against water and lyophilized.
- Example 2 In vitro evaluation of the endocytic pathways in ovarian cancer cells: a. A fluorescence microscopy study:
- MLS cells (2*10 5 ) were cultured on polylysine coated coverslips for 48h. Subsequently, the coverslips were incubated for 1 hour at 37 with daidzein-BSA- FAM (200 ⁇ g/ml) or BSA-FAM (200 ⁇ g/ml) or combination of both in the presence and absence of a blocking dose of nystatin (50 ⁇ g/ml). The excess of fluorescent material was washed 3 times with PBS, and the cells were fixed with 4% PFA, washed, stained with DAPI and mounted.
- daidzein-BSA- FAM 200 ⁇ g/ml
- BSA-FAM 200 ⁇ g/ml
- nystatin 50 ⁇ g/ml
- FIG. IA Upon addition of nystatin (50 ⁇ g/ml, 30 min), an elevated membrane staining and reduced uptake of BSA-FAM was observed (FIG. IA, B), whereas a significant enhanced internalization of daidzein-B SA-FAM by MLS cells was observed (FIG. IA).
- MLS cells (10 6 ) were incubated for 30 minutes with daidzein-BSA-FAM (200 ⁇ g/ml) or BSA-ROX (200 ⁇ g/ml) or a combination of both in the presence and absence of nystatin (50 ⁇ g/ml).
- the excess of fluorescent material was washed three times with PBS containing 0.01% of sodium azide.
- the cellular uptake of fluorescent material was monitored by FACScan (Becoton Dickinson, USA).
- the excitation produced by air-cooled argon laser 288 nm and the emission signal was collected by FLl filter (BP530/30) for FAM and FL2 filter (BP585/42) for ROX.
- Example 3 In vivo targeted delivery of daidzein-BSA-CyTE-777 to ovarian carcinoma cells:
- the NIR signal in the whole animal was monitored by IVIS 100 and IVIS Spectrum (Xenogen, Caliper) at 24, 48 and 72 hours.
- mice were fed with alfalfa-free (chlorophyll-free) diet 72 hours before visualization.
- the data was acquired by 710-760 excitation, 675-720 excitation background and 810- 860 emission filters, hi the IVIS Spectrum the data obtained for the daidzein-BSA- CyTE-777 was acquired by 745 nm excitation and 820 nm emission filters.
- the pharmacokinetics of the fluorescent and MRI BSA based contrast media and their plasma concentration after intravenous administration were previously reported to be similar for all tags (Dafni et al. 2003, Magn. Reson. Med., 50:904-14).
- mice were inoculated subcutaneously with 2.5* 10 6 MLS tumor cells.
- mice administered with daidzein-BSA-CyTE777 or BSA-CyTE777 were inoculated subcutaneously with 2.5* 10 6 MLS tumor cells.
- mice administered with daidzein-BSA-CyTE777 or BSA-CyTE777 were inoculated subcutaneously with 2.5* 10 6 MLS tumor cells.
- mice administered with daidzein-BSA-CyTE777 or BSA-CyTE777 were administered with daidzein-BSA-CyTE777 or BSA-CyTE777.
- mice injected with daidzein-BSA-CyTE777 showed more specific localization in the tumor and in higher concentration than mice administered with BSA-CyTE777.
- Prolonged enhancement of the fluorescent signal in the tumor area was further observed in mice that were injected with both daidzein- BSA-CyTE-777 and the non-specific competitor - BSA-FAM.
- the NIR signal in the tumors was detectable even 10 days after the administration.
- mice were injected intravenously with BSA-Eu chelate (0.34 mg equivalent to 100000 counts of europium in 0.1 ml PBS/mouse) or daidzein-BSA-Eu chelate (0.24 mg of protein equivalent to 100000 counts of europium in 0.1 ml PBS/mouse).
- the Eu chelates were used here due to their chemical similarity to the Gd chelates used for MRI. After 24 and 48 hours the mice were sacrificed and tumors as well as various tissues were removed.
- the tissues were subsequently homogenized in RIPA buffer ((20 mM Tris, pH 7.4, 137 mM NaCl, 10% glycerol, 0.5% (wt/vol) sodium deoxycholate, 0.1% (wt/vol) sodium dodecyl sulfate (SDS), 1% Triton X-100, 2 mM EDTA) containing 1 mM phenylmethylsulfonyl fluoride (PMSF) and protease inhibitor cocktail) and centrifuged in an airfuge.
- the protein content in supernatant was first quantified by Bradford assay and then used for biodistribution studies and Western blot analysis.
- the membrane was blocked over night at 4C with 2% BSA in 10 mM Tris- buffered saline containing 0.05% Tween (TBST), followed by incubation with anti- daidzein antibody IgG (1 mg/ml TBS) for 2 hours at 25C. The membrane was then washed three times in TBST, incubated with an HRP-conjugated goat anti mouse antibody (1:10000 in TBS) and re- washed. The protein bands were visualized by ECL.
- TBST Tris- buffered saline containing 0.05% Tween
- the tumor bearing mice were injected intravenously with BSA-GdDTPA (12 mg in 200 ⁇ L PBS/mouse) or daidzein-BSA-GdDTPA (12 mg in 200 ⁇ L PBS/mouse) or with combination of daidzein-BSA-GdDTPA and BSA-FAM (competition experiment).
- Rl was measure 24, 48 and 72 hours after injection of the contrast material.
- Tl weighted 3D gradient-echo (GE) images, with pulse flip angles of 5°, 15°, 30°, 50° and 70° were acquired for the determination of Rl values.
- the acquisition parameters used TR 10 ms; TE 3.561 ms; 2 averages; field of view 4x4x4; 128x128x128 pixels.
- Three-dimensional gradient-echo data sets were used for generation of Rl maps as well as for calculation of the average Rl values in selected regions of interest by nonlinear best fit to equation [H]:
- I M 0 sin ⁇ (1 -e "TR*Rl ) / (1 - cos ⁇ e "TR*Rl ) (II)
- I is the signal intensity as a function of the pulse flip angle. Student's t test (two tailed, equal variance) was used for statistical analysis of the significance of change in relaxation rate between control and labeled tumors.
- Daidzein-BSA-GdDTPA showed significant relaxivity of 194 mM ' V 1 (per BSA; FIG. 7A). This relaxivity was similar to the relaxivity of BSA-GdDTPA 196 mM ' V 1 (per BSA).
- Time course experiments showed specific localization and retention of daidzein-BSA- GdDTPA in the tumor site 24, 48 and 72 hours after injection as compared to controls or mice injected with BSA-GdDTPA.
- Prolonged detection of daidzein-BSA- GdDTPA was feasible even for a lower administrate dose.
- the specific localization of the targeted contrast agent in the tumor site was detected by MRI at 9.4T 24h after injection (FIG. 7D) and was still detectable and even enhanced 7 days after injection (FIG. 7E).
Abstract
The present invention relates to conjugates comprising at least one isoflavone derivative bound to albumin and at least one bioactive moiety including a diagnostic agent or a therapeutic agent, the conjugate being capable of delivering the bioactive moiety into a tumor cell. The invention further relates to the use of said conjugate for the diagnosis and treatment of cancer.
Description
MULTIFUNCTIONAL ALBUMIN CONJUGATES
FIELD OF THE INVENTION
The invention relates to conjugates comprising at least one isoflavone derivative bound to albumin and at least one bioactive moiety including a diagnostic agent or a therapeutic agent, the conjugate being capable of delivering the bioactive moiety into a tumor cell. The invention further relates to the use of said conjugate for the diagnosis and treatment of cancer.
BACKGROUND OF THE INVENTION
The detection of a target site benefits from a high signal-to-background ratio of detection agent. Therapy benefits from higher percentages of the administered therapeutic agent reaching the target site, as well as a reasonably long duration of uptake and binding. Furthermore, drug targeting spares normal cells and significantly diminishes drug-toxicity.
Chemotherapy constitutes one of the major therapeutic approaches for the treatment of cancer, along with surgery and radiotherapy. However, the usefulness of commonly used anti-cancer drugs such as daunomycin and adriamycin is severely limited by their toxicity towards normal tissues, particularly the myocardium and the rapidly proliferating cells of the gastrointestinal tract and bone marrow. In addition, these drugs are affected by the mechanisms of multi-drug resistance. Affinity targeting of these cytotoxic drugs to tumor cells offers an approach that might overcome some of these drawbacks.
The targeting ratio and amount of agent delivered to a target site can be improved using targeting agents conjugated to diagnostic or therapeutic agents for preferential localization. A variety of materials have been developed over the years for targeted delivery of diagnostic agents and drugs. Examples include specific targeting of tumor cells with monoclonal antibody-drug conjugates (U.S. Patents No.
5,846,545), avidin-biotin conjugates (U.S. Patent No. 5,525,338), the use of proteins or peptide hormones for which specific receptors are located on membranes of tumor cells as carriers or targetors of cytotoxic drugs, for example, liposomes coupled to
glycoproteins (U.S. Patent No. 7,005,139), conjugates of a targeting protein such as transferrin and a drug (U.S. Patent No. 7,001,991), growth factors coupled to anthracycline drugs (WO 88/00837) or melanocyte-stimulating hormone (MSH) (Varga JM et al. 1977 Nature 276:56-58) and luteinizing hormone releasing hormone (LHRH) analogues (Nagy A. et al. 1996 Proc. Natal. Acad. ScL USA 93:7269-7273), conjugated to cytotoxic drugs for targeted chemotherapy of cancers that possess membranal receptors.
Site directed chemotherapy utilizing nuclear receptors (e.g. estrogen receptors) is not well documented. In fact, few studies have been described on the use of estrogen-cytotoxic drug conjugates (e.g. Estracyt, Leo 299; Heiman et al. 1980 J. Med. Chem. 23:994-1002) for affinity therapy, and success with such steroid-drug conjugates has been rather limited. Some inventors of the present invention have recently disclosed the use of carboxy derivatives of isoflavones such as biochanin A, daidzein, formononetin and genistein as selective targeting agents of therapeutic agents to cells having estrogen receptors (International publication WO 2003/079965). Specifically, it was shown that linking the cytotoxic drug daunomycin to the 7-(O)-carboxymethyl derivative of the isoflavone daidzein resulted in an active anti-cancer conjugate both in vitro and in vivo. This daidzein-daunomycin conjugate retained daunomycin' s cytotoxic effects in an ovarian xenograft while averting its toxicity in the myocardium (Somjen, D. et al. J Steroid Biochem. MoI. Biol. 2008 110:144-149).
The delivery of drugs by the intravascular route has also been limited to the administration of soluble drugs because of the danger of embolism formation when insoluble particles are injected. To circumvent some of these problems, methods of microencapsulating drugs in gelable hydrophilic colloids, incorporating active drug in the internal structure of a metabolizable "protein-like" carrier and formulations of polylactide and drug have been described. In yet another suggested method albumin was used as a carrier for drugs taking advantage of its central role in affecting the pharmacokinetics of chemotherapeutics and imaging agents. When using the albumin delivery system intravascularly no emboli formation was detected (U.S. Pat. No. 4147767). Furthermore, water insoluble drugs which formerly could not be administered in this manner because of the risk of embolus formation could be safely given by entrapping them in albumin spherules. Other advantages of albumin
spherules as medicament carriers include their ease of preparation, complete removal from the body by metabolism, nonantigenicity, proven safety for intravascular administration and the capability of accommodating a wide variety of drug molecules in a relatively non-specific fashion. The use of albumin as a carrier of imaging probes has been described (U.S. Pat. No. 4,337,240; Kobayashi H and Brechbiel M.W. 2005 Adv. Drug Deliv. Rev. 57 2271- 2286). In a recent study a biotin-BS A-GdDTPA was used for tracking tumor stroma fibroblasts by MRI. Remarkably, histological staining by the biotinylated albumin based marker showed high specificity to myofibroblast stroma tracks. However subsequent in vivo studies pointed out the exclusion of the contrast medium from the tumor nodules, suggesting that the interaction of therapeutics or contrast medium with albumin could hinder their delivery to the tumor cells. It is also well known in the art that albumin is used as an immunogenic carrier for small molecules which are usually non immunogenic. Wang et al. J. Agric. Food. Chem., 1994, 42:1584-7, disclosed the preparation of a BSA-formononetin conjugate for the preparation of anti-formononetin antibodies.
There is a recognized need for more efficient approaches for the detection and treatment of cancer, and it would be highly advantageous to have improved probes, which can be used for affinity targeting of both therapeutic and imaging agents.
SUMMARY OF THE INVENTION
The present invention relates to conjugates comprising at least one isoflavone derivative bound to albumin and at least one bioactive moiety including but not limited to a diagnostic agent or a therapeutic agent, said conjugates being capable of delivering the bioactive moiety into a cell and their use for the diagnosis and treatment of cancer. The present invention also provides improved targeting methods where internalization and cellular retention of a bioactive moiety (e.g. a diagnostic or a therapeutic agent) are enhanced by binding of the bioactive moiety to an isoflavone- albumin conjugate. It is now disclosed that is the conjugates of the present invention are unexpectedly internalized in target cells to a greater extent and/or faster than without such internalization agent (e.g. isoflavone-albumin).
The present invention is based in part on the unexpected discovery that the conjugation of carboxy isoflavone derivatives to albumin significantly increase the
uptake of the conjugate by cancerous cell lines sensitive to isoflavone. Specifically it was shown, that an imaging agent attached to a daidzein-BSA conjugate was specifically localized in ovarian carcinoma tumor cells, and displayed prolonged retention in the tumor of up to 7 days after administration as compared to the same imaging agent attached to BSA alone. Furthermore, unexpectedly, addition of nystatin, which usually inhibits BSA cellular uptake, resulted in significant augmentation of the cellular uptake of the daidzein-BSA conjugate. Without wishing to be bound to any theory or mechanism of action it is hypothesized that the conjugate is regulating endocytosis by cancerous cell lines sensitive to isoflavone, involving competition between receptor mediated internalization through the binding of the carboxy isoflavone derivative and caveolae mediated internalization via binding of albumin.
"Cells sensitive to isoflavone" as used herein refers to cells whose growth may be affected by isoflavones or by carboxy derivatives of isoflavones. At certain concentrations the isoflavones may enhance growth, while at other concentrations the isoflavones may result in inhibition of cancer cell growth. According to one embodiment, cells sensitive to isoflavone are cancer cells. Non limiting examples to cancer cells which are sensitive to isoflavones include ovarian carcinoma cells, colon cancer cells, breast cancer cells, melanoma, non-small lung cancer, leukemia, endometrial cancer and prostate cancer cells. According to one embodiment, cells sensitive to isoflavone may also be estrogen sensitive cells. According to another embodiment, cells sensitive to isoflavone are cells expressing an estrogen receptor. According to yet another embodiment the cells sensitive to isoflavone are cells expressing a nuclear or putative membranal estrogen receptor subtype β. According to a further embodiment, cell sensitive to isoflavone are cells susceptible to isoflavone.
According to one aspect, the present invention provides a conjugate comprising at. least one isoflavone derivative bound to albumin and at least one compound D, the conjugate represented by the structure of general formula (I):
Albumin — Dn1
(I) wherein m is 1-20; ni is 0-10; n2 is 0 or 1 ;
R1 is selected from the group consisting of -OH, -OCH3, -OGIc, -OR7COOX and -OR7C(=O)-;
R2, R5 and R6 are each independently selected from the group consisting of -H, -R7COOX and -R7C(=0)-;
R3 is selected from the group consisting of -H, -OH, -R7COOX, -OR7COOX, -R7C(O)- and -0R7C(=0)-; R4 is selected from the group consisting of -H, -CH3, -R7COOX and -R7C(=0)-;
D is a active agent selected from the group consisting of a diagnostic agent (e.g. an imaging agent) and a therapeutic agent;
R7 is selected from the group consisting Of Cj-C6 alkylene, (C2-C2o) alkenylene; and (C2-C20) heteroalkylene;
X is selected from the group consisting of -H and -(CH2)n-Y wherein Y is -CH3 or -NH2 and n is 0-10; with the proviso that one of R1, R2, R3, R4, R5 or R6 comprises a carboxy group selected from -0R7C(=0)- and -R7C(=O)- which is bound to albumin, and at least one of ni and n2 is other than zero.
According to one embodiment, the conjugate of the invention is capable of delivering the bioactive moiety into a cell sensitive to isoflavone. According to another embodiment, the conjugate displays improved properties having at least one of increased partition into a cancer cell (e.g. tumor cell), prolonged tumor retention or increased circulation time. The conjugates of the invention comprising an isoflavone bound to albumin and a bioactive moiety bound to the isoflavone, albumin or both, have improved qualities selected from partition to the tumor, tumor retention and circulation time compared to the bioactive moiety alone, the bioactive moiety bound to albumin, or the bioactive moiety bound to isoflavone. According to some embodiments of the present invention, the isoflavone derivative is selected from a derivative of diadzein, genistein, formononetin and biochanin A. According to one exemplary embodiment, the isoflavone derivative is daidzein derivative.
According to some embodiments the carboxy-isoflavone derivative is selected from the group consisting of 7-(O)-carboxymethyl daidzein, 6-carboxymethyl biochanin A, 2-carboxyalkyl biochanin A, 8-carboxymethyl biochanin A, 7-(O)- carboxymethyl formononetin, 2-carboxyalkyl genistein and 6-carboxymethyl genistein. According to one embodiment, the carboxy-isoflavone derivative is 2- carboxyalkyl biochanin A. According to other embodiment, the carboxy-isoflavone derivative is 6-carboxymethyl biochanin A. According to other embodiment, the carboxy-isoflavone derivative is 8-carboxymethyl biochanin A. According to an exemplary embodiment, the carboxy-isoflavone derivative is 7-(O)-carboxymethyl daidzein (i.e., R1 is -0-CH2-C(O)- and R2 - R6 are all -H).
According to some embodiments of the present invention, D is an imaging agent selected from, yet not restricted to paramagnetic particles (such as gadolinium, yttrium, lutetium, europium and gallinium); radioactive moieties (such as radioactive indium, rhenium and technetium); fluorescent dyes (such as fluorescein isothiocyanate (FITC), green fluorescent protein (GFP), Cyan fluorescent protein
(CFP), rhodamine I, II, III and IV, rhodamine B, rosamine and infrared dyes (such as CyTEE-777)). According to certain embodiments the paramagnetic particles as well as the radioactive moieties can be provided within a chelator. Non-limiting examples for chelators include: tetraazacyclododecanetetraacetic acid (DOTA), mercaptoacetylglycylglycyl-glycine (MAG3), diethylenetriamine pentaacetic acid
(DTPA) and N-l-φ-isothiocyanatopheny^diethylenetriamine-N^N^N3- tetraacetate(DTTA).
According to some embodiments of the present invention, D is a therapeutic agent selected from the group consisting of a cytotoxic compound, a cytostatic compound, an antisense compound and an anti-viral agent. According to some embodiments, D is a cytotoxic compound.
According to some embodiments, the cytotoxic compound D is selected from, but not restricted to DNA synthesis and function inhibitory agents (such as adriamycin, bleomycin, chlorambucil, cisplatin, carboplatin, oxaloplatin, daunomycin, ifosfamide and melphalan); microtubule (mitotic spindle) formation and function inhibitory agents (such as vinblastine, vincristine, vinorelbine, paclitaxel (taxol) and docetaxel); anti metabolites (such as cytarabine, fluorouracil, fluroximidine, mercaptopurine, methotrexate, gemcitabin and thioquanine); alkylating agents (such as mechlorethamine, chlorambucil, cyclophosphamide, melphalan and methotrexate); antibiotics (such as bleomycin and mitomycin); nitrosoureas (such as carmustine (BCNU) and lomustine); hormones (such as tamoxifen, leuprolide, flutamide and megestrol acetate) and proteins (such as interferon and asparaginase).
According to some embodiments, the cytotoxic substance D is an anti-tumor agent. According to some other embodiments, the anti-tumor agent D is selected from the group consisting of adriamycin, bleomycin, chlorambucil, cisplatin, daunomycin and melphalan. According to some embodiments, the anti-tumor agent is daunomycin.
According to some other embodiments, the conjugate of the present invention may further comprise an affinity molecule. According to one embodiment, the affinity molecule is attached to the albumin. According to some embodiments, the affinity molecule is selected from the group consisting of at least the antigen-binding portion of a specific antibody and biotin.
According to some embodiments of the present invention, nt is greater than 1 and D may be the same or different at each occurrence. According to other embodiments, n2 is other than zero where one of R1, R2, R3, R4, R5 or R6 comprises a carboxy group selected from -OR7C(=O)- and -R7C(=O)- which is bound to D.
According to some embodiments, both n! and n2 are other than zero where one of R1, R2, R3, R4, R5 or R6 comprises a carboxy group selected from -OR7C(^O)- and - R7C(=O)- which is bound to D, wherein D may be the same or different at each occurrence. According to another aspect the present invention provides a diagnostic composition comprising an effective amount (e.g. an amount effective for enhancing image contrast in an imaging procedure) of a conjugate comprising at least one isoflavone derivative which is bound to albumin and at least one compound D which is an imaging agent. According to another aspect the present invention provides a pharmaceutical composition comprising an effective amount of a conjugate comprising at least one isoflavone derivative which is bound to albumin and at least one compound D which is a therapeutic agent.
According to a further aspect the present invention provides a method of targeting cells sensitive to isoflavone comprising administering to a subject in need thereof an effective amount of a conjugate comprising at least one isoflavone derivative which is bound to albumin and at least one bioactive moiety.
According to another aspect, the invention provides a method for generating enhanced images of a human or animal body and generation of an image of at least part of said body.
According to yet another aspect, the present invention provides a method for diagnosing cancer in a subject comprising administering to the subject a conjugate comprising at least one isoflavone derivative bound to albumin and at least one diagnostic compound for affinity targeting of the diagnostic compound to cells sensitive to isoflavone. According to one embodiment, the cells are cancer cells. According to another embodiment of the invention diagnosis of tumors may be performed in vitro or in vivo. According to various embodiments, diagnosis may be performed either directly or indirectly in an in vivo diagnostic imaging procedure e.g. by magnetic resonance imaging (MRI), near infrared (NIR), optical imaging, scintigraphy, SPECT, PET, X-ray, ultrasound imaging, electrical impedance or magnetometric procedures. According to some embodiments, the diagnostic imaging procedure is MRI. According to other embodiments, the diagnostic imaging procedure
is NIR. According to some embodiments, in vivo diagnosis may be used to detect the presence of a disease state and/or monitor the progression of the disease. According to some embodiments, the conjugates (compositions of matter) of the invention are useful diagnostic contrast agents for in vivo imaging of a mammalian body. According to another aspect the present invention provides a method for treating cancer comprising administering to a subject in need thereof a therapeutical composition comprising a therapeutically effective amount of a conjugate comprising at least one isoflavone derivative bound to albumin and at least one compound D being a therapeutic agent, thereby targeting and internalizing the conjugate to cells susceptible to isoflavone. According to some embodiments, cancer treated by methods of the invention is selected from the group consisting of ovarian cancer, colon cancer, breast cancer, melanoma, non-small lung cancer, leukemia, endometrial cancer and prostate cancer. According to some currently preferred embodiments, the present invention provides a method for treating ovarian cancer. According to some embodiments, the methods of the invention may be used to treat diseases other than cancer. According to some embodiments the disease other than cancer is an estrogen related condition such as osteoporosis, endometriosis, atherosclerosis, cardiovascular disease, hypercholesterolemia, prostatic hypertrophy, obesity, menopausal syndromes, type-II diabetes, and Alzheimer's disease. The present invention will be better understood in conjunction with the description, figures and claims below.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. IA shows the specific binding and endocytosis of daidzein-BSA-FAM by MLS ovarian carcinoma cells. Two-photon fluorescence microscopy of MLS human ovarian carcinoma cells incubated with Daidzein-BSA-FAM or BSA-FAM, in the presence or absence of a blocking dose of nystatin. Panel a. DAPI nuclear staining in gray; panel b. Daidzein-BSA-FAM or BSA-FAM in white; panel c. overlay of panels a and b. Fig. IB shows the specific binding and endocytosis of BSA-ROX and Daidzein-BSA-FAM by MLS ovarian carcinoma cells. Two-photon fluorescence
microscopy of MLS human ovarian carcinoma cells incubated with Daidzein-BSA- FAM and BSA-ROX, with or without nystatin
FIG. 2 shows the binding and endocytosis of BSA-ROX and Daidzein-B SA-FAM by
MLS ovarian carcinoma cells as determined by FACS analysis. A. Histogram of Daidzein-B SA-FAM uptake (grey-control, black-Daidzein-B SA-FAM uptake, light gray- Daidzein-BSA-FAM uptake in presence of nystatin), collected by FLl filter (BP
530/30); B. BSA-ROX uptake (grey-control, black- BSA-ROX uptake, dark gray-
BSA-FAM uptake in presence of nystatin), collected by FL2 filter (BP 585/42); C.
Statistics median of uptake histogram analysis (c=control; n=nystatin; dbf=daidzein- BSA-FAM; br=BSA-ROX).
FIG. 3 Competition of Daidzein-BSA-FAM (light gray) by BSA-ROX (gray) in the absence (A) and presence of nystatin (B) (FLl filter for the collection of FAM fluorescence, FL2 filter for the collection of ROX fluorescence), C and D display control samples without and with nystatin respectively. E. Statistical analysis of the competition assay. Change in percent of positively stained fluorescent cells in the absence and presence of nystatin (n) (light gray-Daidzein-B SA-FAM (dbf), dark gray- BSA-ROX (br)).
FIG. 4 shows the in vivo targeted delivery of daidzein-BSA-CyTE-777 to ovarian carcinoma tumors followed by NIR Imaging. daidzein-BSA-CyTE-777 (A); Control BSA-CyTE-777 (B); daidzein-BSA-CyTE-777 + BSA-FAM after 48 hours (C) and 72 hours (D) respectively; E. In Vivo Imaging of daidzein-BSA-CyTE-777: localization in tumor-free CD-I nude mice. CD-I nude mice were injected intravenously with daidzein-BSA-CyTE-777 (left) or non injected (right). The NIR signal after 24 hours is shown. FIG. 5 shows the biodistribution of daidzein-BS A-EuDTTA versus BSA-EuDTTA in MLS tumor bearing mice. A. Europium signal 24h after injection (n=3-5). B. Europium signal 48h after injection (Tl-injected with BSA- EuDTTA, T2 and T3 - injected with daidzein-B SA-Eu). C. Western blot analysis with anti-daidzein antibody of the extracts of tumors (T), kidneys (K) and livers (L) of mice 48h after injection. FIG. 6 demonstrates that while Daidzein-BSA-FAM accumulates in tumor cells, BSA-FAM is localized in tumor blood vessels. A. Control. B. Section of a tumor from
a mouse injected with BSA-FAM. C. Section of a tumor from a mouse injected with daidzein-BSA-FAM (FAM-white; DAPI-gray).
FIG. 7 demonstrates the advantages of using daidzein-B SA-GdDTPA as a contrast material to MRI. A. The specific R1 relaxivity of daidzein-B SA-GdDTPA was measured to be 194 mM'V1 per BSA; B. shows the specific localization and retention of the contrast material inside the tumor in MLS bearing mice administered intravenously with BSA-GdDTPA (left panel) or daidzein-BSA-GdDTPA (right panel). Tl weighted MRI images and R1 maps were obtained 24, 48 and 72h after injection, and used for derivation of mean R1 values of the tumor; C. shows the statistically significant elevation of Rl relaxation in tumors injected with daidzein- BSA-GdDTPA as compared with non injected animals or mice injected with BSA- GdDTPA; D, E. demonstrate prolonged detection of contrast material inside the tumor in MLS tumor bearing mice administered intravenously daidzein-BSA- GdDTPA after 24h and 7 days respectively.
DETAILED DESCRIPTION OF THE INVENTION
Unless otherwise specified, "a" or "an" means "one or more".
The present invention relates to conjugates comprising at least one isoflavone derivative bound to albumin and at least one bioactive moiety including but not limited to a diagnostic agent (e.g. imaging agent) or a therapeutic agent and their use for the diagnosis and treatment of cancer.
According to some aspects the present invention relates to the use of the conjugate comprising at least one isoflavone derivative bound to albumin and at least one bioactive moiety selected from an imaging agent for targeting of the imaging agent to cancer cells for diagnostic purposes. According to some embodiments, the cancer cells are sensitive to isoflavone.
According to other aspects the present invention relates to the use of the conjugate comprising at least one isoflavone derivative bound to albumin and at least one bioactive moiety selected from a therapeutic agent for targeting of drugs to cancer cells for cancer treatment purposes. According to some embodiments, the cancer cells are sensitive to isoflavone.
The term "targeting" as used herein means that the conjugate is able to induce the formation of a functional response (preferably the accumulation of a diagnostic agent or an anti-cancer drug in cells sensitive to isoflavone) in cancer cells preferentially over normal cells as compared with the diagnostic agents or drugs commonly used which are not given as part of the conjugate of the invention..
As used herein, a "diagnostic agent" is a molecule or atom which is conjugated to a targeting moiety (e.g. isoflavone or isoflavone-albumin), to produce a conjugate, which is useful for diagnosis. Non-limiting examples of diagnostic agents include paramagnetic particles; radioactive moieties; fluorescent dyes and infrared dyes. According to one embodiment, the diagnostic agent is a contrast agent. According to some embodiments, the diagnostic agent may be provided within a chelator. According to other embodiments, the conjugate of the invention comprising isoflavone derivative bound to albumin and a diagnostic agent may be used as a contrast agent. The term "therapeutic agent" as used herein refers to a molecule or atom which is conjugated to a targeting moiety (e.g. isoflavone or isoflavone-albumin conjugate) to produce a conjugate which is useful for therapy. Non limiting examples of therapeutic agents include cytotoxic compounds, cytostatic compounds, antisense compounds or anti-viral agents. Delivery of bioactive moieties to tumor cells:
Despite the high permeability of VEGF stimulated tumor neovasculature to plasma proteins, targeting of contrast media and delivery of therapeutics to tumors is frequently compromised leading to poor sensitivity for tumor detection and resistance to therapy. The low transfer rate is attributed to high interstitial pressure (Bouzin et al., 2007, Drug Resist. Updat.; 10: 109-20). The present invention is directed to a bifunctional targeted conjugate comprising isoflavone, albumin and an active agent (diagnostic and/or therapeutic agents) which effectively overcomes the tumor-blood barrier, thus increasing the delivery of the conjugate to the rumor cells. Without wishing to be bound by any theory or mechanism of action it is hypothesized that tumor cells escape from delivery of extravasated albumin based compounds, through caveolae mediated sequestration of the albumin based compound by perivascular myofibroblasts, thus generating an effective tumor-blood barrier. Evoking an alternate
competing endocytic pathway using isoflavone (e.g. daidzein) resulted in significant partition of the isoflavone-albumin based compound (e.g. the conjugate of the invention) into the tumor. According to some embodiments, the partition of the conjugate of the invention into the tumor could be further enhanced in the presence of free albumin (non conjugated albumin). According to other embodiments, the partition of the conjugate of the present invention into the tumor could be further enhanced by the addition or co-administration of nystatin. Without wishing to be bound by any theory or mechanism of action, it is hypothesized that the free albumin or nystatin increase the partition of the conjugate through suppression of caveolae mediated endocytosis by competition with the conjugate, in the absence of direct modulation of the tumor interstitial pressure.
The term "partition into a cell" or "partition into a cancer cell" or "partition into a tumor cell" as used herein refers to the amount of bioactive moiety (diagnostic agent and/or therapeutic agent) found in the interior part of a cell versus the amount of the bioactive moiety found at the exterior part of the cell, specifically, within or on the cell's membrane. According to one embodiment, the partition into a tumor cell of the bioactive moiety is at least 10% higher than the partition into a tumor cell of the bioactive moiety when administered alone and/or bound to albumin alone and/or bound to isoflavone alone; alternatively, at least 20% higher; alternatively at least 30% higher; alternatively, at least 40% higher; alternatively, at least 50% higher; alternatively, at least 60% higher; alternatively, at least 70% higher; alternatively, at least 80% higher; alternatively, at least 90% higher; alternatively, at least 2 times higher; alternatively at least 3 times higher.
According to some embodiments, the conjugate of the present invention displays prolonged tumor retention and/or increased circulation time as compared to tumor retention and circulation time of the bioactive agent alone, the bioactive agent bound to albumin alone, or the bioactive agent bound to isoflavone alone.
The term "tumor retention" refers to the duration of the presence of a sufficient amount of a bioactive moiety inside a tumor cell since the time it was administered to a subject, or introduced to the cell, or internalized or up taken by the cell. The term "sufficient amount" implies a sufficient amount of a diagnostic agent that will enable detection (e.g. tumor detection) using various diagnostic methods, for example, the diagnostic imaging procedures described. Alternatively, "sufficient
amount" implies an amount of a therapeutic agent which is sufficient to cause a desired therapeutic effect. According to some embodiments, the bioactive moiety of the conjugate is retained inside the tumor cell for at least 7 days; alternatively, for at least 5 days, alternatively, for at least 3 days, alternatively for at least 48 hours, alternatively, for at least 24 hours.
"Circulation time" as used herein refers to the duration of the presence of the conjugate of the invention in the blood or plasma; specifically, to the duration of the presence of the bioactive moiety, which is part of the conjugate, in the blood or plasma. The circulation time of the bioactive moiety is determined by its distribution, metabolism and its removal from the body via excretion. Alternatively, "circulation time" may be referred to as the half-life of the bioactive moiety in the plasma. "Half- life" refers to the period of time required for the concentration or amount of the bioactive moiety in the body to be reduced by one-half. A plasma half-life of a bioactive moiety depends on how quickly the bioactive moiety is eliminated from the plasma. A bioactive moiety that leaves plasma may have any of several fates. It can be eliminated from the body, or it can be translocated to another body fluid compartment such as the intracellular fluid or it can be destroyed in the blood. The removal of a the bioactive moiety from the plasma is known as clearance and the distribution of the bioactive moiety in the various body tissues is known as the volume of distribution. Both of these pharmacokinetic parameters are important in determining the circulation time or half life of a bioactive moiety.
Experimentally the half life can be determined by giving a single dose, usually intravenously, and then measure the concentration of the bioactive moiety in the plasma at regular intervals. The concentration of the drug will reach a peak value in the plasma and will then fall as the bioactive moiety is hydrolyzed or broken down and cleared from the blood.
According to some embodiments of the present invention, the circulation time or the half-life of a bioactive moiety is increased upon introduction or binding of the bioactive moiety to an isoflavone-albumin conjugate. According to one embodiment, the circulation time or half-life of the bioactive moiety is at least 10% higher than the circulation time or half-life of the bioactive moiety when administered alone, bound to albumin, or bound to isoflavone; alternatively, at least 20% higher; alternatively at least 30% higher; alternatively, at least 40% higher; alternatively, at least 50% higher;
alternatively, at least 60% higher; alternatively, at least 70% higher; alternatively, at least 80% higher; alternatively, at least 90% higher; alternatively, at least 2 times higher; alternatively at least 3 times higher.
It should be appreciated that each of the following conjugates consisting of two constituents: isoflavone-albumin, albumin-bioactive moiety and isofiavone- bioactive moiety was known in the prior art, however a three constituents conjugate comprising isoflavone, albumin and a bioactive moiety had been disclosed for the first time in the present invention and shows superior properties such as high cellular partition and tumor retention over those achieved by the conjugates consisting of two constituents s described above, when these properties has been determined.
Chemical definitions:
The term "Cl to C6 alkylene" refers to a saturated, linear or branched hydrocarbon moiety, such as -CH2-, -CH2-CH2-; -CH2-CH2-CH2-; -CH2-(CH2)2-CH2; -CH2-(CH2)3-CH2; -CH2-(CH2)4-CH2;. The term "C2 to C20 alkenylene" as used herein, denotes a divalent group derived from a straight chain or branch hydrocarbon moiety containing from two to twenty carbon atoms having at least one carbon-carbon double bond. Alkenylene groups include, but are not limited to, for example, ethenylene, 2-propenylene, 2- butenylene, l-methyl-2-buten-l-ylene, and the like. The term "heteroalkylene" refers to an alkylene or alkenylene moiety having at least one heteroatom (e.g., N, O, or S). Preferred are heteroalkylenes having at least one O.
The term "GIc" denotes glucosyl or glucoside. Isoflavone compounds Epidemiological in vitro as well as in vivo animal studies indicate that isoflavones present in large quantities in soybeans and soy products (e.g., genistein, daidzein) and red clover (biochanin A) are promising agents for cancer therapy, chemoprevention and inhibition of tumor progression (Aggarwal, B. B. at al, Biochem. Pharmacol. 2006, 71, 1397). In estrogen-sensitive cancer cell lines (e.g., breast, colon, etc.) expressing estrogen receptor ERa, ERβ or both, these isoflavone compounds can act as weak estrogens and stimulate cell growth at concentrations
ranging from 0.1 to 20 μM. The affinity of most isoflavones to the two subtypes of ER is low (Kuiper, G. G. at al, Endocrinology 1998, 139, 4252) with the exception of genistein, which shows a strong selectivity for Erβ over Era. Both genistein and daidzein display 100-fold greater sensitivity for activating transcription in transfected cells via Erβ compared to Era (Harris, D. M. at al., Exp. Biol. Med. 2005, 230, 558). Interestingly, isoflavones inhibit cell growth at concentrations greater than 20 μM. According to some embodiments, isoflavone compounds display estrogenic effects (e.g. stimulate cell growth). According to other embodiments, isoflavone compounds display anti-estrogenic effects (e.g. inhibit cell growth). Thus, according to some embodiments, isoflavone compounds may be referred to as modulators of cell growth.
In addition to the estrogenic and anti-estrogenic effects, isoflavones show a wide spectrum of biological activities not ascribed to activation of the ER such as regulation of cell-signaling pathways, and can inhibit proliferation and induce apoptosis in ER-negative breast cancer cell lines as well as in ER-positive cell lines. Examples include genistein which was shown to inhibit the protein-tyrosine kinase pathway and was further used in a treatment of choroidal neovascularization (U.S. Pat. No. 6,028,099). Genistein was also shown to display topoisomerase II activity, and to induce apoptosis and cell differentiation. Moreover, genistein has been shown to inhibit the proliferation of both cancer and normal cells, and was used for prophylactic treatment of cataract (WO 00/37066).
The 4-methoxy derivative of genistein, biochanin A, is equally potent to genistein as a growth inhibitor in breast cancer lines due to its conversion to genistein
(Peterson et al. Am. J. Clin. Nutr. 1998 68:1505S-1511S). However, when administered in equal doses, biochanin A, and not genistein, inhibited the growth of several tumors derived from the gastrointestinal tract and grown in nude mice.
Among the isoflavones daidzein exhibits unique properties. Daidzein is known to interact with the lipid interface on the cell surface (Lehtonen J.Y et al. Biochim Biophys Acta, 1996 1285: 91-100) thus facilitating endocytosis. Furthermore, acting as a weak estrogen, daidzein may recognize a putative plasma membrane estrogen receptor (Somjen D. et al. J Steroid Biochem MoI Biol, 2005 93: 293-303), a membranal ERβ-related protein (De Wilde A. et al. J Cell Physiol, 2006 209: 786- 801) or a nuclear estrogen receptor of the β-type.
The use of the isoflavone ring as a template for designing isoflavone carboxy derivatives useful as selective estrogen receptor modulators (SERMs) has been described (US 2005/0096381 Al). The contents of the aforementioned reference are incorporated by reference herein in their entirety as if fully set forth herein. The synthesis and evaluation of the anti-proliferative activities of derivatives of carboxyalkyl isoflavones has been described by U.S. Patent Application No. 2005/0096381 and Kohen F. et al., J Med. Chem., 2007, 50, 6405-6410. Methods for the conjugation of a bioactive moiety to carboxy derivatives of isoflavones are described by U.S. Patent Application No. 2005/0096381. The contents of the aforementioned references are incorporated by reference herein in their entirety as if fully set forth herein. It is to be appreciated that the conjugation of a bioactive moiety to a carboxy derivative of isoflavone may be done by any other means known in the art.
Albumin As used herein, the term albumin includes human serum albumin, animal albumin, recombinant albumin, and fragments thereof. Additionally, the albumin may exist as a monomer, a dimer, a polymer, or may be enclosed in microspheres. Albumin as disclosed herein may also be treated with polyethylene glycol (PEG) by well-known techniques to increase its immunocompatibility. According to one embodiment, albumin comprises human serum albumin. According to another embodiment, albumin comprises bovine serum albumin (BSA). It is to be appreciated that species-specific serum albumin is necessary for compatibility reasons. Thus, when treating or diagnosing human patients, human serum albumin may preferably be used and when treating or diagnosing other animals, the serum albumin should likewise be species-specific, e.g., bovine serum albumin for treating or diagnosing cattle.
According to one embodiment the albumin in the conjugate is used as a carrier. The isoflavone carboxy derivatives and the bioactive moieties according to the invention may be conjugated to the albumin carrier by any means know in the art, non-limiting examples include: conjugation through the albumin's lysine residues (amino groups), conjugation through the N-terminus and conjugation through cy stein residues (thiol groups). For example, amino, hydroxyl and hydrazine groups can each
form a covalent bond with a reactive carbonyl group (e.g., a carboxylic acid chloride or activated ester such as an N-hydroxysuccinimide ester (NHS)). Other suitable bond forming groups are well-known in the literature and can be used to prepare the conjugates of the present invention. Specifically, carboxy derivatives of isoflavones as well as bioactive moieties may be coupled to an amino group of albumin (e.g. lysine group) via N-hydroxysuccinimide ester. Alternatively N-sulfo succinimide and a water soluble carbodiimide may be used for coupling a carboxy group of the isoflavone or of the bioactive moiety to an amino group of albumin through the formation of a peptide linkage. Bioactive moieties
According to some embodiments, the conjugate of the invention comprises a bioactive moiety selected from a diagnostic agent and a therapeutic agent. According to some embodiments the bioactive moiety is a therapeutic agent selected from the group consisting of a cytotoxic compound, a cytostatic compound, an antisense compound, an anti-viral agent.
According to some embodiments, the cytotoxic compound is selected from, but not restricted to DNA synthesis and function inhibitory agents; microtubule (mitotic spindle) formation and function inhibitory agents; anti metabolites; alkylating agents; antibiotics; nitrosoureas; hormones and proteins. According to some embodiments, the therapeutic agent is an anti-tumor agent.
As referred to herein, the term "anti-cancer reagent" refers to any type of reagent that may be used in the treatment of cancer and/or cancer related conditions.
The anti-cancer reagent may include any naturally occurring or synthetically produced molecule that is capable of affecting directly or indirectly the growth and/or viability of cancer cells. The anti-cancer reagent may include, for example, a naturally occurring protein or peptide, a modified protein or peptide, a recombinant protein, a chemically synthesized protein or peptide, a chemical molecule, a synthetic chemical molecule, a chemotherapeutic drug, a biologically therapeutic drug, and the like, or any combination thereof. The anti-cancer reagent may be cytotoxic (toxic to cells) and/or cytostatic (suppress cell growth) and/or antiproliferative to the cancer cells and may exert its effect on cancer cells directly and/or indirectly.
Non limiting examples of anti-cancer agents and chemotherapeutic drugs may include such drugs as, but not limited to: Alkaloids, such as, but not limited to: Docetaxel, Etoposide, Irinotecan, Paclitaxel, Teniposide, Topotecan, Vinblastine, Vincristine, Vindesine; Alkylating agents, such as, but not limited to: Busulfan, Improsulfan, Piposulfan, Benzodepa, Carboquone, Meturedepa, Uredepa, Altretamine, triethylenemelamine, Triethylenephosphoramide,
Triethylenethiophosphoramide, Chlorambucil, Chloranaphazine, Cyclophosphamide, Estramustine, Ifosfamide, Mechlorethamine, Mechlorethamine Oxide HcI, Melphalan, Novemebichin, Perfosfamide Phenesterine, Prednimustine, Trofosfamide, Uracil Mustard, Carmustine, Chlorozotocin, Fotemustine, Lomustine, Nimustine, Semustine Ranimustine, Dacarbazine, Mannomustine, Mitobronitol, Mitolactol, Pipobroman, Temozolomide; Antibiotics and analogs, such as, but not limited to: Aclacinomycins, Actinomycins, Anthramycin, Azaserine, Bleomycins, Cactinomycin, Carubicin, Carzinophilin, Cromomycins, Dactinomycins, Daunorubicin, 6-Diazo-5-oxo-L- norleucine, Doxorubicin, Epirubicin, Idarubicin, Menogaril, Mitomycins, Mycophenolic Acid, Nogalamycine, Olivomycins, Peplomycin, Pirarubicin, Plicamycin, Porfiromycin, Puromycine, Streptonigrin, Streptozocin, Tubercidin, Zinostatin, Zorubicin; Antimetabolites, such as, but not limited to: Denopterin, Edatrexate, Methotrexate, Piritrexim, Pteropterin, Tomudex, Trimetrexate, Cladridine, Fludarabine, 6-Mercaptopurine, Pentostatine Thiamiprine, Thioguanine, Ancitabine, Azacitidine, 6-Azauridine, Carmofur, Cytarabine, Doxifluridine, Emitefur, Floxuridine, Fluorouracil, Gemcitabine, Tegafur; Platinum complexes, such as, but not limited to: Caroplatin, Cisplatin, Miboplatin, Oxaliplatin; alkylators including, but not limited to, busulfan (Myleran, Busulfex), chlorambucil (Leukeran), ifosfamide (with or without MESNA), cyclophosphamide (Cytoxan, Neosar), glufosfamide, melphalan, L-PAM (Alkeran), dacarbazine (DTIC-Dome), and temozolamide (Temodar); anthracyclines, including, but not limited to doxorubicin (Adriamycin, Doxil, Rubex), mitoxantrone (Novantrone), idarubicin (Idamycin), valrubicin (Valstar), and epirubicin (Ellence); antibiotics, including, but not limited to, dactinomycin, actinomycin D (Cosmegen), bleomycin (Blenoxane), daunorubicin, and daunomycin (Cerubidine, DanuoXome); aromatase inhibitors, including, but not limited to anastrozole (Arimidex) and letroazole (Femara); bisphosphonates, including, but not limited to zoledronate (Zometa); cyclo-oxygenase inhibitors, including, but not limited to, celecoxib (Celebrex); estrogen receptor modulators
including, but not limited to tamoxifen (Nolvadex) and fiilvestrant (Faslodex); folate antagonists including, but not limited to methotrexate and tremetrexate; inorganic aresenatesincluding, but not limited to arsenic trioxide (Trisenox); microtubule inhibitors (e.g. taxanes) including, but not limited to vincristine (Oncovin), vinblastine (Velban), paclitaxel (Taxol, Paxene), vinorelbine (Navelbine), epothilone B or D or a derivative of either, and discodermolide or its derivatives, nitrosoureas including, but not limited to procarbazine (Matulane), lomustine, CCNU (CeeBU), carmustine (BCNU, BiCNU, Gliadel Wafer), and estramustine (Emcyt); nucleoside analogs including, but not limited to mercaptopurine, 6-MP (Purinethol), fluorouracil, 5-FU (Adrucil), thioguanine, 6-TG (Thioguanine), hydroxyurea (Hydrea), cytarabine (Cytosar-U, DepoCyt), floxuridine (FUDR), fludarabine (Fludara), pentostatin (Nipent), cladribine (Leustatin, 2-CdA), gemcitabine (Gemzar), and capecitabine (Xeloda); osteoclast inhibitors including, but not limited to pamidronate (Aredia); platinum containing compounds including, but not limited to cisplatin (Platinol) and carboplatin (Paraplatin); retinoids including, but not limited to tretinoin, ATRA (Vesanoid), alitretinoin (Panretin), and bexarotene (Targretin); topoisomerase 1 inhibitors including, but not limited to topotecan (Hycamtin) and irinotecan (Camptostar); topoisomerase 2 inhibitors including, but not limited to etoposide, VP- 16 (Vepesid), teniposide, VM-26 (Vumon), and etoposide phosphate (Etopophos); tyrosine kinase inhibitors including, but not limited to imatinib (Gleevec); various other proteins, peptides and enzymes, various other molecules, such as, for example, Super Oxide dismutase (SOD), leptin; flavanoids; or any combinations thereof.
According to some embodiments the bioactive moiety is a diagnostic agent selected from the group consisting of paramagnetic particles; radioactive moieties; dyes, fluorophores, and infrared dyes. Typical diagnostic radioactive moieties include "01Tc, 95Tc, 111In, 62Cu, 64Cu, 67Ga, and 68Ga; and therapeutic radioactive moieties include 186Re, 188Re, 153Sm, 166Ho, 177Lu, 149Pm, 90Y, 212Bi, 103Pd, 109Pd, 159Gd, 140La, 198Au, 199Au, 169Yb, 175Yb, 165Dy, 166Dy, 67Cu, 105Rh, 111Ag, and 192Ir. Typical paramagnetic particles include rare earth metals, typically, gadolinium, manganese, yttrium, ytterbium, europium, lutetium, gallinium and the like. Iron ions may also be used.
Preferred fluorophore moieties include fluorescent dyes having (a) high fluorescence intensity; (b) sufficiently long excitation and emission wavelength
maxima so that interference from natural fluorescence of either diseased or normal tissue is minimized; (c) sufficiently long measured fluorescence decay time to allow accurate measurement of emitted light over background fluorescence and scattering (at least about 2, preferably at least about 10 nanoseconds); and (d) high degree of fluorescence polarization. Fluorophores include macrocyclic fluorescent dye compounds, especially compounds having aromatic π-electron systems. These fluorophore moieties may comprise a substantially planar multidentate macrocyclic ligand and may be coordinated to a complexing central ion or atom such as aluminum, phosphorous, and the group FVB elements, e.g. silicon, germanium, and tin. Other suitable fluorophores include coumarin dyes, nitrobenzoxazole dyes, cyanine dyes, dipyrrometheneboron dyes, xanthene dyes (including the benzo- and naphtho- xanthene dyes), phenoxazine dyes (as well as the benzo- and naphtho-phenoxazine dyes) and compounds from other classes of dyes well known to those of skill in the art. Other suitable fluorophores include the fluorophores in the following non- exclusive list: 1,5 IAEDANS; 1,8-ANS; 4-Methylumbelliferone; 5-carboxy-2,7- dichlorofluorescein; 5-Carboxyfluorescein (5 -FAM); 5-Carboxynapthofluorescein; 5- Carboxytetramethylrhodamine (5-TAMRA); 5-FAM (5-Carboxyfluorescein); 5-HAT (Hydroxy Tryptamine); 5 -Hydroxy Tryptamine (HAT); 5 -ROX (carboxy-X- rhodamine); 5-TAMRA (5-Carboxytetramethylrhodamine); 6-Carboxyrhodamine 6G; 6-CR 6G; 6- JOE; 7-Amino-4-methylcoumarin; 7-Aminoactinomycin D (7-AAD); 7- Hydroxy-4-methylcoumarin; 9-Amino-6-chloro-2-methoxyacridine; ABQ; Acid Fuchsin; ACMA (9-Amino-6-chloro-2-rnethoxyacridine); Acridine Orange; Acridine Red; Acridine Yellow; Acriflavin; Acriflavin Feulgen SITSA; Aequorin (Photoprotein); AutoFluorescent Protein-(Quantum Biotechnologies) see sgGFP, sgBFP; Alexa Fluor (various)™; Alizarin Complexon; Alizarin Red; AUophycocyanin (APC); AMC, AMCA-S; AMCA Aminomethylcoumarin); AMCA-X; Aminoactinomycin D; Aminocoumarin; Aminomethylcoumarin (AMCA); Anilin Blue 600; Anthrocyl stearate; APC (AUophycocyanin); APC-Cy7; APTRA- BTC=Ratio Dye, Zn2+; APTS; Astrazon Brilliant Red 4G, Orange R, Red 6B, and Yellow 7 GLL; Atabrine; ATTO-TAG™ CBQCA and FQ; Auramine; Aurophosphine; BAO 9 (Bisaminophenyloxadiazole); BCECF (high or low pH); Berberine Sulphate; Beta Lactamase; BFP blue shifted GFP; Blue Fluorescent Protein; blue shifted GFP (Y66H); BFP/GFP FRET; Bimane; Bisbenzamide; bis-BTC=Ratio
Dye, Zn2+; Blancophor FFG and SV; BOBO™-1 and -3; Bodipy (various); BO-
PRO™- 1 and -3; Brilliant Sulphoflavin; BTC-Ratio Dye Ca2+; BTC-5N; Calcein; Calcein Blue; Calcium Crimson™; Calcium Green (various) and Orange; Calcofluor White; Carboxy-X-rhodamine (5-ROX); Cascade Blue™; Cascade Yellow; Catecholamine; CCF2 (GeneBlazer); CFDA; CFP-Cyan Fluorescent Protein; Cyan Fluorescent Protein; CFP/YFP FRET; Chlorophyll; Chromomycin A; CL-NERF (Ratio Dye, pH); CMFDA; Coelenterazine Dye (various); Coumarin Phalloidin; C- phycocyanine; Methylcoumarin; Methylcoumarin CTC; CTC Formazan; Cy2™ and various others; Cyan GFP; cyclic AMP Fluorosensor (FiCRhR); Dabcyl (various); Dansyl (various); DAPI; Dapoxyl (various); DCFDA; DCFH (Dichlorodihydrofluorescein Diacetate); DDAO; DHR (Dihydorhodamine 123); Di-4- ANEPPS; Di-8-ANEPPS; DiA (4-Di- 16- ASP); Dichlorodihydrofluorescein Diacetate (DCFH); DiD-Lipophilic Tracer; DiD (DiICl 8(5)); DIDS; Dihydorhodamine 123 (DHR); DiI (DiICl 8(3)); Dinitrophenol; DiO (DiOCl 8(3)); DiR (various); DM-NERF (high pH); DNP; Dopamine; DsRed; DTAF; DY-630-NHS; DY-635-NHS; EBFP; Enhanced Blue Fluorescent Protein; Enhanced Cyan Fluorescent Protein; Enhanced Green Fluorescent Protein; ELF; Eosin; Erythrosin; Erythrosin; Ethidium Bromide; Ethidium homodimer-1 (EthD-1); Euchrysin; EukoLight; Europium (III) chloride; EYFP; Enhanced Yellow Fluorescent Protein; Fast Blue; FDA; Feulgen (Pararosaniline); FIF (Formaldehyd Induced Fluorescence); Flazo Orange; Fluo-3; Fluo-4; Fluorescein (FITC); Fluorescein Diacetate; Fluoro-Emerald; Fluoro-Gold (Hydroxystilbamidine); Fluor-Ruby; FluorX; FM 1-43™; FM 4-46; Fura Red™ (various); Genacryl Brilliant Red B, Brilliant Yellow 10GF, Pink 3G, and Yellow 5GF; GeneBlazer (CCF2); GFP (various); Gloxalic Acid; Granular Blue; Haematoporphyrin; Hoechst 33258, 33342, and 34580; HPTS; Hydroxycoumarin; Hydroxystilbamidine (FluoroGold); Hydroxytryptamine; Indo-1 (various); Indodicarbocyanine (DiD); Indotricarbocyanine (DiR); Intrawhite Cf; JC-I; JO-JO-I; JO-PRO-I; LaserPro; Laurodan; LDS 751; Leucophor PAF, SF, and WS; Lissamine Rhodamine (various); Calcein/Ethidium homodimer; LOLO-I; LO-PRO-I; Lucifer Yellow; Lyso Tracker (various); LysoSensor (various); Mag Green; Magdala Red (Phloxin B); Mag-Fura Red; Mag-Fura-2; Mag-Fura-5; Mag-Indo-1; Magnesium Green and Orange; Malachite Green; Marina Blue; Maxilon Brilliant Flavin; Maxilon Brilliant Flavin; Merocyanin; Methoxycoumarin; Mitotracker Green, Orange, and Red; Mitramycin; Monobromobimane; Monobromobimane (mBBr-GSH);
Monochlorobimane; MPS (Methyl Green Pyronine Stilbene); NBD; NBD Amine;
Nile Red; Nitrobenzoxadidole; Noradrenaline; Nuclear Fast Red; Nuclear Yellow; Nylosan Brilliant lavin; Oregon Green™ (various); Pacific Blue; Pararosaniline (Feulgen); PBFI; PE-Cy5 and Cy7; PerCP; PE-TexasRed [Red 613]; Phloxin B (Magdala Red); Phorwite (various); Phosphine; PhotoResist; Phycoerythrin B and R; PKH26 and PKH67; PMIA; Pontochrome Blue Black; POPO-I and -3; PO-PRO-I and -3; Primuline; Procion Yellow; Propidium lodid (PI); PYMPO; Pyrene; Pyronine; Pyronine B; Pyrozal Brilliant Flavin; QSY; Quinacrine Mustard; Red 613 [PE- TexasRed]; Resorufin; Rhodamine (various); Rose Bengal; R-phycocyanine; R- phycoerythrin (PE); red shifted GFP (various); Sapphire GFP; SBFI; Serotonin; Sevron Brilliant Red, Orange, and Yellow L; SuperGlo™GFP (various); SITS (various); SNAFL (various); SNARF; Sodium Green; SpectrumAqua, Green, Orange, and Red; SPQ (6-methoxy-N-(3-sulfopropyl)quinolinium); Stilbene; Sulphorhodamine B and G; SYTO (various); SYTOX Blue, Green, and Orange; Tetracycline; Tetramethylrhodamine (TRITC); Texas Red™; Texas Red-X™ conjugate; Thiadicarbocyanine (DiSC3); Thiazine Red R; Thiazole Orange; Thioflavin 5, S, and TCN; Thiolyte; Thiozole Orange; Tinopol CBS (Calcofluor White); TMR; TO-PRO-I, -3 and -5; TOTO-I and -3; TriColor (PE-Cy5); TRITC; TetramethylRodaminelsoThioCyanate; True Blue; TruRed; Ultralite; Uranine B; Uvitex SFC; X-Rhodamine; XRITC; Xylene Orange; Y66F, H, and W; Yellow shifted Green Fluorescent Protein; Yellow Fluorescent Protein; YO-PRO-I and -3; and; YOYO-I and -3.
Infrared dyes include cyanine dyes. Non limiting examples of cyanine dyes include l,r,3,3,3',3'-Hexamethylindotricarbocyanine iodide; 1,1',3,3,3',3'- Hexamethylindotricarbocyanine perchlorate; l,l'-Diethyl-2,2'-dicarbocyanine iodide; l,l'-Diethyl-2,2'-quinotricarbocyanine iodide; l,l'-Diethyl-4,4'-carbocyanine iodide; l,l '-Diethyl-4,4'-dicarbocyanine iodide; l,3-Bis[4-(dimethylamino)-2- hydroxyphenyl]-2,4-dihydroxycyclobutenediylium dihydroxide, bis(inner salt); 1 ,4,8, 11,15,18,22,25-Octabutoxy-29H,3 lH-phthalocyanine; 1,8,15,22-
Tetrakis(phenylthio)-29H,3 lH-phthalocyanine; 2,11 ,20,29-Tetra-tert-butyl-2,3- naphthalocyanine; 2,3 ,9, 10, 16, 17,23,24-Octakis(octyloxy)-29H,31 H-phthalocyanine; 2,3-Naphthalocyanine; 2,9, 16,23-Tetrakis(phenylthio)-29H,31 H-phthalocyanine; 2,9, 16,23 -Tetra-tert-butyl-29H,31 H-phthalocyanine; 2,9, 16,23-Tetraphenoxy-
29H,31 H-phthalocyanine; 29H,31H-Phthalocyanine β-form; 3,3'-
Diethylthiadicarbocyanine iodide; 3,3'-Diethylthiatricarbocyanine iodide; 5,9,14,18,23,27,32,36-Octabutoxy-2,3-naphthalocyanine; Aluminum
1 ,4,8, 11,15,18,22,25-octabutoxy-29H,31 H-phthalocyanine triethylsiloxide;
Aluminum phthalocyanine chloride; Boron sub-2,3-naphthalocyanine chloride; Cobalt(II) 1,2,3,4,8,9,10,1 l,15,16,17,18,22,23,24,25-hexadecafluoro-29H,31H- phthalocyanine; Cobalt(II) 2,3-naphthalocyanine; Cobalt(II) phthalocyanine β-form; Copper phthalocyanine-3,4',4",4'"-tetrasulfonic acid tetrasodium salt; Copper(II) 3, 10, 17,24-tetra-tert-butyl- 1 ,8, 15,22-tetrakis(dimethylamino)-29H,31 H- phthalocyanine; Copper(II) 5,9,14,18,23,27,32,36-octabutoxy-2,3-naphthalocyanine; Copper(II) phthalocyanine; Dilithium phthalocyanine; Gallium(III) 2,3- naphthalocyanine chloride; Gallium(III)-phthalocyanine chloride; IR-1048; IR-1061; IR- 140; IR-27; IR-676 iodide; IR-676; IR-775 chloride; IR-780 iodide; IR-783; IR- 786; IR-786 perchlorate; IR-792 perchlorate; IR-797 chloride; IR-800; IR-806; IR- 813 perchlorate; IR-820; IR-895; Indocyanine green Dye; Iron(II) phthalocyanine; Lead(II) phthalocyanine; Magnesium phthalocyanine; Manganese(II) phthalocyanine; Methylsilicon(IV) phthalocyanine chloride; Nickel(II) phthalocyanine Dye; Propyl Astra Blue Iodide; Silicon 2,3-naphthalocyanine dichloride; Tetrakis(4- cumylphenoxy)phthalocyanine; Tin(II) phthalocyanine; Titanium(IV) phthalocyanine dichloride; Vanadyl 2,3-naphthalocyanine; Zinc phthalocyanine and Zinc(II) tetranitrophthalocyanine. According to currently preffered embodiments, the infarared dye is CyTEE-777. Other examples of suitable cyanine dyes are described in U.S. Patent No. 7,514,069, the contents of the aforementioned reference are incorporated by reference herein in their entirety as if fully set forth herein.
According to certain embodiments the paramagnetic particles as well as the radioactive moieties can be provided within a chelator. Non-limiting examples for chelators include: tetraazacyclododecanetetraacetic acid (DOTA), mercaptoacetylglycylglycyl-glycine (MAG3), diethylenetriamine pentaacetic acid
(DTPA), N- 1 -(p-isothiocyanatophenyl)diethylenetriamine-N1 ,N2,N3 -tetraacetate
(DTTA), l,4,7-triaza-cyclononane-N-N'-N"-triacetic acid (NOTA) and tetraazacyclotetradecane-N,N',N",N'"-tetraacetic acid (TETA). The preparation of metal chelates may be carried out by any means know in the art
According to some embodiments, the conjugate comprising at least one isoflavone derivative bound to albumin and at least one diagnostic compound is
selected from the group of 7-(O)-carboxymethyl daidzein-albumin-CyTE-777, 7-(O)- carboxymethyl daidzein-albumin-GdDTPA, 7-(O)-carboxymethyl daidzein-albumin- FAM and 7-(O)-carboxymethyl daidzein-albumin-EuDTTA.
Diagnosis and treatment of cancer In yet another aspect the present invention provides methods for the diagnosis and treatment of cancer in a subject comprising administering a conjugate comprising at least one isoflavone derivative bound to albumin and at least one bioactive moiety selected from a diagnostic agent and/or a therapeutic agent. According to some embodiments, the conjugate of the invention is useful for targeting cells sensitive to isoflavone, preferably, cancer cells sensitive to isoflavone.
The present methods find broad applicability in the detection and treatment of a number of cancers. According to some embodiments, the cancer may include solid tumors, non-solid tumors, primary tumors, metastasis or any combination thereof. The cancer may include carcinomas, sarcomas, myelomas, leukemias, lymphomas or any combination thereof. The cancer may include lymphoproliferative disorders, breast cancer, ovarian cancer, prostate cancer, cervical cancer, endometrial cancer, bone cancer, liver cancer, stomach cancer, colon cancer, pancreatic cancer, cancer of the thyroid, head and neck cancer, cancer of the central nervous system, cancer of the peripheral nervous system, skin cancer, kidney cancer, a metastasis thereof or any combination thereof. The cancer may include hepatocellular carcinoma, hematoma, hepatoblastoma, rhabdomyosarcoma, esophageal carcinoma, thyroid carcinoma, ganglioblastoma, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, Ewing's tumor, leimyosarcoma, rhabdotheliosarcoma, invasive ductal carcinoma, papillary adenocarcinoma, melanoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, renal cell carcinoma, hypernephroma, hypernephroid adenocarcinoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, testicular tumor, lung carcinoma including small cell, non- small and large cell lung carcinoma, bladder carcinoma, glioma, astrocyoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, retinoblastoma, neuroblastoma, colon carcinoma, rectal carcinoma, hematopoietic malignancies including all types of leukemia and lymphoma including: acute myelogenous leukemia, acute myelocytic leukemia, acute lymphocytic leukemia, chronic
myelogenous leukemia, chronic lymphocytic leukemia, mast cell leukemia, multiple myeloma, myeloid lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma or any combination thereof. According to some embodiments, the cancer comprises cancer cells sensitive to isoflavone. According to some embodiments, cancer may include ovarian carcinoma, colon cancer, breast cancer, melanoma, non-small lung cancer, leukemia, endometrial cancer and prostate cancer. According to some embodiment, the cancer is ovarian cancer. According to some embodiments, the cancer is breast cancer. According to some embodiments, the cancer is colon cancer. According to some embodiments, the cancer is prostate cancer. According to the present invention provides methods for detecting or imaging cancer cells in a subject, comprising (a) administering to the subject an effective amount of a conjugate comprising at least one isoflavone derivative bound to albumin and at least one diagnostic agent; and (b) detecting or imaging cells that take up the conjugate to determine if cancer is present in a subject. Detection of the conjugate can be performed using essentially any detection device to obtain an image of the cancerous cells. According to various embodiments, diagnosis may be performed either directly or indirectly in an in vivo diagnostic imaging procedure e.g. by magnetic resonance imaging (MRI), near infrared (NIR), optical imaging, scintigraphy, SPECT, PET, X-ray, ultrasound imaging, electrical impedance or magnetometric procedures. According to some embodiments, the diagnostic imaging procedure is MRI. According to other embodiments, the diagnostic imaging procedure is NIR. According to some embodiments, in vivo diagnosis may be used to detect the presence of a disease state and/or monitor the progression of the disease. According to some embodiments, the conjugates of the invention are useful diagnostic contrast agents for in vivo imaging of a mammalian body.
The diagnostic conjugates of the present invention can be used in a method which comprises administering to a subject's body, or to selected regions thereof, effective amounts of the diagnostic conjugate. The agent can be injected directly into the vicinity of the body to be imaged, or it can be intravenously, intradermaly, intralesionaly, intramusculary, intravesiculary, subcutaneously injections or gastrointestinally administered. Then, an image of the body or of the indicated region is obtained using conventional imaging equipment and techniques as described above.
The image thus produced by that equipment can optionally be fixed in hard copy form, in photographic negative or positive form, or stored within a computer memory for subsequent recall onto a screen or for subsequent conversion into hard copy.
A "diagnostically effective amount" as used herein refers to a dose of the diagnostic conjugate, or diagnostic agent that is sufficient for detection (e.g. tumor detection) using the various diagnostic methods described. Typical doses of the diagnostic conjugates are in the range from about 0.001 to about 20 mmol/kg body weight, and preferably in the range from about 0.005 to about 5 mmol/kg body weight. The diagnostically effective amount may be different depending on the diagnostic agent attached to the conjugate of the invention as well as the diagnostic apparatus used for detection.
According to a further aspect the present invention provides a method for site targeted chemotherapy in a subject in need thereof comprising administering to the subject a therapeutical composition comprising a therapeutically effective amount of a conjugate comprising at least one isoflavone derivative bound to albumin and at least one cytotoxic compound for targeting of the cytotoxic compound to cancer cells. According to some embodiments, the cancer cells are sensitive to isoflavone.
The term "therapeutically effective amount" as used herein refers to that amount of the therapeutic conjugate of the invention which elicits a biological or medicinal response that will contribute to the cancer-treating ability of the therapeutic conjugate.
The term "treating" as used herein refers to partial or total inhibition of the growth, spreading, or metastasis of cancer, as well as partial or total destruction of the cancer cells. The term "treating" includes the reduction or elimination of cancer, and also the reduction in the incidence of the disease.
Diagnostic and therapeutic compositions
According to another embodiment, the present invention provides pharmaceutical composition i.e., diagnostic and therapeutic compositions, comprising as an active ingredient a conjugate comprising at least one isoflavone derivative bound to albumin and at least one compound selected from a diagnostic agent and a therapeutic agent according to embodiment of the invention and a pharmaceutically acceptable carrier, excipient or diluent.
As used herein, a "diagnostic composition" refers to a preparation of one or more of the active ingredients described herein, e.g. a conjugate comprising at least one isoflavone derivative bound to albumin and at least one compound which is a diagnostic agent, with other components such as physiologically suitable carriers and excipients. The purpose of a diagnostic composition is to facilitate the administration of the conjugate of the invention to a subject for diagnostic purposes.
As used herein, a "therapeutic composition" refers to a preparation of one or more of the active ingredients described herein, e.g. a conjugate comprising at least one isoflavone derivative bound to albumin and at least one compound which is a therapeutic agent, with other components such as physiologically suitable carriers and excipients. The purpose of a therapeutic composition is to facilitate the administration of the conjugate of the invention to a subject for treatment purposes.
Hereinafter, the phrases "therapeutically acceptable carrier" and "pharmaceutically acceptable carrier", which may be used interchangeably, refer to a carrier or a diluent that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered compound.
Herein, the term "excipient" refers to an inert substance added to a diagnostic or a pharmaceutical composition to further facilitate administration of an active ingredient. Examples, without limitation, of excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils, and polyethylene glycols.
In another embodiment of the present invention, a diagnostic or a pharmaceutical composition further comprises a pharmaceutically acceptable carrier. As used herein, a "carrier" refers to any substance suitable as a vehicle for delivering a conjugate of the present invention to a suitable in vivo or in vitro site. As such, carriers can act as a pharmaceutically acceptable excipients of a diagnostic or a therapeutical composition containing a conjugate of the present invention. Preferred carriers are capable of maintaining a conjugate of the present invention in a form that, upon arrival of the conjugate to a cell, the conjugate is capable of entering the cell. Non limiting examples of suitable carriers include: water, phosphate buffered saline, Ringer's solution, dextrose solution, serum-containing solutions, Hank's solution, other aqueous physiologically balanced solutions, oils, esters and glycols. Aqueous carriers can contain suitable auxiliary substances required to approximate the
physiological conditions of the recipient, for example, by enhancing chemical stability and isotonicity.
Suitable auxiliary substances include, for example, sodium acetate, sodium chloride, sodium lactate, potassium chloride, calcium chloride, and other substances used to produce phosphate buffer, Tris buffer, and bicarbonate buffer. Auxiliary substances can also include preservatives, such as thimerosal, m- and o-cresol, formalin and benzol alcohol. Preferred auxiliary substances for aerosol delivery include surfactant substances non-toxic to a subject, for example, esters or partial esters of fatty acids containing from about six to about twenty-two carbon atoms. Examples of esters include: caproic, octanoic, lauric, palmitic, stearic, linoleic, linolenic, olesteric, and oleic acids. Diagnostic and therapeutic compositions of the present invention can be sterilized by conventional methods.
Pharmaceutical composition for use in accordance with the present invention thus may be formulated in conventional manner using one or more acceptable diluents or carriers comprising excipients and auxiliaries as described, which facilitate processing of the active compounds into preparations, which can be used pharmaceutically. Proper formulation is dependent on the route of administration chosen.
The diagnostic and therapeutic composition of the present invention may be formulated for administration by a route selected from the group consisting of intravenous injections, intravenous infusion, intradermal, intralesional, intramuscular, intravesicular and subcutaneous injections or depots. Alternatively, the composition of the invention may be administered parenterally by means other than injection, for example, they could be introduced laparascopically, intravesicularly, or via any orifice not related to the gastrointestinal tract. Alternatively, the compositions of the present invention may be formulated for oral administration.
The diagnostic and therapeutic compositions can take the form of solutions, suspensions, emulsions, syrups, gels, tablets, pills, capsules, powders, suppositories and the like. Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Such compositions will contain an effective amount of the conjugate of the invention, preferably in a substantially purified form, together with a
suitable amount of carrier so as to provide the form for proper administration to the subject.
Pharmaceutical composition of the present invention may be manufactured by processes well known in the art, e.g. by means of conventional mixing, dissolving, granulating, grinding, pulverizing, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.
The principles of the invention, using an albumin conjugate isoflavone derivative bound to a bioactive moiety such as an imaging agent or a therapeutic agent for selective delivery to cells susceptible to isoflavone according to the present invention, may be better understood with reference to the following non-limiting examples.
EXAMPLES
Reagents: BSA, nystatin, diethylenetriamine pentaacetic acid (DTPA) anhydride, GdCl3 and 4',6-diamidino-2-phenylindole (DAPI) - sigma-Aldrich (St. Louis, MO).
Carboxyfluorescein succinimide ester (FAM-NHS)), Carboxy-X-rhodamin succinimide ester (ROX-NHS) - Molecular Probes, Invitrogen (California, USA).
N- 1 -(p-isothiocyanatophenyl)diethylenetriamine-N ' ,N2,N3-tetraacetate(DTTA) chelated with Eu 3+- Perkin-Elmer (Turku, Finland).
Example 1: Synthesis of daidzein-BSA-imaging agent conjugate:
The conjugates were prepared in a three-step procedure. In the first step of the reaction, both the carboxy derivative of daidzein and the imaging agent were treated with N-hydroxysuccinimide and carbodiimide to form an active ester. In the second step the activated ester of the imaging agent reacted at pH 8.5 with the amino group of lysine residues of BSA to form a BSA-imaging agent conjugate. In the third step the activated ester of daidzein reacted at pH 8.5 with the amino group of lysine residues of BSA to form a daidzein-BSA-imaging agent conjugate The synthesis of Daidzein-BSA-GdDTPA: BSA-DTPA was synthesized as described (Dafni et al., 2003, Magn. Reson. Med.; 50:904-14). Briefly, DTPA anhydride 1.6 gr
(suspended in 4 ml of dry DMF) was slowly added with stirring to BSA 1.3 gr (in 40 ml Hepes 0.1 M, pH 8.8) while the reaction was titrated with NaOH 5N and stirred for 2 hours. The product was dialyzed against NaHCO3. Afterwards, the N- hydroxysuccinimide ester of 7-(O)-carboxymethyl (daidzein-NHS), synthesized according to Kohen et al, 2007, J Med. Chem.; 50:6405-10, (11 mg in 800 μl of anhydrous DMF) was added to BSA-DTPA (in 40 ml OfNaHCO3, 0.1M, pH 8.5) and stirred overnight. The product was dialyzed first against NaHCO3, followed by sodium citrate (0.1 M, pH 6.5). GdCl3 650 mg (in 5 ml sodium acetate 0.1M, pH 6.0) was added to Daidzein-B SA-DTPA in sodium citrate (0.1 M pH 6.5). The final product (Daidzein-BSA-GdDTPA) was dialyzed extensively against water and lyophilized.
The synthesis of daidzein-BSA-CvTE-777/FAM/ROX: CyTE-777-NHS (44 mg) prepared according to Hilderbrand et al., 2005, Bioconjug. Chem.; 16:1275-81, or FAM-NHS (35 mg) or ROX-NHS (35 mg) (in 200 μl of dry DMF) were added to BSA (450 mg in 15 ml NaHCO3, 0.1M, pH 8.5), slowly with stirring. The reaction was stirred overnight, and the product was dialyzed against NaHCO3, 0.1M, pH 8.5, followed by several changes of water and lyophilized. The preparation of N- hydroxysuccinimide ester of 7-(O)-carboxymethyl (daidzein NHS) has been reported previously (Kohen, et al. 2007, J Med. Chem. 50:6405-6410; Dafni et al. 2002. NMR Biomed 15:120-131).
N-hydroxysuccinimide ester of 7-(O)-carboxymethyl (daidzein-NHS), (8 mg in 600 μl of anhydrous DMF) was added to BSA-CyTE-777 (100 mg in 6 ml of NaHCO3, 0.1M, pH 8.5) and stirred overnight. The product was purified by dialyzed against NaHCO3 0.1M, pH 8.5, followed by extensive dialysis against water and lyophilized.
Example 2: In vitro evaluation of the endocytic pathways in ovarian cancer cells: a. A fluorescence microscopy study:
MLS cells (2*105) were cultured on polylysine coated coverslips for 48h. Subsequently, the coverslips were incubated for 1 hour at 37 with daidzein-BSA- FAM (200 μg/ml) or BSA-FAM (200 μg/ml) or combination of both in the presence and absence of a blocking dose of nystatin (50 μg/ml). The excess of fluorescent material was washed 3 times with PBS, and the cells were fixed with 4% PFA,
washed, stained with DAPI and mounted. The images were monitored by two-photon microscopy (2PM; Zeiss LSM 510 META NLO; equipped with a broadband Mai Tai- HP-fentosecond single box tunable Ti-sapphire oscillator, with automated broadband wavelength tuning 700-1020 nm from Spectraphysics, for two-photon excitation). In this experiment the uptake of BSA-FAM, targeting cellular caveolae, and daidzein- BSA-FAM, targeting both caveolae and cell surface receptors with affinity to daidzein, by MLS human epithelial ovarian carcinoma cells was detected by fluorescence microscopy. It was shown that the fluorescent probes internalized the interacellular vesicles (FIG. IA). Upon addition of nystatin (50 μg/ml, 30 min), an elevated membrane staining and reduced uptake of BSA-FAM was observed (FIG. IA, B), whereas a significant enhanced internalization of daidzein-B SA-FAM by MLS cells was observed (FIG. IA).
Without being bound by theory or mechanism of action it is hypothesized that albumin binding mediated by caveolae interferes with the internalization of daidzein- BSA-FAM into the cells, despite the role of caveolae uptake of BSA-FAM.
To further test this hypothesis, the ability of BSA to compete with daidzein-BSA- FAM on the albumin binding site in caveolae, thus facilitating the internalization of the material into the cells, was tested (FIG. IB). Here again, internalization of daidzein-BSA-FAM was augmented by addition of nystatin. b. A flow cytometry study:
MLS cells (106) were incubated for 30 minutes with daidzein-BSA-FAM (200 μg/ml) or BSA-ROX (200 μg/ml) or a combination of both in the presence and absence of nystatin (50 μg/ml). The excess of fluorescent material was washed three times with PBS containing 0.01% of sodium azide. The cellular uptake of fluorescent material was monitored by FACScan (Becoton Dickinson, USA). The excitation produced by air-cooled argon laser 288 nm and the emission signal was collected by FLl filter (BP530/30) for FAM and FL2 filter (BP585/42) for ROX.
In this experiment the treatment of cells with nystatin resulted in a significant 4 fold enhancement in the fluorescence intensity of cells incubated with daidzein-BSA-FAM (FIG. 2A, B). On the other hand, binding and uptake of BSA-ROX were only slightly reduced by nystatin. Incubation of the cells with both BSA-ROX and daidzein-BSA- FAM resulted in differential response to nystatin, with increased labeling of cells with
daidzein-BSA-FAM (3 fold induction in the intensity and increase of 20% in the population of labeled cells) and decreased fluorescence of BSA-ROX (1.3 fold in intensity and 51% decrease in the labeled population) (FIG. 3 A-E).
Example 3: In vivo targeted delivery of daidzein-BSA-CyTE-777 to ovarian carcinoma cells:
All in vivo experiments were approved by the Animal Care and Use Committee of the Weizmann Institute. CD-I nude mice were inoculated s.c. with 2.5*106 MLS rumor cells. Tumors were allowed to grow until 5-7 mm in diameter (for approximately 14- 21 days). a. A NIR imaging study:
Tumor bearing mice were injected intravenously with daidzein-BSA-CyTE-777 (i.v.; lmg (for IVIS 100) or 0.5 mg (for IVIS Spectrum) in 0.1 ml PBS/mouse; n=5 and n=2 respectively); or with BSA-CyTE-777 (1 mg or 0.5 mg in 0.1 ml PBS/mouse; n=2 and n=2) as control or with and BSA-FAM (lmg in 0.1 ml PBS/mouse) as a non specific competitor. The NIR signal in the whole animal was monitored by IVIS 100 and IVIS Spectrum (Xenogen, Caliper) at 24, 48 and 72 hours. The mice were fed with alfalfa-free (chlorophyll-free) diet 72 hours before visualization. In the IVIS 100 the data was acquired by 710-760 excitation, 675-720 excitation background and 810- 860 emission filters, hi the IVIS Spectrum the data obtained for the daidzein-BSA- CyTE-777 was acquired by 745 nm excitation and 820 nm emission filters. The pharmacokinetics of the fluorescent and MRI BSA based contrast media and their plasma concentration after intravenous administration were previously reported to be similar for all tags (Dafni et al. 2003, Magn. Reson. Med., 50:904-14). Systemic delivery of daidzein-BSA-CyTE-777 resulted in tumor selective enhancement of NIR fluorescent for subcutaneous ovarian carcinoma tumor xenografts. Mice were inoculated subcutaneously with 2.5* 106 MLS tumor cells. Ten days after tumor inoculation, mice administered with daidzein-BSA-CyTE777 or BSA-CyTE777. Already in the first 30 minutes after administration, mice injected with daidzein-BSA-CyTE777 showed more specific localization in the tumor and in higher concentration than mice administered with BSA-CyTE777. Competition of daidzein-BSA-CyTE777 with BSA-ROX overload increased the NIR signal of
daidzein-BSA-CyTE777 in the tumor. This experiment further demonstrated different pharmacokinetic behavior in the elimination of the contrast materials from the tumor. Control mice injected with BSA-CyTE777 showed first order clearance of the contrast media. Daidzein-BSA-CyTE777 was eliminated with rapid initial kinetics, however it was followed by residual retention of daidzein-BSA-CyTE777 with very slow clearance. Thus, after the initial elimination mice administered with daidzein- BSA-CyTE777 showed specific NIR signal in the tumor area with maximal tumor to background ratio 48 hours after administration (n=8; FIG. 4A). Control mice that were injected with BSA-Cy TE-777 did not show any residual NIR signal 48 hours after administration (n=2; FIG. 4B). Prolonged enhancement of the fluorescent signal in the tumor area was further observed in mice that were injected with both daidzein- BSA-CyTE-777 and the non-specific competitor - BSA-FAM. In these mice the NIR signal could be detected even 72 hours after administration (n=2-4; FIG. 4C and D). The NIR signal in the tumors was detectable even 10 days after the administration. b. A biodistribution study:
The tumor bearing mice were injected intravenously with BSA-Eu chelate (0.34 mg equivalent to 100000 counts of europium in 0.1 ml PBS/mouse) or daidzein-BSA-Eu chelate (0.24 mg of protein equivalent to 100000 counts of europium in 0.1 ml PBS/mouse). The Eu chelates were used here due to their chemical similarity to the Gd chelates used for MRI. After 24 and 48 hours the mice were sacrificed and tumors as well as various tissues were removed. The tissues were subsequently homogenized in RIPA buffer ((20 mM Tris, pH 7.4, 137 mM NaCl, 10% glycerol, 0.5% (wt/vol) sodium deoxycholate, 0.1% (wt/vol) sodium dodecyl sulfate (SDS), 1% Triton X-100, 2 mM EDTA) containing 1 mM phenylmethylsulfonyl fluoride (PMSF) and protease inhibitor cocktail) and centrifuged in an airfuge. The protein content in supernatant was first quantified by Bradford assay and then used for biodistribution studies and Western blot analysis.
For biodistribution studies an aliquot (20μg) from each of the supernatants was added to a microtiter plate. Enhancement solution (200μl) was added to each aliquot and the plate was shaken for 15 minutes on a plate shaker. The Europium signal in the wells was measured by time resolved fluorescence using Victor (Perkin-Elmer, USA).
For Western blot analysis, aliquots (100 mg/lane) from the supernatants were subjected to 8% SDS-PAGE. Proteins were electrophoretically transferred from the SDS-polyacrilamide gel to a nitrocellulose membrane (Protan BA 85, Schleicher & Schuell). The membrane was blocked over night at 4C with 2% BSA in 10 mM Tris- buffered saline containing 0.05% Tween (TBST), followed by incubation with anti- daidzein antibody IgG (1 mg/ml TBS) for 2 hours at 25C. The membrane was then washed three times in TBST, incubated with an HRP-conjugated goat anti mouse antibody (1:10000 in TBS) and re- washed. The protein bands were visualized by ECL. These experiments demonstrated that 24 and 48 hours after injection, a 2 to 3 fold increase in Eu in tumors of mice injected with daidzein-BSA-Eu chelate was observed as compared to those injected with BSA-Eu chelate (FIG. 5A, B). Western blot analysis of tissues isolated 48 hours after injection from these mice showed a specific protein band of daidzein-BSA in the tumor, liver and kidney of the daidzein-BSA-Eu chelate treated animal, but not in the BSA-Eu chelate treated animal (FIG. 5C).
The distribution of contrast material inside the tumors was visualized by fluorescence microscopy, in tumors isolated 24 hours after injection with daidzein-B SA-FAM or BSA-FAM. Daidzein-BSA-FAM was localized in the tumor cells areas, while BSA- FAM was localized to the tumor blood vessels and their surrounding stroma cells (Fig. 6A - C). c. An MRI study:
MRI studies were performed on a horizontal 4.7T Bruker Biospec spectrometer using an actively radio-frequency decoupled 1.5 cm surface coil embedded in a Perspex board and a birdcage transmission coil. For in-vitro experiments: R1 measurements spin echo images were acquired at 8 different repetition times ranging between 2000 and 100 ms; 2 averages, field of view 4x4 cm, slice thickness 1 mm, matrix 128x128). R] relaxation rates for the in vitro experiments were derived by non linear single exponential fitting of images acquired at different repetition times according to equation I: I = M0 (l-e"TR*Rl) (I)
Where I is the measured signal intensity for each TR and Ri is derived from optimization of the curve fitting; Mo is the steady state signal intensity in fully relaxed images.
For in vivo experiments: The tumor bearing mice were injected intravenously with BSA-GdDTPA (12 mg in 200 μL PBS/mouse) or daidzein-BSA-GdDTPA (12 mg in 200 μL PBS/mouse) or with combination of daidzein-BSA-GdDTPA and BSA-FAM (competition experiment). Rl was measure 24, 48 and 72 hours after injection of the contrast material. Tl weighted 3D gradient-echo (GE) images, with pulse flip angles of 5°, 15°, 30°, 50° and 70° were acquired for the determination of Rl values. The acquisition parameters used: TR 10 ms; TE 3.561 ms; 2 averages; field of view 4x4x4; 128x128x128 pixels. Three-dimensional gradient-echo data sets were used for generation of Rl maps as well as for calculation of the average Rl values in selected regions of interest by nonlinear best fit to equation [H]:
I = M0 sin α (1 -e"TR*Rl) / (1 - cos α e"TR*Rl) (II) Where I is the signal intensity as a function of the pulse flip angle. Student's t test (two tailed, equal variance) was used for statistical analysis of the significance of change in relaxation rate between control and labeled tumors.
Daidzein-BSA-GdDTPA showed significant relaxivity of 194 mM'V1 (per BSA; FIG. 7A). This relaxivity was similar to the relaxivity of BSA-GdDTPA 196 mM'V1 (per BSA). MRI data acquired from MLS tumor bearing mice 24 hours after administration of daidzein-BSA-GdDTPA or BSA-GdDTPA, showed significantly higher contrast enhancement, consistent with accumulation of daidzein-BSA- GdDTPA (targeted contrast agent) in the tumor area as compared to vehicle injected mice or mice injected with BSA-GdDTPA (non-targeted contrast agent) (FIG. 7B). Time course experiments showed specific localization and retention of daidzein-BSA- GdDTPA in the tumor site 24, 48 and 72 hours after injection as compared to controls or mice injected with BSA-GdDTPA. Statistically significant elevation of Ri relaxation was visualized in tumors injected with daidzein-BSA-GdDTPA as compared to non injected mice or mice injected with BSA-GdDTPA (for 24h p=0.01 ; 48h p-0.016, 72h p=0.0488) (FIG. 7C). Prolonged detection of daidzein-BSA- GdDTPA was feasible even for a lower administrate dose. MLS tumor bearing mice were injected with daidzein-BSA-GdDTPA (4 mg/200 μl; n=3). The specific
localization of the targeted contrast agent in the tumor site was detected by MRI at 9.4T 24h after injection (FIG. 7D) and was still detectable and even enhanced 7 days after injection (FIG. 7E).
Claims
1. A conjugate comprising at least one isoflavone derivative bound to albumin and at least one compound D, the conjugate represented by the structure of general formula (I):
Albumin — Dn1
I wherein m is 1-20; ni is 0-10; n2 is 0 or 1 ;
R1 is selected from the group consisting of -OH, -OCH3, -OGIc, -OR7COOX and -OR7C(=O)-;
R2, R5 and R are each independently selected from the group consisting of -H, -
-R7COOX and -R7C(O)-;
R3 is selected from the group consisting of -H, -OH, -R7COOX, -OR7COOX, -
R7C(K))- and -OR7C(=O)-;
R4 is selected from the group consisting of -H, -CH3, -R7COOX and -R7C(=0)-;
D is a bioactive moiety selected from a diagnostic agent and a therapeutic agent;
R7 is selected from the group consisting of Cj-C6 alkylene, (C2-C20) alkenylene; and (C2-C20) heteroalkylene;
X is selected from the group consisting of -H and -(CH2V Y wherein Y is -CH3 or -NH2 and n is 0-10; with the proviso that one of R1, R2, R3, R4, R5 or R6 is comprises a carboxy group selected from -OR7C(O)- and -R7C(O)- which is bound to albumin, where at least one of ni and n2 is other than zero.
2. The conjugate of claim 1, wherein the conjugate is capable of delivering the bioactive moiety into a cell sensitive to isoflavone.
3. The conjugate of claim 2, wherein the cell is a cancer cell.
4. The conjugate of claim 3, wherein the cancer cell is selected from the group consisting of an ovarian carcinoma cell, a colon cancer cell, a breast cancer cell, a melanoma cell, a non-small lung cancer cell, a leukemia cell, an endometrial cancer cell and a prostate cancer cell.
5. The conjugate of claim 1 , wherein n\ is other than zero and when n\ is greater than 1 , D is the same or different at each occurrence.
6. The conjugate of claim 1, wherein n2 is other than zero, wherein one of R1, R2, R3, R4, R5 or R6 comprises a carboxy group selected from -OR7C(=O)- and -R7C(=O)- which is bound to D.
7. The conjugate of claim 6, wherein n2 is other than zero, wherein one of R1, R2, R3, R4, R5 or R6 comprises a carboxy group selected from -OR7C(=O)- and -R7C(O)- which is bound to D, wherein D is the same or different at each occurrence.
8. The conjugate of claim 1 wherein the isoflavone derivative is selected from a derivative of daidzein, genistein, formononetin and biochanin A.
9. The conjugate of claim 1 wherein the isoflavone derivative is a derivative of daidzein.
10. The conjugate of claim 1 wherein the isoflavone derivative is selected from the group consisting of 7-(O)-carboxymethyl daidzein, 6-carboxymethyl biochanin A, 2-carboxyalkyl biochanin A, 8-carboxymethyl biochanin A, 7-(O)-carboxymethyl formononetin, 2-carboxyalkyl genistein and 6-carboxymethyl genistein.
11. The conjugate of claim 1 wherein the isoflavone derivative is 7-(O)- carboxymethyl daidzein.
12. The conjugate of claim I5 wherein D is an diagnostic agent selected from the group consisting of paramagnetic particles such as gadolinium, yttrium, lutetium, europium and gallinium; radioactive moieties such as radioactive indium, rhenium and technetium; fluorescent dyes such as fluorescein isothiocyanate (FITC), green fluorescent protein (GFP), Cyan fluorescent protein (CFP), rhodamine I, II, III and IV, rhodamine B and infrared dyes such as CyTE-777 and rosamine.
13. The conjugate of claim 12, wherein the paramagnetic particle is gadolinium.
14. The conjugate of claim 12, wherein the paramagnetic particles are provided within a chelator.
15. The conjugate of claim 14, wherein the chelator is selected from the group consisting of: diethylenetriamine pentaacetic acid (DTPA), tetraazacyclododecanetetraacetic acid (DOTA), mercaptoacetylglycylglycyl- glycine (MAG3) and N-l-φ-isothiocyanatophenyOdiethylenetriamine-N^N^N3- tetraacetate(DTTA).
16. The conjugate of claim 15, wherein the chelator is diethylenetriamine pentaacetic acid (DTPA).
17. The conjugate of claim I5 wherein D is a therapeutic agent selected from the group consisting of cytotoxic compounds, cytostatic compounds, antisense compounds and anti-viral agents.
18. The conjugate of claimlό, wherein D is a cytotoxic compound selected from the group consisting of: DNA synthesis and function inhibitory agents such as adriamycin, bleomycin, chlorambucil, cisplatin, carboplatin, oxaliplatin, daunomycin and melphalan; microtubule (mitotic spindle) formation and function inhibitory agents such as vinblastine, vincristine, vinorelbine, paclitaxel (taxol) and docetaxel; anti metabolites such as cytarabine, fluorouracil, fluroximidine, mercaptopurine, methotorexate, gemcitabin and thioquanine; alkylating agents such as mechlorethamine, chlorambucil, cyclophosphamide, melphalan ifosfamide and methotrexate; antibiotics such as bleomycin and mitomycin; nitrosoureas such as carmustine (BCNU) and lomustine; hormones such as tamoxifen, leuprolide, flutamide and megestrol acetate and proteins such as interferon and asparaginase.
19. The conjugate of claim 1, further comprising an affinity molecule selected from biotin and at least the antigen binding portion of a specific antibody.
20. A diagnostic composition comprising as an active ingredient a conjugate comprising at least one isoflavone derivative bound to albumin and at least one compound D, having the general formula (I): Albumin — Dn1
wherein m is 1-20; ni is 0-10; n2 is 0 or 1 ;
R1 is selected from the group consisting of -OH, -OCH3, -OGIc, -OR7COOX and -OR7C(=O)-;
R2, R5 and R6 are each independently selected from the group consisting of -H, -
R7COOX and -R7C(=O)-; R3 is selected from the group consisting of -H, -OH, -R7COOX, -OR7COOX, -
R7C(O)- and -OR7C(=O)-;
R4 is selected from the group consisting of -H, -CH3, -R7COOX and -R7C(=0)-;
D is a bioactive moiety selected from a diagnostic agent and a therapeutic agent;
R7 is selected from the group consisting of Ci-C6 alkylene, (C2-C20) alkenylene; and (C2-C20) heteroalkylene;
X is selected from the group consisting of -H and -(CH2)n-Y wherein Y is -CH3 or -NH2 and n is 0-10; with the proviso that one of R1, R2, R3, R4, R5 or R6 comprises a carboxy group selected from -OR7C(=O)- and -R7C(=0)- which is bound to albumin and at least one of n\ and n2 is other than zero; and with the proviso that at least one D is a diagnostic agent.
21. The diagnostic composition of claim 20, wherein ni is other than zero and when ni is greater than 1, D is the same or different at each occurrence.
22. The diagnostic composition of claim 21, wherein n2 is other than zero, wherein one of R1, R2, R3, R4, R5 or R6 comprises a carboxy group selected from -
OR7Q=O)- and -R7C(=O)- which is bound to D.
23. The diagnostic composition of claim 21, wherein n2 is other than zero, wherein one of R1, R2, R3, R4, R5 or R comprises a carboxy group selected from - OR7C(O)- and -R7C(=O)- which is bound to D, wherein D is the same or different at each occurrence.
24. The diagnostic composition of claim 20, wherein the isoflavone derivative is a derivative of daidzein, genistein, formononetin and biochanin A.
25. The diagnostic composition of claim 24, wherein the isoflavone derivative is daidzein derivative.
26. The diagnostic composition of claim 20, wherein the isoflavone derivative is selected from the group consisting of 7-(O)-carboxymethyl daidzein, 6- carboxymethyl biochanin A, 2-carboxyalkyl biochanin A, 8-carboxymethyl biochanin A, 7-(O)-carboxymethyl formononetin, 2-carboxyalkyl genistein and 6- carboxymethyl genistein.
27. The diagnostic composition of claim 26, wherein the isoflavone derivative is 7- (O)-carboxymethyl daidzein.
28. The diagnostic composition of claim 20, wherein D is an diagnostic agent selected from the group consisting of paramagnetic particles such as gadolinium, yttrium, lutetium, europium and gallinium; radioactive moieties such as radioactive indium, rhenium and technetium; fluorescent dyes such as fluorescein isothiocyanate (FITC), green fluorescent protein (GFP), Cyan fluorescent protein
(CFP), rhodamine I, II, III and IV, rhodamine B and infrared dyes such as CyTE- 777 and rosamine.
29. The diagnostic composition of claim 28, wherein the paramagnetic particle is gadolinium.
30. The diagnostic composition of claim 28, wherein the paramagnetic particles is provided within a chelator.
31. The diagnostic composition of claim 30, wherein the chelator is selected from the group consisting of: diethylenetriamine pentaacetic acid (DTPA), tetraazacyclododecanetetraacetic acid (DOTA), mercaptoacetylglycylglycyl- glycine (MAG3) and N-l-φ-isothiocyanatophenytydiethylenetriamine-N'jN^N3- tetraacetate(DTTA).
32. The diagnostic composition of claim 31, wherein the chelator is diethylenetriamine pentaacetic acid (DTPA).
33. The diagnostic composition of claim 20, further comprising nystatin.
34. A method for diagnosing a disease or disorder in a subject comprising administering to the subject a diagnostic composition according to claim 20.
35. The methods according to claim 34, wherein the disease or disorder is associated with cells which are sensitive to isoflavone.
36. The method according to claim 34, wherein the disease or disorder is cancer.
37. The method according to claim 35, wherein cancer is selected from ovarian cancer, breast cancer, colon cancer, melanoma, non-small lung cancer, leukemia, endometrial cancer and prostate cancer.
38. The method according to claim 34, wherein the disease or disorder is an estrogen related condition selected from the group consisting of osteoporosis, endometriosis, atherosclerosis, cardiovascular disease, hypercholesterolemia, prostatic hypertrophy and Alzheimer's Disease.
39. A method for enhancing image contrast in in vivo imaging procedure comprising administering a diagnostic composition according to claim 20.
40. The method of claim 39, wherein the in vivo imaging procedure is selected from the group consisting of MRI, NIR, optical imaging, scintigraphy, SPECT, PET, X- ray, ultrasound imaging, electrical impedance and magnetometric procedures.
41. The method of claim 40, wherein the in vivo imaging procedure is MRI.
42. The method of claim 40, wherein the in vivo imaging procedure is NIR.
43. A pharmaceutical composition comprising as an active ingredient a conjugate comprising at least one isoflavone derivative bound to albumin and at least one compound D, the conjugate represented by the structure of general formula (I): Albumin — Dn1
I wherein m is 1-20; n! is 0-10; n2 is 0 or 1 ;
R1 is selected from the group consisting of -OH, -OCH3, -OGIc, -OR7COOX and -OR7C(O)-;
R2, R5 and R6 are each independently selected from the group consisting of -H, -
R7COOX and -R7C(O)-; R3 is selected from the group consisting of -H, -OH, -R7COOX, -OR7COOX, -
R7C(K))- and -0R7C(=0)-;
R4 is selected from the group consisting of -H, -CH3, -R7COOX and -R7C(=0)-;
D is a bioactive moiety selected from a diagnostic agent and a therapeutic agent;
R7 is selected from the group consisting Of C1-C6 alkylene, (C2-C20) alkenylene; and (C2-C20) heteroalkylene;
X is selected from the group consisting of -H and -(CH2)n-Y wherein Y is -CH3 or -NH2 and n is 0-10; with the proviso that one of R1, R2, R3, R4, R5 or R6 comprises a carboxy group selected from -OR7C(O)- and -R7C(=0)- which is bound to albumin, where at least one of n\ and n2 is other than zero; and, with the proviso that at least one D is a therapeutic agent.
44. The pharmaceutical composition of claim 43, wherein ni is other than zero and when n\ is greater than 1 , D may be the same or different at each occurrence.
45. The pharmaceutical composition of claim 43, wherein n2 is other than zero, wherein one of R1, R2, R3, R4, R5 or R6 comprises a carboxy group selected from -
0R7C(=0)- and -R7C(O)- which is bound to D.
46. The pharmaceutical composition of claim 44, wherein n2 is other than zero, wherein one of R1, R2, R3, R4, R5 or R6 comprises a carboxy group selected from - OR7C(=O)- and -R7C(=O)- which is bound to D, wherein D is the same or different at each occurrence.
47. The pharmaceutical composition of claim 43, wherein the isoflavone derivative is selected from a derivative of daidzein, genistein, formononetin and biochanin A.
48. The pharmaceutical composition of claim 47, wherein the isoflavone derivative is daidzein derivative.
49. The pharmaceutical composition of claim 43, wherein the isoflavone derivative is selected from the group consisting of 7-(O)-carboxymethyl daidzein, 6- carboxymethyl biochanin A, 2-carboxyalkyl biochanin A, 8-carboxymethyl biochanin A, 7-(O)-carboxymethyl formononetin, 2-carboxyalkyl genistein and 6- carboxymethyl genistein.
50. The pharmaceutical composition of claim 49, wherein the isoflavone derivative is 7-(O)-carboxymethyl daidzein.
51. The pharmaceutical composition of claim 43, wherein D is a therapeutic agent selected from the group consisting of cytotoxic compounds, cytostatic compounds, antisense compounds and anti-viral agents.
52. The pharmaceutical composition of claim 51, wherein D is a cytotoxic compound selected from the group consisting of: DNA synthesis and function inhibitory agents such as adriamycin, bleomycin, chlorambucil, cisplatin, carboplatin, oxaliplatin, daunomycin and melphalan; microtubule (mitotic spindle) formation and function inhibitory agents such as vinblastine, vincristine, vinorelbine, paclitaxel (taxol) and docetaxel; anti metabolites such as cytarabine, fluorouracil, fluroximidine, mercaptopurine, methotorexate, gemcitabin and thioquanine; alkylating agents such as mechlorethamine, chlorambucil, cyclophosphamide, melphalan ifosfamide and methotrexate; antibiotics such as bleomycin and mitomycin; nitrosoureas such as carmustine (BCNU) and lomustine; hormones such as tamoxifen, leuprolide, flutamide and megestrol acetate And proteins such as interferon and asparaginase.
53. The pharmaceutical composition of claim 43, further comprising nystatin.
54. A method for treating a disease or disorder in a subject in need thereof comprising administering to the subject a pharmaceutical composition according to claim 41.
55. The method according to claim 54, wherein the disease or disorder is associated with cells which are sensitive to isoflavone.
56. The method according to claim 55, wherein the disease or disorder is cancer.
57. The method according to claim 56, wherein cancer is selected from ovarian cancer, breast cancer, colon cancer, melanoma, non-small lung cancer, leukemia, endometrial cancer and prostate cancer.
58. The method according to claim 54, wherein the disease or disorder is an estrogen related condition selected from the group consisting of osteoporosis, endometriosis, atherosclerosis, cardiovascular disease, hypercholesterolemia, prostatic hypertrophy and Alzheimer's Disease.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9755308P | 2008-09-17 | 2008-09-17 | |
US61/097,553 | 2008-09-17 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2010032248A2 true WO2010032248A2 (en) | 2010-03-25 |
WO2010032248A8 WO2010032248A8 (en) | 2010-06-03 |
WO2010032248A3 WO2010032248A3 (en) | 2010-08-19 |
Family
ID=41786279
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IL2009/000911 WO2010032248A2 (en) | 2008-09-17 | 2009-09-17 | Multifunctional albumin conjugates |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2010032248A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011133728A3 (en) * | 2010-04-23 | 2012-05-24 | Kineta, Inc. | Anti-viral compounds |
US9458492B2 (en) | 2011-02-25 | 2016-10-04 | Kineta, Inc. | Methods and cells for identifying RIG-I pathway regulators |
WO2018187631A1 (en) * | 2017-04-05 | 2018-10-11 | Cornell University | Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies |
US10806806B2 (en) | 2016-06-23 | 2020-10-20 | Cornell University | Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003079965A2 (en) * | 2002-03-21 | 2003-10-02 | Yeda Research And Development Co. Ltd. | Derivatives of isoflavones |
-
2009
- 2009-09-17 WO PCT/IL2009/000911 patent/WO2010032248A2/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003079965A2 (en) * | 2002-03-21 | 2003-10-02 | Yeda Research And Development Co. Ltd. | Derivatives of isoflavones |
Non-Patent Citations (10)
Title |
---|
BENNETAU-PELISSERO C: "synthesis of haptens and conjugates for ELISAs of phytoestrogens" JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US LNKD- DOI:10.1021/JF990896V, vol. 48, 1 January 2000 (2000-01-01), pages 305-311, XP002364305 ISSN: 0021-8561 * |
GRANOT D ET AL: "Labeling fibroblasts with biotin-BSA-GdDTPA-FAM for tracking of tumor-associated stroma by fluorescence and MR imaging" MAGNETIC RESONANCE IN MEDICINE 200510 US LNKD- DOI:10.1002/MRM.20628, vol. 54, no. 4, October 2005 (2005-10), pages 789-797, XP002586889 ISSN: 0740-3194 * |
KOHEN F ET AL: "The measurement of the isoflavone daidzein by time resolved fluorescent immunoassay: A method for assessment of dietary soya exposure" JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY 19980201 GB LNKD- DOI:10.1016/S0960-0760(97)00156-8, vol. 64, no. 3-4, 1 February 1998 (1998-02-01), pages 217-222, XP002586647 ISSN: 0960-0760 * |
KOHEN FORTUNE ET AL: "Synthesis and Evaluation of the Antiproliferative Activities of Derivatives of Carboxyalkyl Isoflavones linked to N-t-Boc-hexylenediamine" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US LNKD- DOI:10.1021/JM070727Z, vol. 50, no. 25, 1 January 2007 (2007-01-01), pages 6405-6410, XP002482822 ISSN: 0022-2623 cited in the application * |
LAPCIK O ET AL: "Radioimmunoassay of free genistein in human serum" JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY 19980301 GB LNKD- DOI:10.1016/S0960-0760(97)00199-4, vol. 64, no. 5-6, 1 March 1998 (1998-03-01), pages 261-268, XP002586652 ISSN: 0960-0760 * |
MIGALOVICH H S ET AL: "Harnessing competing endocytic pathways for overcoming the tumor-blood barrier: Magnetic resonance imaging and near-infrared imaging of bifunctional contrast media" CANCER RESEARCH 20090701 AMERICAN ASSOCIATION FOR CANCER RESEARCH INC. USA LNKD- DOI:10.1158/0008-5472.CAN-08-4967, vol. 69, no. 13, 1 July 2009 (2009-07-01), pages 5610-5617, XP002586648 * |
PATHAK A P ET AL: "Characterizing extravascular fluid transport of macromolecules in the tumor interstitium by magnetic resonance imaging" CANCER RESEARCH 20050215 US LNKD- DOI:10.1158/0008-5472.CAN-04-3682, vol. 65, no. 4, 15 February 2005 (2005-02-15), pages 1425-1432, XP002586888 ISSN: 0008-5472 * |
SOMJEN D ET AL: "A daidzein-daunomycin conjugate improves the therapeutic response in an animal model of ovarian carcinoma" JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, ELSEVIER SCIENCE LTD., OXFORD, GB LNKD- DOI:10.1016/J.JSBMB.2008.03.033, vol. 110, no. 1-2, 1 May 2008 (2008-05-01) , pages 144-149, XP022707403 ISSN: 0960-0760 [retrieved on 2008-04-04] cited in the application * |
SOMJEN D ET AL: "Membranal effects of phytoestrogens and carboxy derivatives of phytoestrogens on human vascular and bone cells: New insights based on studies with carboxy-biochanin A" JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, ELSEVIER SCIENCE LTD., OXFORD, GB LNKD- DOI:10.1016/J.JSBMB.2004.12.029, vol. 93, no. 2-5, 1 February 2005 (2005-02-01), pages 293-303, XP025298416 ISSN: 0960-0760 [retrieved on 2005-02-01] * |
Worthington Biomedical Corporation: "Ovalbumin" Worthington Enzyme Manual XP002586893 Retrieved from the Internet: URL:http://www.worthington-biochem.com/OA/default.html [retrieved on 2010-06-11] * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011133728A3 (en) * | 2010-04-23 | 2012-05-24 | Kineta, Inc. | Anti-viral compounds |
US9408826B2 (en) | 2010-04-23 | 2016-08-09 | Kineta, Inc. | Isoflavone anti-viral compounds |
US9458492B2 (en) | 2011-02-25 | 2016-10-04 | Kineta, Inc. | Methods and cells for identifying RIG-I pathway regulators |
US10806806B2 (en) | 2016-06-23 | 2020-10-20 | Cornell University | Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies |
WO2018187631A1 (en) * | 2017-04-05 | 2018-10-11 | Cornell University | Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies |
US11285227B2 (en) | 2017-04-05 | 2022-03-29 | Cornell University | Trifunctional constructs with tunablepharmacokinetics useful in imaging and anti-tumor therapies |
Also Published As
Publication number | Publication date |
---|---|
WO2010032248A3 (en) | 2010-08-19 |
WO2010032248A8 (en) | 2010-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Indoria et al. | Recent advances in theranostic polymeric nanoparticles for cancer treatment: A review | |
Cai et al. | A nanostrategy for efficient imaging‐guided antitumor therapy through a stimuli‐responsive branched polymeric prodrug | |
Lu et al. | Thermosensitive magnetic liposomes for alternating magnetic field-inducible drug delivery in dual targeted brain tumor chemotherapy | |
EP1743174B1 (en) | Multimodality nanostructures, methods of fabrication thereof, and methods of use thereof | |
US6989140B2 (en) | Methods for cancer imaging | |
JP5237821B2 (en) | Polyglutamic acid-amino acid conjugates and methods | |
Lu et al. | Poly (l-glutamic acid) Gd (III)-DOTA conjugate with a degradable spacer for magnetic resonance imaging | |
Li et al. | A photosensitizer-conjugated magnetic iron oxide/gold hybrid nanoparticle as an activatable platform for photodynamic cancer therapy | |
DE69819925T2 (en) | Contrast-enhanced diagnostic image generation method for monitoring therapeutic interventions | |
Zhou et al. | Bone-targeting polymer vesicles for simultaneous imaging and effective malignant bone tumor treatment | |
Sang et al. | CD44 targeted redox-triggered self-assembly with magnetic enhanced EPR effects for effective amplification of gambogic acid to treat triple-negative breast cancer | |
JP6618680B2 (en) | Self-assembled pharmaceutical composition for photodynamic therapy | |
CA2108362A1 (en) | Melanin-based agents for image enhancement | |
EP1830879B1 (en) | Mri guided photodynamic therapy for cancer | |
WO2010032248A2 (en) | Multifunctional albumin conjugates | |
Akakuru et al. | Self-assembled, biocompatible and biodegradable TEMPO-conjugated nanoparticles enable folate-targeted tumor magnetic resonance imaging | |
US10201622B2 (en) | Tumour-targeted theranostic | |
EP2547369B1 (en) | A nanoparticle comprising a micelle formed by an amphiphilic block-copolymer and encapsulating a gadolinium complex | |
Shabani et al. | The brilliance of nanoscience over cancer therapy: Novel promising nanotechnology-based methods for eradicating glioblastoma | |
US20190076555A1 (en) | Tumor targeting nanoagent for imaging and fluorescent guided resection of tumors | |
Zhao et al. | Tumor microenvironment-specific functional nanomaterials for biomedical applications | |
Herlan et al. | Lanthanide conjugates as versatile instruments for therapy and diagnostics | |
WO2005067982A2 (en) | Methods for imaging the lymphatic system using dendrimer-based contrast agents | |
JP2016069358A (en) | Mri contrast agent composition for contrast imaging of cancer cells | |
EP3691670A1 (en) | Methods and compositions for efficient delivery through multiple bio barriers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09748153 Country of ref document: EP Kind code of ref document: A2 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09748153 Country of ref document: EP Kind code of ref document: A2 |